Identification of biomarkers for type 2 diabetes: analysis of a primary prevention study among Asian Indians with impaired glucose tolerance by Jagannathan, Ram
 
 
Identification of biomarkers for type 2 diabetes – Analysis 
of a primary prevention study among Asian Indians with 
impaired glucose tolerance 
 
Thesis submitted for the degree of 
DOCTOR OF PHILOSOPHY 
to 
 
 
 
by 
Ram Jagannathan 
(CID No: 00628791) 
Section of Endocrinology and Metabolic Medicine 
Division of Diabetes, Endocrinology & Metabolism 
St. Mary’s Campus, Imperial College, London 
 
 
 
 
 
For my “AMMA” 
 
                         
                                       
 
-           
 
 
Translation in English: 
 
When mother hears him named 'fulfill'd of wisdom's lore,' Far greater joy she 
feels, than when her son she bore. 
- Thirukkural 
 
 
 iii 
 
ACKNOWLEDGEMENTS 
 
No man is an island, 
Entire of itself, 
Every man is a piece of the continent, 
A part of the main… 
- John Donne (1572-1631) 
 
 
I have not travelled in isolation in this journey in an effort to finish my PhD degree. This 
research work has been placed on track seen through completion with the support, 
constructive comments and encouragement of numerous people including my supervisors, 
well wishers, friends and colleagues. I would like to thank all those who have contributed in 
many ways for the success of this study and made this thesis possible and an unforgettable 
experience for me. 
 
First and foremost I wish to thank my supervisor and mentor Prof. A. Ramachandran, for 
offering me this opportunity to pursue my doctorate degree. It has been an honour and great 
learning experience to work under him. He is truly inspirational and under his supervision I 
have honed the skills required for performing this research work. I would like to extend my 
sincere gratitude to Prof. Desmond G Johnston for guiding my work at the Imperial 
College, London. His endless support and scientific advice has been of outmost importance.  
 
I am very grateful to Dr. C. Snehalatha for her scientific advice and knowledge and many 
insightful discussions and suggestions. As an ardent teacher she has been my primary 
resource for getting all scientific and statistical questions clarified. I am also thankful to                          
Dr. Ian F Godsland for his one-to-one brainstorming sessions on statistical modelling and 
principles of diabetes pathogenesis in his cabin. They both have been instrumental in my 
thesis writing and have untiringly proof read my drafts. 
I am very grateful and obliged to Dr. Shobana Ramachandran, Vice President, India 
Diabetes Research Foundation, Chennai for her support. She is really kind towards me and 
offered me the space to do my research work. Thanks also to Dr. Nanditha Arun and Dr. 
Samith A. Shetty for their scientific support and suggestions during my PhD work.  
 
I gratefully acknowledge the funding source that made my PhD work possible. My research 
was funded by the United Kingdom India Education Research Initiative (UKIERI), British 
Council. I am also obliged to Mr.MES Raghavan, financial advisor, IDRF for sanctioning 
my stipend and study related expenses promptly on time. 
 iv 
 
The members of the Epidemiology team, India Diabetes Research Foundation (IDRF) have 
contributed immensely to my personal and professional time. The group has been a source of 
comradeship as well as good advice and collaboration. I am really thankful to Mary Simon 
for her unconditional care and support. She is a person with impeccable integrity, pivotal to 
the epidemiology survey team and has been a true saviour at a time of great need. Special 
thanks to Vijaya Balaji for her consistent statistical help and relentless motivation during my 
difficult times. I extend my thanks to cheerful team mates Sathish CS, Tamil Selvan, 
Catherine, Priscilla S and Dr. Satheesh. We worked together in conducting epidemiological 
surveys, biochemical analysis and data management. I extend my thanks to my past team 
mates Dr. Thirupurasundari, Dr. Subash Babu, Muruganandham, and Devaraj for their 
help and support during various junctures. I am really thankful to my fellow PhD colleague, 
Sundaram Selvam for his support throughout the study in India and UK. He helped me to 
face the hardships into joyful challenge. 
I would like to acknowledge the software set-up (for messaging) and technical support 
rendered by Vivek. Though he was not part of the study, he swiftly solved the bugs on 
schedule and helped us in the background for the smooth functioning of the messaging 
platform. 
I am also indebted to Vishakhapatnam steel plant hospital, and administrative team for 
helping us to carry out this massive recruitment programme. Special thanks to  Dr. Naveen 
Kumar AP, Dr. Srikantha, Dr. Maturi, Dr. Chalam and Dr. Lalitha for their continued 
support in conducting the epidemiological study. 
My deepest gratitude is reserved for my family, for their unconditional love, trust in my 
abilities, and support they have extended throughout my pursuit. Special thanks (I should not 
tell him thanks, BTW!) to my twin “Latchu”. He has been my real stress buster to whom I 
pour all my problems (both personal and scientific).  He guides me well to come out of it (at 
times he enmesh me with the problems!).  I would also like to thank my closest friend Amrit, 
for his statistical advice. His friendship is highly protective (Hazard Ratio: 0) and statistically 
significant (P<0.0001). Much love to all of you, without your support I would not have 
reached where I am. 
 
Finally it is no easy task, reviewing a thesis, and I am grateful for the thoughtful and patient 
readings of my examiners. 
 
 
Gratitude is the memory of the heart. - Jean Baptiste Massieu 
 
Thank you!!! 
 v 
 
STATEMENT OF ORIGINALITY 
 
 
This thesis is submitted to Imperial College, London in fulfilment of the requirements of the 
degree of Doctor of Philosophy. This thesis represents my own original work towards this 
research degree and contains no material which has been previously submitted for a degree or 
diploma at this University or any other institution, except where due acknowledgement is 
made. 
 
Ram Jagannathan 
 
 
vi 
 
Copyright Declaration 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use it 
for commercial purposes and that they do not alter, transform or build upon it. For any reuse 
or redistribution, researchers must make clear to others the licence terms of this work 
 
 
vii 
 
 
ABSTRACT 
Primary prevention of type 2 diabetes (T2DM) is an important strategy for curbing its rising 
global burden. Though lifestyle modification has provided an effective method of 
preventing/delaying incidence of diabetes in high-risk individuals, it has not been widely 
implemented even in developed countries due to its high-cost, need for expertise and 
difficulties in translating the benefits of lifestyle intervention to the community at large. 
Hence, there is an urgent need to identify an alternate mode of delivery to transmit healthy 
lifestyle information to high-risk individuals. In this trial, we sought to determine whether 
lifestyle advice through mobile phone text messaging could reduce incident diabetes 
compared to standard lifestyle advice in Asian Indian men with prediabetes. The study 
showed for the first time that mobile phone messaging is an effective and acceptable method 
to deliver advice and support towards lifestyle modification to prevent T2DM in men at high 
risk. 
 
The identification of novel predictors for T2DM is an arduous task. The glycaemic markers 
of diabetes (fasting plasma glucose, 2hr post glucose load and HbA1c) are, in fact, risk 
factors for microvascular complications of diabetes and it was on this basis that diagnostic 
cut-offs’ for diabetes were arrived at. Nevertheless, elevated levels of glycaemic markers in 
the sub-clinical, or pre-diabetic, range are associated with increased risk of progression to 
diabetes. However, there is already considerable deterioration of beta cell function by the 
time diabetic dysglycaemia occurs. The way forward is clearly to identify biomarkers that 
serve as reliable predictors of progression to diabetes rather than simply reflecting 
accompanying levels of glycaemia. In this thesis using the database of the above mentioned 
trial it was aimed to identify the predictors of T2DM in Asian Indian cohort with prediabetes 
at baseline. 
 
The classical risk factors studied here are: 1) increased prevalence of the 
hypertriglyceridemic waist phenotype, 2) a combination of HbA1c and gamma glutamyl 
transferase and 3) a measure of beta cell compensation (disposition index) predicted incident 
diabetes. Among these, the disposition index was the most powerful predictor in the cohort. 
 
In addition to these classical risk factors mentioned above, in a small nested-case control, 
cross sectional study, the association of adipokines (adiponectin, leptin, interleukin-6 (IL-6), 
retinol-binding protein4 (RBP4)) and vitamin D3 were assessed to study the mechanistic  link 
of novel biomarkers  with diabetes. In this cohort, lower levels of baseline adiponectin, and 
higher IL-6 and RBP4 were associated with diabetes. Though, many of these provided a 
novel mechanistic pathogenic link with diabetes they did not improve prediction over and 
above that of glycaemic measures in identifying individuals with diabetes. However, the non-
glycaemic biomarkers appear to have a role in the underlying pathogenesis of diabetes. 
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1 PROLOGUE 
 
 
 
"… Today there are 382 million people living with diabetes. Without concerted 
action to prevent diabetes, in less than 25 years’ time there will be 592 million 
people living with the disease.” 
 
- Sir Michael Hirst, President, IDF.   
                                            Melbourne, 2013 
 
1.1   “Epidemic” of type 2 diabetes 
The cataclysmic increase in type 2 diabetes (T2DM) has become a major healthcare 
burden. According to  the  recent  global update  by  the  International  Diabetes  
Federation (IDF), 382  million (8.3%)  adults  aged  20–79  years  had diabetes  in  2013; 
this number is expected to rise to 591.9 million by 2035
1
. For India, the  IDF estimated  
that  there  were  65.1  million  people  with  diabetes  in 2013,  with  a  projected  rise  
of  67.4%  to  109.0  million  by  2035
1
.  
The development of T2DM is preceded by an intermediate prediabetic stage (impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG)) in which blood glucose is 
elevated when compared to normal but is below diabetic thresholds. Prediabetes is a risk 
state that may last for several years and increases the prognosis of developing diabetes
2
. 
In a meta-analysis of prospective studies published between 1979 and 2004, when 
compared to normoglycaemic individuals the relative risk [95%CI] for diabetes was: 
5.52 [3.13-7.91] in people with isolated IGT; 7.54 [4.63-10.45] in people with isolated 
IFG and 12.13[4.27-20.0] in people with both IFG and IGT
3
. A recent report from the 
IDF estimates approximately 316 million adults (aged 20–79 years) having IGT in 2013, 
with a projected increase by 49.1% to 471 million by 2035
1
. 
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1.2 Risk factors for diabetes 
The identification of risk factors is essential for the successful implementation of primary 
prevention programmes. The risk determinants for diabetes are divided into non-
modifiable and modifiable risk factors. It should be emphasized that complex diseases 
such as T2DM result from the interaction of genetic and environmental risk factors. The 
most notable risk factors for T2DM are depicted in Figure 1-1. 
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Figure 1-1: Modifiable and non-modifiable risk factors for type 2 diabetes 
The major modifiable and non-modifiable risk factors for T2DM are shown. 
Diabetes results from an interaction of both modifiable and non-modifiable risk 
factors. The figure is reproduced from the review by Ramachandran et al 
4
. The 
genetically susceptible individuals are probably predisposed to developing diabetes, 
either directly or through intermediate factors (e.g., weight gain and obesity), or via 
interactions between multiple genes as well as between genes and 
environmental/behavioural factors.  
 
1.2.1 Non-modifiable risk factors 
Some of the most prominent non-modifiable risk factors include: age, parental 
longevity, positive family history of diabetes and ethnicity, a history of gestational 
diabetes, polycystic ovarian syndrome and adverse intrauterine environment. T2DM 
aggregates in families
5
. The lifetime risk (at age 80 years) for T2DM has been 
calculated to be 38% if one parent had T2DM
6
. If  both  parents  were  affected,  the 
incidence  of  T2DM  in  the  offspring  is estimated to approach 60% by the age of 
Chapter-1 
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60 years
7
. Longevity is a complex process resulting from genetic or environmental 
risk factors, and their interactions with families
8,9
.  More than 100 genes are shown 
to be associated with  human longevity, including those in the insulin/insulin-like 
growth factor-1pathway, lipoprotein metabolism (Apolipoprotein E and 
paraoxonase-1), and cell cycle regulators
10
.  The findings from US diabetes 
prevention program (DPP) showed that parental longevity is inversely associated 
with diabetes incidence in individuals at high risk of T2DM compared with 
offspring’s whose parents died prematurely11. Family studies, including those 
involving monozygotic or dizygotic twins, and differences in diabetes prevalence 
between ethnic groups, indicate that the heritability of T2DM exceeds 50%
12-16
. 
Ethnicity is also one of the main contributory factors for the development of 
diabetes. Though, all ethnic groups are at risk of T2DM, certain non-white 
Caucasian groups, such as Indo-Asians and Native Americans, appear to have a 
particularly strong genetic predisposition
17
. 
1.2.2 Modifiable risk factors 
Some of the major modifiable environmental risk factors include: sedentary behaviour, 
nutritional over-indulgence, overweight or obesity, central adiposity, rapid urbanization, 
smoking, increased psychological stress and sleep irregularities
18-22
. The scientific 
evidence, relative risk and mechanism of action of important modifiable risk factors are 
summarized in Table 1-1. 
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Table 2-1: Association between modifiable and non-modifiable risk factors for type 2 diabetes and disease development 
 
 
Risk factors Scientific evidence Hazard ratio 
[95%CI] 
Proposed mechanism 
Overweight / 
obesity 
Meta-analysis: 
 18 prospective cohort studies 
23
 
Obesity:  
7.28 [6.47- 8.28] 
Overweight:  
2.92 [2.57-3.32] 
Increased insulin resistance and increased pancreatic β- cell 
compensation and increased ectopic fat accumulation. 
Smoking Meta-analysis of 25 prospective studies in 
multi-ethnic cohort 
24-26
 
1.61 [1.43-1.80] Smoking has been identified as a possible cause of insulin 
resistance, a precursor for diabetes. Smoking has also been 
shown to cause deterioration in glucose metabolism, which 
may lead to the onset of T2DM. There is also some evidence 
that suggests smoking increases diabetes risk through a BMI-
independent mechanism. 
 
Sleeping Quantity and quality of sleep and diabetes: 
10 studies in multi-ethnic populations 
27
 
Short duration: 
1.28 [1.03–1.60] 
Long duration:  
1.48 [1.13–1.96] 
Difficulty in 
maintaining sleep: 
1.84 [1.39 –2.43] 
Difficulty in initiating 
sleep:  
1.57 [1.25–1.97] 
Reciprocal changes in circulating levels of leptin and ghrelin. 
These in turn would increase appetite and caloric intake, 
reduce energy expenditure and facilitate the development of 
obesity and impaired glycaemic control, increasing 
cardiovascular risk. Increased cortisol secretion, acute-
inflammatory biomarkers and altered growth hormone 
metabolism have also been implicated. 
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Table 1-1: Association between modifiable and non-modifiable risk factors for type 2 diabetes and disease development (Continued) 
Risk factors Scientific evidence Hazard ratio [95%CI] Proposed mechanism 
Lack of physical 
activity Sedentary habits and 
television watching 
28,29
 
TV watching (2h/day 
increment): 
1.14 [1.05-1.23] 
Alter energy expenditure by displacing time spent on physical 
activities, TV viewing is associated with unhealthy eating (eg, 
higher intake of fried foods, processed meat, and sugar-sweetened 
beverages and lower intake of fruits, vegetables, and whole grains) 
Diet Increased white rice 
consumption 
30
 
Meta-analysis of 4 studies (2 
Asians and 2 Western) 
1.55 [1.20-2.01] 
A dose-response analysis 
showed that each serving 
per day of white rice 
consumption was 
associated with an 11% 
increase in risk of diabetes 
in the overall population 
White rice consumption leads to an increased glycaemic load which 
results in increased insulin resistance and pancreatic beta cell 
exhaustion. 
Increased consumption of red 
meat: 
Meta-analysis of 10 studies in 
multi-ethnic populations 
31
. 
1.51 [1.25, 1.83] 
Mediated through the effects of heme-iron derived from red meats; 
Iron is the pro-oxidant and increase oxidative stress thereby causing 
damage to tissues. 
Sugar sweetened beverages: 
8 prospective studies in multi-
ethnic populations 
32
 
1.26  [1.12–1.41] 
Increased sugar sweetened beverages leads to increased weight gain 
and worsens cardiovascular risk profile. 
Fruit and vegetable intake and 
diabetes: 
Meta-analysis of 6 multi-
ethnic observational studies 
33
. 
0.86 [0.77-0.97]  The plausible mechanisms responsible for the beneficial effects of 
fruits and vegetables on diabetes risk are likely to be diverse. 
Besides their contribution to 
low energy intake, high fiber content, and low glycemic load, fruits 
and vegetables are also rich in antioxidants, vitamins, magnesium, 
potassium, plant proteins, and other individual phytochemicals, 
which could be beneficial in reducing risk of T2DM. 
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Coffee, tea consumption and 
diabetes: 
Meta-analysis of 18 studies in 
multi-ethnic cohort 
34
. 
 
0.93 [0.91-0.95] 
 The biological mechanism responsible for the inverse relationship 
between coffee and tea consumption and T2DM is unclear. The 
protective effect was independent of magnesium, potassium, 
caffeine or blood pressure effects. Coffee is rich in the antioxidant 
chlorogenic acid and tea contains flavonols and flavones as 
antioxidants which reduce oxidative stress. Therefore, it  improves 
insulin sensitivity and beta cell function. 
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1.3 Pathophysiology 
The development of T2DM involves both environmental and genetic components as 
described in the previous sections
35
. The recent epidemic of the disease cannot be 
attributed primarily by genetic influences because these factors do not change in a short 
duration. Therefore, a marked worsening of unhealthy environmental risk factors such as 
decreased energy expenditure, increased calorie intake and stress may be the main 
causative factor for the increasing prevalence of diabetes and its associated 
complications. This concept is broadly referred to as “gene × environment interaction”, in 
which the “gene” is usually one or more DNA variants and the “environment” can be any 
nongenetic factor that impacts risk
36
. Furthermore, the in-utero environment, maternal 
under nutrition (prior to and during the pregnancy) and lower birth weight (defined as the 
proportion of newborns weighing less than 2,500 grams (the measurement taken within 
the first hours of life, before significant postnatal weight loss has occurred)) could result 
in epigenetic and gene-expression changes that affect the risk of development of obesity 
and T2DM for the offspring. The incidence of low birth weight is higher in the South 
East Asian regions compared with developed nations. Furthermore, Indian babies are the 
smallest in the world.
 
Approximately one-third of the child born is of low birth weight 
37
. 
This has been attributed to the “thrifty phenotype” in which a low birth weight due to 
poor intrauterine growth followed by a rapid childhood weight gain due to nutritional 
transition and physical inactivity promotes development of obesity and associated 
metabolic complications
38,39
.  Pooled estimates of 14 studies involving a total of 132,180 
individuals showed that low birth weight (<2,500 g), as compared with a birth weight of 
2,500 g or more, was associated with increased risk of T2DM (odds ratio (OR) 1.32 [95% 
CI: 1.06, 1.64])
40
. 
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According to the current understanding of the pathophysiology of diabetes, both insulin 
resistance and first phase insulin secretion are the important determinants for the 
development of diabetes.  Individuals with impaired glucose regulation were 
maximally/near maximally insulin resistant and have lost almost 80% of the β-cell 
function. Therefore, decompensation of β-cell function relative to the prevailing insulin 
sensitivity is important for the development of clinical diabetes because without a relative 
deficiency of insulin production, hyperglycaemia would not occur
41,42
. In addition to the 
liver, muscle and the β-cell (triumvirate), the fat cell (accelerated lipolysis), 
gastrointestinal tract (incretin deficiency/resistance), α-cell (hyperglucagonemia), kidney 
(increased glucose reabsorption), and brain (insulin resistance, appetite regulation) all 
play important roles in the development of impaired glucose regulation (ominous octet) 
43,44
. 
1.3.1 Insulin resistance 
Insulin resistance is a conspicuous feature of the prediabetic state. Insulin resistance in 
apparently healthy individuals differs from more extreme endocrine system abnormalities 
in that there is not a complete loss of the action of insulin, but rather a relative defect in 
the insulin response in target organs, especially liver
45
.   
The obese, insulin resistant individual has disrupted pulsality of insulin secretion, higher 
plasma levels of free fatty acids and increased inflammatory cytokines
46,47
. However, the 
relationship between dysglycaemia and obesity is complex and may be modified by 
ethnicity
7
. For a given range of body mass index (BMI), age-matched, apparently healthy 
Asian Indians were more insulin-resistant, had reduced insulin clearance rate, greater 
hyperinsulinaemia and poorer lipid profile compared with white populations
7
 and are thus 
at increased risk of developing metabolic syndrome
48
. Several multi-ethnic studies have 
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found that the strength of association of diabetes with anthropometric measures might 
differ between Asians and Caucasians
49
.  
1.3.2 Pancreatic Beta cell dysfunction 
Pancreatic β-cell dysfunction is a critical determinant for T2DM and is compounded by 
insulin resistance
50,51
. Glucose is a major regulator of transcription and translation in 
pancreatic β-cells and a critical regulator of β- cell function52. A decrease in β-cell mass 
of >60% has been reported in T2DM 
53
. Multiple factors, including genetic 
predisposition
54
, gluco-lipo toxicity
55
, impaired pulsatile insulin secretion 
45
 and 
pancreatic steatosis
56
, exacerbate insulin resistance, which ultimately leads to the 
development of β-cell dysfunction 43,57,58. Finally, inefficient proinsulin processing to 
insulin
59
 and a reduction in the release of islet amyloid polypeptide, known also as 
amylin
60
, have been observed in established T2DM. In the majority of ethnic groups 
decreased 2-hr OGTT insulin levels and impaired first phase insulin secretion 
(insulinogenic index) predict conversion of IGT to T2DM
61-63
.  In addition, the first-
degree relatives of patients with T2DM exhibit impaired pulsatile insulin secretion with a 
complete loss of regular oscillatory capacity
64,65
. Therefore, novel interventions designed 
to preserve β-cell function and / or increase β- cell mass are of paramount importance to 
prevent/delay conversion of IGT to T2DM. 
1.3.3  Insulin resistance and beta cell measures in the prediction of T2DM 
From the aforementioned chapters it is clear that decreased insulin action and inadequate 
insulin secretion are central features in the pathogenesis of T2DM. Hence, the ability to 
accurately measure insulin action and/or early phase insulin secretion is of substantial 
importance to identify high-risk individuals. In order to measure insulin sensitivity and β-
cell function clinicians have used euglycaemic-hyperinsulinemic and hyperglycaemic 
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clamp techniques 
66
 and intravenous glucose administration according to a frequent 
sampling protocol (FSIVGT). However, these techniques are time consuming, invasive, 
labour intensive and not feasible in large epidemiological settings. Consequently, a 
number of simple (surrogate) indices derived from transformations or weighted 
combinations of insulin or insulin and glucose concentrations in the fasted state and at 
various time points during the OGTT have been proposed as alternate simple tools to 
measure insulin secretion and action
67-71
. In fact, several prospective and cross-sectional 
epidemiological studies demonstrate that high insulin resistance and low insulin secretion 
often precede the onset of diabetes in different race/ethnic groups with varying states of 
glucose tolerance, family history of diabetes, or obesity 
61,72-74
. Recently, prospective 
studies have shown that the product of insulin secretion and insulin sensitivity 
(disposition index), can be used to identify high-risk individuals according to the inability 
of their β-cell to compensate for the compounding insulin resistance75-79; importantly, 
disposition index appears to decline well before glucose levels rise
80
. Thus, a low 
disposition index is an early marker of inadequate β-cell function81,82. 
1.4  Diagnosis of type 2 diabetes 
The present diagnostic cut points for diabetes (fasting plasma glucose (FPG) of 7.0 
mmol/l and 2-hr post oral glucose load (OGTT) plasma glucose (2-hr PG) of 11.1 
mmol/l) are derived based on glycaemic levels above which a substantially increased 
risk of diabetes-associated microvascular complications is apparent, particularly diabetic 
retinopathy 
83,84
 (Table 1-2). These criteria exploit the observation that there appears to 
be a clear glycaemic cut-off that separates persons at high and low risk of diabetic 
retinopathy
85,86
. In 2009, an International Expert Committee that included 
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representatives of the American Diabetes Association (ADA), the IDF, and the 
European Association for the Study of Diabetes (EASD) recommended measurement of 
glycated haemoglobin, HbA1c, (the ‘A1C test’) to diagnose diabetes, with a threshold of 
≥6.5%, and the ADA adopted this criterion in 2010 87. The A1C test has several 
advantages over FPG and OGTT, including greater convenience (since fasting is not 
required), greater preanalytical stability, and less day-to-day perturbations during 
periods of stress and illness. Recently, a data-pooling analysis of nine studies from five 
countries with 44,623 participants aged 20 –79 years with gradable retinal photographs 
from DETECT-2 collaborators suggests that the current FPG level for diagnosis of 
diabetes should be lowered to 6.5 mmol/l and that an A1C of 6.5% (47.5 mmol/mol) is a 
suitable alternative diagnostic criterion
88
. 
Based on the current recommendations from the World Health Organization (WHO), 
pre-diabetic states may also be distinguished as: IFG with a range of FPG of 6.1–6.9 
mmol/L (in the absence of IGT) and IGT defined as 2-hr PG of 7.8–11.0 mmol/L based 
on the 75g glucose load OGTT, or a combination of both. The ADA also recommends 
using HbA1c 5.7-6.4% (38.8-46.4 mmol/mol) for diagnosis of pre-diabetes (using the 
term ‘category of increased risk for diabetes’) 84. 
 
 
 
 
Chapter-1 
 
13 
 
Table 2-2: Diagnostic criteria for type 2 diabetes 
Diabetes test Diagnosis 
of diabetes 
Prediabetes 
/ IGT / IFG 
HbA1c (%; mmol/mol) * 
Using a method certified by NGSP and 
standardized to the DCCT assay
89
; or 
≥6.5% 
(47.5) 
5.7-6.4 
(38.8-46.4) 
Fasting plasma glucose (mmol/l) * 
(Fasting is defined as no caloric intake for at least 8 
hrs) or 
≥7.0 6.1-6.9** 
2-hr plasma glucose (mmol/l) (OGTT) * 
The test should be performed as described by the 
WHO, using a glucose load containing equivalent 
of 75 gms of glucose dissolved in water; or 
≥11.1 7.8-11.0 
Random blood glucose (mmol/l) 
In a patient with classic symptoms of 
hyperglycaemia  
≥11.1 7.8 
*: In the absence of unequivocal hyperglycaemia, criteria 1–3 should be confirmed 
by repeat testing. NGSP: National Glycohemoglobin Standardization Program; 
DCCT: Diabetes Control and Complications trial; OGTT: oral glucose tolerance; 
IGT: impaired glucose tolerance; IFG: impaired fasting glucose.  
Table adopted from 
84
;  
**: IFG diagnostic criteria for ADA: 5.6-6.9 mmol/l.
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The existing glucose-based diagnostic tests, FPG and the 2-hr PG derived from the 
OGTT, though they are rapid and inexpensive, have well-known performance limitations 
90,91
.   The observed variability in the course of prediabetes is mostly because of inherent 
variability in glucose tolerance (particularly as evaluated by the OGTT). Although, 
determination of HbA1c was a better and alternate marker for chronic hyperglycaemia, it 
must be stressed that HbA1c measurement alone is not a sufficiently reliable tool for 
recognizing particularly the early stages of T2DM or prediabetes. For instance, analyses 
of the U.S. National Health and Nutrition Examination Survey (NHANES-3) data from 
2005-2006 indicate that, assuming universal screening of the undiagnosed, the A1C test 
cut point of ≥6.5% (47.5 mmol/mol) identifies one-third fewer cases of undiagnosed 
diabetes than a fasting plasma glucose cut point of ≥7.0 mmol/L92. Similar observations 
were also noted in other studies
93-95
. In essence, HbA1c  is  an alternative marker  for 
microvascular risk, but it a weak  marker  to identify undiagnosed diabetes
96
.  
1.5 Economic burden of treating diabetes 
T2DM poses a huge fiscal burden on national health care systems 
97
. The IDF estimated 
that the global annual health expenditure due to diabetes in 2013 has been more than 
$578 billion
1
. This health care expenditure may continue to increase if diabetes 
continues to be undiagnosed within an appropriate time. Globally, 174.8 million of all 
diabetes cases in adults are estimated to be undiagnosed
98
. India, accounts for nearly 
31.9 million cases of these cases. A study  based on the American population showed 
non-diagnosing diabetes in patients resulted in expenditure of an additional $18 billion 
in healthcare costs per year 
99
.  Thus, early identification and prevention of diabetes at 
initial stages is paramount for public health priority to prevent diabetes-associated 
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complications and disability. There is also a huge disparity in diabetic healthcare 
spending between age groups, gender, regions and countries. For instance, the average 
cost of treating diabetes in the USA is $9800 / person; whereas it is $84.4 for a patient 
living in India (i.e. less that 1% of the expenditure in the USA) 
1
. Therefore, the 
challenge is immense, particularly in developing countries like India, which are 
undergoing rapid socioeconomic transition, directly linked with the adoption of a 
“Western lifestyle”, mainly in terms of diet and physical activity habits. 
1.6 Need for the prevention of diabetes 
The enormous human and financial costs that accompany T2DM, and the challenge of 
treating it effectively once it has developed, make it an appropriate target for 
prevention
100
. Identification of individuals at high-risk of developing T2DM, especially 
at the prediabetic stage is itself the pre-eminent strategy to prevent diabetes and its 
associated complications. It is to be noted that prediabetes is not a benign condition. In 
addition to the risk of progression to diabetes, the presence of prediabetic condition can 
itself increase risk for vascular complications that traditionally are attributed to diabetes. 
For instance, data from the DPP research group showed that 7.9% of individuals with 
IGT and 12.6% with newly diagnosed diabetes were affected with non-proliferative 
diabetic retinopathy
101
. Several prospective and cross-sectional studies have 
demonstrated an increased risk of neuropathy and cardiovascular risk in individuals with 
prediabetes 
102
. Hyperglycaemia is a well-established risk factor for cardiovascular 
disease
103
. A meta-analysis of 34 prospective studies showed a modest association 
between increased cardiovascular disease risk and prediabetes 
104
. Thus, prevention of 
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diabetes by modalities that prevent or delay the conversion of prediabetes to T2DM is 
the need of the hour to reduce the global burden of diabetes. 
Primary prevention is defined as the prevention of a disease by controlling modifiable 
risk factors through population prevention programs
105
. Primary prevention strategies are 
broadly classified as: a) downstream programs which target individuals having the 
highest risk of the disease (e.g, prediabetes or obesity); b) midstream approaches which 
target populations or communities found to be at increased risk of diabetes (eg, Pima 
Indians, Asian Indians); and c) upstream programs which target the whole population, 
which include public policy and environmental interventions planned to increase the 
support for maintaining a healthy lifestyle. The high risk / downstream program approach 
is the appropriate strategy for primary prevention of diabetes. For identification of high-
risk individuals, non-invasive multivariable risk scores derived from age, gender, weight, 
family history of T2DM and physical activity 
106-110
 have been found to be simple and 
economical as the cost of screening by blood tests in large numbers can be avoided. 
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1.7 Prevention of diabetes 
Table 1-3 shows the details of the major diabetes prevention studies that used lifestyle 
modification as an intervention. The Finnish Diabetes Prevention study (DPS) 
111
 and 
American DPP 
112
 found that the risk of T2DM could be reduced by 58% in individuals 
with IGT over a period of 3 years compared with control. Similar results were also 
observed in Swedish 
113
, Chinese 
114
 and Japanese 
115
 populations. The results from 
Indian Diabetes Prevention Programme-1 (IDPP-1), a community-based, randomized, 
controlled study in 531 participants with persistent IGT (421 men and 110 women) 
showed that diabetes is preventable in high-risk, comparatively lean, Asian Indians. The 
study aims were to find out whether the progression to diabetes could be postponed by 
interventions using lifestyle modification by repeated personal contacts, metformin, or a 
combination of both in Asian Indians with IGT who were younger, leaner, and more 
insulin resistant than the Caucasian population. The results at the end of 30 months 
follow-up showed that all three modalities of intervention were equally effective 
(relative risk reduction approximately 28.5%). There was no additional benefit by 
combining lifestyle modification and metformin
116
. 
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Table 2-3: Landmark primary prevention studies using lifestyle modification in primary prevention of diabetes 
Study 
*
 
Study population 
characteristics 
No of patients by 
treatment group 
Duration 
(Years) 
Lifestyle goals 
Cumulative 
incidence (%) 
RRR (%) 
Da Qing 
Study 
(1997)
114
 
 
 
 
Chinese  
Mean BMI: 26 
Mean Age: 45 
Control: 133 
Diet: 130 
Exercise: 141 
Diet + Exercise:  
126 
Mean, 6 
 
 
 
 
 
Weight loss and maintenance of  
healthy diet and / or exercise 
Control: 67.7;  
Diet: 43.8 
Exercise: 41.1 
Diet + exercise: 46 
Diet: 31 
Exercise: 46 
Diet + 
exercise: 42.0 
Diabetes 
Prevention 
study 
(2001)
111
 
Finnish, White 
Mean BMI: 31.1 
Mean Age: 55.0 
Control: 257 
Intervention: 265 
Mean 3.2 Reducing weight, total intake of 
fat, and intake of saturated fat and 
increasing intake of fibre and 
physical activity. 
Control: 23 
Intervention: 11.0 
58.0 
DPP Research 
Group 
(2002)
112
 
Multi ethnic: 3234 
Mean BMI: 34.0  
Mean Age: 50.6 
Control: 1082 
Intervention: 
1079 
Median, 
2.8 
7% weight loss + 150 min 
exercise per week 
Control: 11 
Intervention: 4.8 
(Effective in Asian 
American) 
54.0 
Indian 
Diabetes 
Prevention 
Programme-1; 
(2006) 
116
 
Asian Indian 
Mean BMI: 25.8 
Mean Age: 45.9 
Control: 136 
Intervention: 133 
Median, 
2.6 
Weight maintenance by 
restricting refined carbohydrates 
and fat + 30 min exercise 
Control: 55 
Intervention: 39.3 
28.5 
Japanese 
Prevention 
Programme. 
(2005)
 ** 115
 
Japanese Men 
Mean BMI: 23.5 
Mean Age: 51.5 
Control: 102 
Intervention: 356 
Mean, 
4.0 
Reduction in BMI to ≤22 kg/m2 
by 30–40 min exercise per day 
Control: 9.3 
Intervention: 3.0 
67.4 
BMI: Body mass index; RRR: relative risk reduction; *:All study population had impaired glucose tolerance at the baseline of the study; **: in this 
study, the oral glucose tolerance test used 100g glucose and modified criteria for recruitment. 
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1.8 Prediction of diabetes 
Identification of the prediabetic stage (IGT and IFG) has been used to identify individuals 
with high risk for T2DM. Indeed, all the major landmark primary prevention studies that 
have evaluated intervention strategies for preventing T2DM have recruited individuals 
with IGT
111,112,114-116
 for assessing the benefits of intervention strategies. However, in 
large, prospective, epidemiological studies, only ~ 30-40% of the individuals with 
IGT/IFG develop overt T2DM eventually
117-119
. Furthermore, ~40% of individuals who 
develop T2DM  have NGT at baseline 
117
. This limits the use of IGT/IFG as the sole 
means to identify individuals at high risk for T2DM.  
Dysregulation of many biological pathways leads to the development and progression of 
T2DM
120
. The measurement of glucose alone cannot reflect the complexity of metabolic 
disorders arising from a combination of excessive adipose tissue
121
, peripheral insulin 
resistance
120, dysfunctional pancreatic β- cells122, increased free fatty acids123,124, 
impaired incretin effects
125
, abnormal glucagon secretion
126
 and obesity-induced 
inflammation
127,128
. Hence, it is imperative to identify simple, inexpensive and accurate 
predictive markers to identify high risk individuals.  
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1.9  Structure and overview of thesis: 
In the context of diabetes prevention it is important to identify improved strategies to 
disseminate the principles of lifestyle modification to the individuals at high risk of 
developing T2DM. Importantly, it is imperative to identify simple, routinely measurable –
“predictors” and novel biochemical markers for better identification of the progressive 
pathogenesis of diabetes.  
The main objectives of this thesis are: 
 To determine whether lifestyle advice through mobile phone text messaging could 
reduce incident diabetes in Asian Indian men with prediabetes compared with 
standard lifestyle advice.  
 To identify the association of glycaemic measures, and routine measures such as 
gamma-glutamyl transferase, enlarged waist, hypertriglyceridemia and surrogate 
insulin measures with incident diabetes. 
 To unravel the association of mechanistic biomarkers such as adiponectin, leptin, 
retinol binding protein-4, interleukin-6 and Vitamin D3 with incident diabetes. 
 
This thesis is structured around five chapters to achieve the above research objectives. 
Each of these chapters is described separately, as a standalone chapter with relevant 
background information, statistical methods and in-depth discussion. Below is the brief 
description of the content of all following chapters: 
 
 Chapter-2: Study design and methods 
 Chapter-3: Primary and secondary outcomes of the study and mechanism of 
action of intervention. 
 Chapter-4: Association of classical risk factors (glycaemic markers, liver 
enzymes, hypertriglyceridaemic waist and surrogate insulin measures) with 
incident diabetes was studied. 
 Chapter-5: In a small nested, case-control study, the association of novel risk 
factors (adipokines and 25-hydroxy vitamin D3) with incident diabetes was studied. 
 Chapter-6: overall summary and conclusions. 
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 2 METHODOLOGY 
2.1 Study design 
This was a prospective, parallel-group, randomised controlled trial at 10 sites in southeast 
India between Aug 10, 2009, and Nov 30, 2012. Total duration of the study was 2 years 
with 6 monthly reviews. The trial synopsis is shown in Table 2-1. In total, individuals 
with impaired glucose tolerance (IGT) on two repeated occasions at baseline were 
randomly allocated either into: arm:1 - control arm, which received standard care advice at 
baseline only; and arm:2- an intervention arm that received automated, repeated 
motivational messages about healthy lifestyle habits in addition to the standard lifestyle 
advice (ClinicalTrial.Gov no: NCT00819455).  
2.2 Objectives 
The primary objective was to assess the  effect  of  educational  and  motivational  text  
messaging  (short  message  service,  SMS)  by mobile phone in reducing incident cases of 
diabetes among prediabetic individuals. Secondary objectives were to study the 
improvements in:  (1)  body  mass  index (BMI)  (kg/m
2
); (2)  waist  circumference  (cm);  
(3)  systolic  and diastolic blood pressure (mmHg); (4) lipid profile - total and high density 
lipoprotein cholesterol (mmol/l);  (5)  serum  triglycerides  (mmol/l);  (6) dietary  energy  
intake  by  24- hr  food  recall  diary (kcals);  and (7) physical activity score by 
questionnaire  in the intervention group compared with control group. Acceptability of 
SMS by the participants was assessed during the follow-up visits in the intervention arm 
only. 
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Table 2-1: Trial synopsis 
Title: The Role of Information Technology in the Primary 
Prevention of Type 2 Diabetes (NCT00819455) 
Principal Investigators: Prof. Dr. A. Ramachandran (IDRF) 
Prof. Desmond G Johnston (Imperial college, London) 
Funding source: India Diabetes Research Foundation (IDRF) & Dr. A. 
Ramachandran’s Diabetes Hospitals, India 
Collaborators: Imperial College, Faculty of Medicine, London 
Sponsors: United Kingdom India Education Research Initiative 
(UKIERI), British Council, UK 
Trial design: Prospective, Parallel design, randomized, controlled trial 
Population: Asian Indian men; middle class, industrial workers 
Main inclusion criteria: Non-diabetic; Age: 35 – 55 years; BMI ≥ 23.0 Kg/m
2
; 
positive family history; ability to read messages; sedentary 
lifestyle. 
Main exclusion criteria: Known diabetes; physical conditions impeding exercise 
such as arthritis, knee surgery, physically challenged etc., 
known serious illness (cancer, heart problems); mental 
illness; illiterate. 
Study arm: Standard advice: Received personalized education and 
motivation on healthy lifestyle principles and written 
information on diet and physical activity. 
Intervention: Received personalized lifestyle advice at 
baseline. Also, the intervention group received educational 
and motivational messages through tailored text messages at 
frequent intervals for two years. 
Planned sample size: Standard advice: 257; Intervention: 257 
Study Duration: Two years (6 months interim visits) 
Primary objectives: 
 
The effect of educational and motivational text messaging 
(short message service, SMS) by mobile phone in reducing 
incident diabetes among prediabetic individuals. 
Secondary objectives: Improvement in body mass index; waist circumference; 
systolic and diastolic blood pressure; total and HDL 
cholesterol; triglycerides; dietary energy intake and physical 
activity by questionnaire; overall compliance with lifestyle 
advice. 
Endpoint: Conversion to diabetes 
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2.3 My responsibility 
Field visit: 
 Site identification and contacting the occupational health officers and 
administrative officials. 
 Involved in the field visit throughout the study. 
Message construction and questionnaire development: 
 Assist psychologist with the questionnaire development (thoughtful inputs to 
improve / simplify the transtheoretical model inventory and SMS acceptability 
questionnaire(contribution- my role: 30%; psychologist:40%; dieticians and 
physicians: 30%)). 
 Assist psychologist in text messages development (simplifying the messages, 
provided study materials for adding the messages, construction of diabetes 
awareness messages (contribution- my role: 30%; psychologist:40%; dieticians and 
physicians: 30%)). 
 Involved in the development of web-based software algorithm for sending the 
messages (created proto-type along with Intel corp, Bangalore, India (contribution-
my role: 30%; software personnel: 70%). 
 Conceptualized, implemented and helped in the development of computerized diet 
inventory tool (contribution-my role: 50%; software personnel: 30%; dietician: 
20%; complied with the national institute of nutrition, India ) 
 Grouping of the participants according to transtheoretical model stages (already 
scored by the psychologist) in the website and delivery of the text messages to the 
intervention group participants (contribution-my role: 60%; psychologist : 40%. 
Database management: 
 Created spreadsheet template specific for this study to capture all the data 
efficiently with appropriate data entry validations (automatic coding, data 
validation and conditional formatting of the data). 
 Data entry (screening, randomization and follow-up visits data); in charge of 
complete database (to date). 
Biochemistry and data analyses: 
 Blood sample collection, separation, aliquoting and storage. 
 Biochemical estimations specific for this trial. 
 Conceptualized and created automated laboratory reports (given to the participants) 
specific for this trial. 
 Setting up the laboratory (research) and estimation of biomarkers. 
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 Statistical data analysis (planning and performance of main paper results; 
conceptualization and statistical analysis plan for subsequent ancillary post hoc 
data analysis) 
2.4  Study population 
In order to recruit participants with IGT, 10 private and public sector organisations with a 
large number of employees (>500) in Chennai, Tamil Nadu and Visakhapatnam, Andhra 
Pradesh, India were identified. Because > 96% of the employees were men, we included 
only men in the trial.  Initially, we planned to recruit along family members into the trial 
however this could not be implemented owing to the differences in the randomization 
allocation procedures (cluster randomization, with permuted blocks of random size and 
number of participants in the family [one vs more than one]) involved in recruitment. 
Furthermore, the intervention principles employed in this trial was based on the healthy 
lifestyle changes in an individual rather than that of family based intervention techniques. 
Participants’ jobs were self-classed as unskilled, skilled, clerical or executive.  
2.5 Eligibility criteria and screening 
At baseline, eligibility criteria were: no diabetes (self-reported) or major illness, such as 
cancer, chronic liver or kidney disease; no disorders with cognitive impairment, severe 
depression or mental imbalance; no physical disability that would prevent regular physical 
activity; no recruitment in another trial; age 35–55 years; ownership of a mobile phone and 
ability to read and understand mobile phone messages in English; a positive family history 
of type 2 diabetes (T2DM); and a BMI of 23 kg/m² or more. 
After screening for eligibility, capillary blood glucose was measured with a glucometer 
(Accu-Check Sensor, Roche Diagnostics, Mannheim, Germany) at the participants’ 
workplace 2-hr after consuming 75 g oral glucose. 
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2.6  Confirmatory oral glucose tolerance test / Recruitment 
During the confirmatory oral glucose tolerance test (OGTT), we collected venous blood 
samples at fasting, at 30 min and 2-hr after 75 g glucose consumption; study staff checked 
to make certain that all of the solution was consumed. Blood was collected into an EDTA 
and serum tube, was centrifuged for 20 minutes at 2000 RPM at room temperature, and 
frozen to -20°C until the sample was assayed for biochemical, insulin and for the 
estimations of biomarkers. Two-hour plasma glucose (2-hr PG) was estimated using a 
glucometer (Accu-Check Sensor, Roche Diagnostics, Mannheim, Germany) at the 
participant’s place of work using a drop of venous blood collected during the OGTT.  The 
correlation between the glucometer (capillary blood glucose measurement) and venous 
plasma glucose values were tested in 100 blood samples and it was found to be highly 
correlated (r=0.91, P<0.0001 with coefficient of variation (CV) 4.9%) between the 
readings.  
2.7  Ethical statement 
All participants provided written informed consent prior to baseline assessments (see 
appendix-1). The informed consent process involved communicating information about 
the study aims, procedures, expectations, confidentiality, risks, and benefits associated 
with participating in the research study. The risks to participants in this study were 
minimal and included lab assessments that could cause slight discomfort (e.g., blood draw) 
as well as questions about behaviours and feelings that could cause psychological distress. 
Benefits included receiving results from study assessments. The study protocol was 
approved by the Ethics Review Committee of the India Diabetes Research Foundation, 
Chennai, India. All the study data were stored (with restricted access) in locked file 
cabinets. 
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2.8 Randomisation and masking 
A central investigator not involved in analysis of trial data used a computer-generated 
randomisation sequence (Matlab randperm version 6) based on Marsaglia’s algorithm129 to 
randomly allocate patients (1:1) to individually-tailored mobile phone messaging or to a 
control group that received standard lifestyle modification advice at baseline only. 
Laboratory personnel and principal and co-investigators were masked to the participants’ 
group allocation until the end of the study. Field staff and participants were, by necessity, 
not masked. 
2.9  Lifestyle advice 
Although the study was conducted in two different states of the country, the participants’ 
lifestyles were similar with regard to diet and physical activity practices owing to the 
proximity of the geographical location. During recruitment, all participants were educated 
on the causes, effects, symptoms, treatment, and management of diabetes, they were also 
educated on the possibility of preventing or delaying the onset of T2DM. The participants’ 
queries regarding diet and physical activity were answered and beliefs regarding diabetes 
were also clarified.  
The participants were randomly allocated into control (standard lifestyle advice only at 
baseline) and intervention (individually tailored TTM based text messages for two years) 
group. 
The standard lifestyle advice followed a holistic approach, taking the following key 
healthy lifestyle factors into consideration, as explained by the nutritionist: healthy and 
unhealthy food products, foods to be avoided or limited, the benefits of vegetables and 
fruits; the ill effects of sweets, sugars and carbonated drinks were also explained. The 
amount of oil to be consumed by a family based on their family size was also explained. 
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Their daily nutrient intake was assessed by 24h recall method. Based on the self-reported 
diet practices, all subjects were given an individualized written diet chart to achieve the 
desired goals. These goals were to reduce portion size (total calories) and, to avoid simple 
sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, 
include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits). Subjects 
who had been following these healthy diet practices were encouraged to continue the same 
and changes were recommended if there was a need to change their diet habit. The details 
of the diet prescription are given in table 2.2. 
Participants were educated on the benefits of physical activity. The physical activity 
advice was intended to be simple and easy to follow and was tailored to the participant’s 
present activity level. In sedentary subjects, the recommendations were to initiate or 
enhance aerobic exercise like walking, cycling, and jogging in sedentary subjects. Brisk 
walk for minimum 30 minutes per day (or equivalent) on all days, or at least five days a 
week; walk 3 – 4 km in 30 min at least 5 days a week; cycle 6 -7 Km in 30 min at least 5 
days a week. If the participant’s occupation involved strenuous work or if participants 
were already engaged in walking or cycling for more than 30 min a day the advice given 
was to continue the same. Sedentary participants were advised to initiate physical activity, 
participants with light activity were advised to increase physical activity and participants 
were asked to maintain the level in order to achieve and maintain ideal bodyweight and 
glycemic improvement. The prescribed physical activity and diet recommendations are 
shown in table 2.2 and were similar to those used in a previous trial in India
116
.  
Participants, both in the control and intervention groups, were advised to achieve healthy 
lifestyle goals at baseline. The goals comprised of: a) decreased consumption of 
carbohydrates; b) decreased consumption of oil; c) decreased portion size; d) decrease in 
BMI of at least 1 unit (1 kg/m
2
) from baseline; and e) to sustain good physical activity. At 
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the end of the follow-up, the number of goals scored were calculated according to 
participants’ success in achieving the lifestyle principles (success score between 0 and 5) 
using standard procedures. For those who developed diabetes, the values at the time of 
diagnosis were considered as the final data.  
Individuals were given a grade for achieving each goal of the intervention at the end of the 
study (with “0” indicating goal not achieved and “1” indicating the goal achieved), and a 
success score was computed as the sum of these grades. The possible association between 
incidence of diabetes and lifestyle goals achieved was calculated using logistic regression 
analyses. The success score of ≥ 3 goals was compared with < 3 goals (reference category) 
after adjusting for baseline values of age, BMI and 2-hr PG. Since both the groups 
received standard lifestyle advice at baseline, the intervention and control groups were 
pooled together for this analysis. 
After prescribing lifestyle changes, we reassessed all participants clinically and 
biochemically every 6 months from baseline. No additional lifestyle information or advice 
was routinely given by personal contact after the baseline visit in either the control or the 
intervention groups, except in response to specific queries from participants. 
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Table 2-2: Dietary advice and physical activity recommendations to the participants 
Dietary advice: 
 
The dietary recommendations were individualized to balance food intake and physical 
activity and to maintain appropriate body weight. The advice includes:  
a) Avoid simple sugars and refined carbohydrates 
b) Reduce total fat intake (not to exceed 20 g/day) 
c) Restrict use of saturated fat 
d)  Include more fibre-rich food – whole grains, legumes, vegetables and fruits. 
 
Dietary adherence: 
 Poor: not following the advice for more than 5 days a week (non-adherent) 
 Fair: occasional deviation, following advice for 2-4 days a week (adherent) 
 Good: strictly following diet advice for more than 5 days a week (adherent) 
 
 
Physical activity recommendation: 
 
a) To enhance aerobic exercise like walking, cycling and jogging in sedentary 
individuals  
b) Brisk walk for a minimum of 30 min/day (or equivalent), as a realistic goal which 
has proven efficacy 
c) Walking 3 – 4 Km in half an hour at least five days a week  
d) Cycling 6 – 7 Km in half an hour  
e) If occupation involves strenuous work , no specific advice  
 
Physical activity adherence 
 Poor: less than 150 min per week (non-adherent) 
 Fair: 150-250 min per week (adherent) 
 Good: more than 250 min per week or if occupation involved strenuous work 
(adherent) 
Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013 
130
. 
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2.10 Text messaging (intervention) 
Both control and SMS groups received lifestyle recommendations at baseline as described 
above. Only the latter subsequently received educational and motivating SMS at frequent 
intervals.  
The SMS content at any time was based on the transtheoretical model (TTM) stages of 
change, based on the following principles.  The TTM model explains how people vary in 
terms of motivational readiness to quit unhealthy behaviour and move through specific 
stages for behaviour change. The TTM consists of 5 stages of change (precontemplation, 
contemplation, preparation, action and maintenance) developed by Prochaska and 
DiClemente 
131,132
. Each stage is unique in its characteristics:  Precontemplation: no 
awareness of the benefits of healthy lifestyle, hence no change;  contemplation: aware but 
has not taken any realistic steps toward the goal, intend to change in the next six month; 
preparation: working out strategies to meet the desired goal;  action: practicing healthy 
lifestyle for less than six months duration;  maintenance: following healthy lifestyle more 
than six months and working to prevent relapse to the previous stage. 
According to this model, people use both cognition and behavioural strategies and 
techniques to progress through these 5 stages which are described as process of change. 
The first 3 stages involve changes at the cognitive level, including: 
 Create awareness and increase awareness 
 Awareness raising of the ill effects associated with unhealthy lifestyle 
 Impact of unhealthy lifestyle on his or her family, friends and at the community 
level 
 Benefits of healthy lifestyle 
 Increase awareness of opportunities for physical activity and healthy diet practices. 
 The fourth and fifth stage involves changes at the behavioural level including: 
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 To adhere to healthy lifestyle even when stressed out or tired or when there are 
opportunities to slip down 
 To associate with people who aspire to achieve similar goals 
 To reward or reinforce themselves when achieving desired goals 
 To stay more active and follow healthy diet 
 To avoid cues for unhealthy lifestyle and to leave reminders for healthy lifestyle 
 
An essential aspect of this work was to define a subject’s TTM stage with respect to 
physical activity and dietary habits. In order to assess the effect of tailored text messages 
in transitions in TTM stages in the intervention group and to compare them with the 
control group, the researcher constructed a project-specific TTM inventory. This 
comprises a questionnaire of 20 items, 10 items each to determine the participant’s TTM 
stage in relation to dietary habits and physical activity practices (appendix) .  
A two stage pilot study was conducted in the development of this tool. The first stage of 
the pilot study was conducted among 10 members of the study team. Modifications were 
made based on the feedback and suggestions from the team members about the items. The 
second stage pilot study was conducted among 40 non-diabetic volunteers and further 
modifications were made based on the response from these non-diabetic volunteers. The 
present version of the questionnaire was approved to be used in this study after ‘face 
validation’ (comprising an expert assessment tool, viewed as covering the concept it 
proposed to measure) by two health psychologists.  
It is well-documented that TTM model is a widely applied behavioural theory in health 
research, however there is no sufficient data to show the usage of the Prochaska’s 
originally developed TTM questionnaire in healthy behavioural lifestyle research. Hence 
the researcher developed the questionnaire specifically to meet the study objective. 
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According to Prochaska’s stages of change model, duration of lifestyle practices 6 months 
is the criterion to decide the subject’s TTM stage on a particular behaviour. The 
questionnaire was developed taking duration of diet and physical activity practices into 
consideration but although duration of an individual’s habits is the major criteria for stage 
assessment, additional questions were posed to ascertain their actual diet and physical 
activity practices. These additional questions are called lie scales. Lie scales are the set of 
items or questions included in a psychological evaluation to ascertain whether or not the 
respondent has been truthful in answering the other items in the questionnaire. The 
responses to the questions are yes or no format. Question numbers 1, 3, 6 and 9 assesses 
the participants TTM stage, and the other 6 questions are lie scales. Similar questionnaire 
was constructed to assess the TTM diet stages of change. The questionnaire and scoring 
key are given in the appendices. 
2.10.1 TTM based message construction 
The SMS content at any time was based on the transtheoretical model (TTM) of 
behavioural change
131,132
. A TTM stage-based SMS delivery manager algorithm was 
created in a partnership with the Intel Corporation, India (C# programming language). The 
SMS messages were delivered by a commercial service provider (Unicel technologies, 
India). They contained <160 characters and there were 60-80 messages for each TTM 
stage, with simple words and easy to understand. The SMS content was on the causes, 
effects and prevention of diabetes and other associated lifestyle diseases. SMS messages 
on benefits of healthy lifestyle, pros and cons of changing and not changing the behaviour; 
cues to initiate or start physical activity and overcome unhealthy dietary habits were 
delivered. Strategies to avoid or overcome relapse to the previous unhealthy behaviour and 
to sustain healthy lifestyle were also included. In general, the objective of the SMS was to 
create awareness, assist, guide and support the individual to change unhealthy lifestyle and 
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motivate to move across stages by providing various cues and strategies to follow and 
remain motivated throughout the life. It was constructed based on the fact that  participants 
would not normally receive the same message in a 6 month period (based on their 
receiving 2-4 messages per week).   
2.10.2 Concepts in the development of text messages 
As mentioned earlier, TTM is the underlying behavioural theory in this intervention. It 
consists of 4 core constructs; the “stages of change”, “process of change”, “decisional 
balance”, and “self-efficacy”. The stages of change (precontemplation, contemplation, 
preparation, action and maintenance stage) is the main construct of this model which 
explains the steps involved in progressing to the desired behaviour. Although, stages of 
change is the major construct of this model which demonstrates the benefit of SMS 
through change in subject’s progression and regression between stages, the process of 
change explains how people change their behaviour. The detailed description of the 
processes of change is shown in table 2.3. Briefly, processes of change include ten 
cognitive (i.e. involving thinking) and behavioural (i.e. involving action) strategies that 
can help subjects’ to make changes and maintain them. The cognitive processes include; 
consciousness raising, dramatic relief, environmental re-evaluation, self-re-evaluation, 
social liberation. The behavioural processes of change are counter conditioning, helping 
relationships, reinforcement management, self-liberation, and stimulus control. These 
strategies state that, different strategies (process) are most effective and relevant at 
different stages of change when people move from one stage to the other. For example, 
counter-conditioning and stimulus control can really help people in the action and 
maintenance stages, but these processes are not helpful for someone who is in the first 
three stages. 
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Table 2-3: Transtheoretical model - the processes for each stage of change 
Stages Process of change Explanation 
Precontemplation 
to 
Contemplation 
Consciousness raising Increased awareness of causes, 
consequences, and cues to 
overcome the problem; increasing 
information about self and the 
unhealthy behaviour 
Dramatic relief   Experiencing and releasing 
feelings about the possible 
consequences of the behaviour; 
using feelings to help motivate 
change. 
Environmental 
re-evaluation 
Cognitive and affective 
assessments of how the presence 
or a absence of the behaviour 
affects one’s social  environment; 
becoming aware that one can serve 
as a positive or negative role 
model to others 
Social liberation Recognizing changes in the 
environment or social changes that 
influence personal change 
Contemplation 
to 
Preparation 
Self re-evaluation Cognitive and affective 
assessments of the subject’s self-
image with and without behaviour 
in order to change how one thinks 
about oneself in relation to the 
behaviour 
Preparation  
to 
Action 
Self-liberation Recognizing choices related to 
available actions and making a 
commitment to change a 
behaviour 
Action  
to 
Maintenance 
Reinforcement 
management 
Applying consequences in the 
form of rewards to oneself for 
making changes 
Helping 
relationships 
Seeking and accepting support 
from others in the form of caring, 
trust, acceptance, and openness 
Counter 
conditioning 
Learning new and healthier 
alternative behaviours to substitute 
for the unhealthy behaviour 
Stimulus control   Avoiding or removing 
environmental cues for unhealthy 
behaviour and adding cues for 
healthier alternatives 
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2.10.3 Validation of the SMS 
The investigator compiled the messages as a comprehensive list of short statements (the 
SMS) which incorporate five cognitive and five behavioural strategies of processes of 
changes. The messages covered both physical activity and dietary dimensions. The SMS 
were validated by the following validation process method. The SMS were analyzed by 5 
expert psychologists, specialized in health psychology, psychological training assessments 
and psychometrics. In the first step, the experts were asked to rate each message for its 
loading as a cognitive or behavioural component. The ratings were collected based on 
concurrence for each item, the higher the concurrence the more valid the message. In the 
next step, the experts were asked to classify the SMS in any one of the ten process 
strategies based on the principle that the processes differ when people move from one 
stage to the other. For example, cognitive processes of change (consciousness raising, 
dramatic relief, environmental re-evaluation, social liberation and self-re-evaluation) are 
relevant for the first three stages and behavioural processes (reinforcement management, 
helping relationship, counter conditioning, stimulus control and self-liberation) are 
relevant for the action and maintenance stage. Messages were written taking the 
characteristics of the above variables into consideration. 
The details of the message construction along with the examples of the messages were 
given below: 
2.10.3.1 Pre-contemplation: 
Pre-contemplation is the stage in which an individual has no intent to change behaviour in 
the near future, usually defined as the next six months. Individuals at this stage may not be 
informed or may lack information about the consequences of their behaviour, or they have 
attempted to change their behaviour and failed and, therefore, are demoralized in their 
ability to change their behaviour. These people are often characterized as resistant or 
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unmotivated and tend to avoid information, discussion, or thought with regard to the 
targeted health behaviour
132,133
. 
Example messages – physical activity 
 Walk for 60 minutes a day 
 Regular walking keeps you healthy and fit 
 Exercise helps to reduce the risk of heart disease 
 Physical activity helps to maintain normal blood sugar and blood pressure 
 Lifestyle modification enhances quality of life 
 Active life makes you live longer 
 Physical activity is good for your heart. 
Example messages – Diet 
 Eat healthy, be healthy and be happy 
 Too much of anything is bad 
 Regular eating pattern helps to maintain normal blood sugar 
 Moderate use of starchy food, oil, sweets and sugars are advisable 
 Do not skip any meal 
 Fruits have antioxidants, vitamins, minerals which are essential for daily life 
 Maintain good health 
2.10.3.2 Contemplation  
Contemplation is the stage where individuals openly state their intent to change within the 
next six months. The individuals have increased awareness of the benefits of changing but 
are still considering the cost involved in changing the behaviour. These people are 
seriously undecided to change and are stuck at this stage for a longer period of time. They 
are also known as contemplators or procrastinators and are often not ready for traditional 
action-oriented programs
132,133
. 
Example messages – physical activity 
 Moderate physical activity keeps you healthy 
 Feeling bored, go for a walk 
 Desk-bound job? Take short walk to relax your body and mind 
 Actively apply your body muscles to some tasks (running, swimming, sports, 
stair climbing and stretching) for good health 
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 Ideal young man becomes unhappy old man, be active always 
 A good exercise can keep you mind fresh 
Example messages – Diet 
 Avoid snacks while watching T.V. you may over eat 
 Take timely food and avoid over eating 
 Intake of fruits, best natural protection against high BP and high cholesterol 
and there by prevent heart diseases 
 Neither fast nor feast, have a balanced diet 
 Avoid sweets and sugars in any forms as it increase your blood sugar 
2.10.3.3 Preparation 
Preparation is the stage in which the person intends to take steps to change, usually 
occurring within the next six months. These individuals have attempted some important 
action in the past and most often have a plan of action, for example attending health 
education classes and talking to the counsellor. These are the people who are best suited 
for action-oriented programs. However, the individuals have not met the criteria for 
effective action and can be considered as at the early stirrings of the action stage
132,133
. 
Example messages – physical activity 
 Use stairs instead of lift 
 Park you vehicle at far end of the parking area and walk to your 
destination 
 Walk to the place of worship or market, which is close by 
 Include walking /  cycling as part of the daily routine like going to 
market, place of worship or even to your office 
 Choose a form of exercise that suits your interest 
Example messages – Diet 
 Starchy and oily foods need to be consumed in moderate 
 Increase fibre rich foods, fruits and vegetables and whole cereals 
 Do not skip any meal, you may over eat at the following meal 
 Make your plate colourful by adding lot of vegetables 
 Eat one fruit daily as a snack 
 Avoid over eating at any meal 
 Fruits are delicious and nutritious; include them as part of your diet 
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2.10.3.4 Action 
Action stage refers to when people made overt modifications in their lifestyles within the 
past six months. Individuals must meet the criteria agreed by professionals to reduce the 
risk of a disease. Action is defined as the most explicit behavioural transformation and 
needs considerable commitment of time and energy. For example, a successful change of 
addictive behaviour means achieving a specific criterion such as abstinence
132,133
. 
Example messages – physical activity 
 All you need is 30-45 minutes of moderate physical activity on most days of 
the week 
 Hope it had been a healthy week 
 Physical activity helps in proper digestion 
 Be relaxed, anger is never without a reason, but seldom with a good one 
 A good exercise can keep your mind fresh 
 The key to relaxing your body is to focus on the physical sensation of 
relaxation 
Example messages – Diet 
 Take six split servings instead of 3 big servings of food 
 Have a healthy meals always 
 Use sugar free in moderate quantities 
 Regular intake of 8 to 10 nuts a day is good for the hear 
 Avoid sweets and sugars in any form to keep normal blood glucose 
 Take fruits as a whole and not as a juice 
2.10.3.5 Maintenance  
Maintenance is the stage in which individuals work to avoid relapse and are most often 
less tempted to deteriorate as they increasingly become confident and able to continue 
their changes. Conventionally, maintenance was viewed as a static stage, whereas it is 
actually a continuation and not merely an absence of change. Thus, the characteristics of 
this stage are stabilizing behaviour change and avoiding relapse
132,133
.
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Example messages – physical activity 
 Were there many missed walks this month 
 Are you stressed out?  Stress increases blood sugar, go for a walk and relax 
 Physical activity helps to control or reduce weight 
 Mental agitation can affect you. Hope enables as to endure the hardships of 
physical and mental life. 
Example messages – Diet 
 Skipping breakfast will make you overeat at lunch 
 Avoid fried and salty foods 
 Healthy diet is essential, relish your food 
 Drink water when you feel like drinking beverages  
 Junk food is no way healthy, avoid it 
The assumption was that by motivating participants on healthy lifestyle principles through 
SMS they will move from a pre-action stage to an action stage.  The timing and frequency 
of messages were tailored to the participants’ preference assessed at the 6 monthly visits. 
Although, SMS in the participants’ own vernacular is ideal, this could not be implemented 
due to the fact that large number of basic mobile phones (personal digital assistant (PDA)) 
were not compatible to multiple language systems (to South Indian languages such as 
Tamil and Telugu). The contents of the messages were based on: a. To emphasise the 
benefits achieved by healthy lifestyle habits; b. Simple reminders to reinforce participants 
to practice and adhere to the principles of lifestyle modification; c. Information about the 
consequences of progression to diabetes; and d. Methods to sustain healthy lifestyle habits. 
2.11  Measurements: 
2.11.1 Anthropometric measurements 
Supine Blood pressure (BP) was measured (mean of two readings) at each visit using a 
sphygmomanometer. Height and weight were measured to the nearest 0.1 cm and 0.5 kg, 
respectively (BMI was calculated). Waist circumference was measured midway between 
the lower rib margin and the iliac crest using a steel measuring tape to the nearest 0.1cm. 
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Body fat percentage was measured using bioimpedence method (OMRON, Karadia Scan, 
Japan).  
2.11.2 Clinical measurements 
Clinical assessments specific for the trial is given in the table 2.4. We have used COBAS 
Intergra 400 plus automated system for estimating the routine clinical measures and 
plasma insulin was estimated in Elecsys® analyzer. 
Table 2-4: Clinical assessments performed during the trial 
Clinical test Principle Coefficient 
of variation 
Detection range 
Glucose Hexokinase method <3.0 0.11-25 mmol/l 
HbA1c Turbidimetric inhibition 
immuno assay; Tina-quant® 
HbA1c 
<1.5 Hb: 4 - 40 g/dL; 
HbA1c: 0.3-2.6 g/dl 
Triglycerides GPO-PAP <2.0 0.05-11.3 mmol/l 
Total cholesterol CHOD-PAP <2.0 0.08-20.7 mmol/l 
HDL cholesterol HDL plus-3
rd
 generation <3.0 0.08-3.10 mmol/l 
gamma-glutamyl 
transferase 
GGT-2 <2.0 3-1200 U/L 
Alanine 
transaminase  
ALT IFCC with pyridoxal 
phosphate activation 
<4.0 4-600 U/L 
Insulin electrochemiluminescence 
immunoassay 
<3 1.39–6945 pmol/L 
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2.12 Questionnaires 
Physical activity and dietary intake were assessed by questionnaires completed by field 
workers at baseline and during the 6-monthly reviews. Assessments were done by seven 
field staff trained in undertaking glucose tolerance tests, questionnaire administration and 
biometric measurements. Training was provided by central training staff with use of 
continuous training methods previously used in our diabetes projects in India
116
. Each 
person had a designated role to minimise inter-individual error. 
2.12.1 Physical activity 
Physical activity was quantified on a score of 7–70.The activity questionnaire was based 
on that used previously in south-Asian Indians in a UK epidemiological survey 
134,135
, 
which we used in our previous study of diabetes prevention in India, but was slightly 
modified for the Indian environment 
116
. The copy of the physical activity questionnaire 
and the scoring schema (published material; appendix-2) are provided in the 
accompanying appendix. Researcher did not play a role in developing this questionnaire as 
it was already validated and has been used extensively in other observational 
134,135
 and 
primary prevention programmes
116,136
 conducted by our group. 
2.12.2 Habitual dietary energy intake 
At each visit we assessed dietary intake by 24-hr recall. The energy intake from individual 
food constituents was calculated with a dietary analysis program using the National 
Institute of Nutrition guidelines for India 
137
. The details of the 24hr recall questionnaire 
and the development of diet analyses software are given in the appendix-3. Information 
about adherence to recommendations for dietary intake and physical activity was recorded 
at the 6-monthly reviews. Adherence was self-reported, on the basis of weekly patterns, 
and was scored as poor, moderate, or good. 
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2.12.3 Text messaging acceptability 
A project-specific SMS acceptability questionnaire comprising of 8 items was developed 
by the researcher (psychologist). A similar SMS acceptability questionnaire was used in a 
clinic-based study in which the utility of SMS was tested to reinforce Asian Indian 
diabetes patients visiting their hospital clinic to adhere to prescription recommendations
138
. 
The study showed that frequent communication via SMS was acceptable to diabetic 
patients and it helped to improve their health outcomes. The questionnaire used in the 
present study was a modified version with questions to suit the study’s specific needs. This 
modified questionnaire was intended to help measure the acceptability, frequency, 
difficulty in understanding, advantage, preferred time and problems due to the SMS. One 
question invites participant’s suggestions to improve. The response to the questions was 
“Yes or No” (scoring: yes: 1; no: 0), and each correct response was given a score of 1. The 
SMS acceptability questionnaire was used at each follow up to assess the acceptance of the 
SMS received by the intervention group. The assessment also helped the researcher to 
make changes in the frequency, timing and type of SMS (diet or physical activity) 
delivered to the subjects. A copy of the questionnaire is included in appendix-4. A total 
score of 6 was the most acceptable and 0 the least. 
2.13 Surrogate insulin measures caluculations 
HOMA-IR
67
 was calculated using the formula: (fasting insulin (mU/l X fasting glucose 
(mmol/l)) / 22.5); since, it is a measure of insulin resistance the inverse of HOMA-IR (i.e., 
1/HOMA-IR) was used to express insulin sensitivity. Matsuda’s insulin sensitivity index 
(ISI) was calculated by the formula: (10
4
/ square root of (fasting glucose * insulin) X 
(mean OGTT glucose * mean OGTT insulin)), with mean glucose and insulin calculated 
from values at fasting, 30 and 2-hr of the OGTT test
139
. The insulinogenic index (IGI) was 
calculated as the ratio of the change in insulin to the change in glucose from 0 to 30 
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minutes following the oral glucose load (ΔI0-30/ ΔG0-30)
61
. Total area under the curve 
(AUC) for insulin and for glucose were calculated using the trapezoidal rule, and a ratio of 
the two was calculated (AUCins/glu)
140
. 
2.14 Definition of variables 
 Diabetes was diagnosed on the basis of an annual oral glucose tolerance test 
(OGTT) or a semi-annual 2-hr post glucose load test, according to the World 
Health Organization criteria 
2
: plasma glucose of a value of 126 mg /dl (7.0 
mmol/l) or higher in the fasting state or 11.1 mmol/l or higher two hours after a 
75-g oral glucose load. During interim visits, if the values were ≥11.1 mmol/l by 
2-hr PG test, an OGTT was performed within a week to re-confirm the diagnosis 
of diabetes. 
 BMI between 23.0 and 24.9 kg/m2 was considered as overweight, and BMI > 25.0 
kg/m
2
 was defined as obese 
141
.  
 Central obesity was indicated by waist circumference of > 90 cm 6.  
Individuals with a history of hypertension and newly diagnosed cases with blood 
pressure readings ≥ 130/85 mmHg (on two repeated occasions) were categorized as 
hypertensive. 
 Hypertriglyceridemia: Fasting serum triglycerides ≥ 1.7 mmol/l6. 
 
Figure 2-1 shows the study timeline and progress of the study. The total duration of the 
study was 40 months (screening period: 16 months). The schedule procedures are given in 
Table 2-4. 
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Figure 2-1: Trial - Study timeline     
 
Table 2-5: Schedule procedures  
 Baseline 6 months 12 months 18 months 24 months 
Informed consent X     
Questionnaires 
a
 
Demographic 
Clinical History 
Habitual dietary pattern 
Physical activity 
General Health Awareness 
Quality of life 
Transtheoretical model assessment 
Text messaging acceptability 
b
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
Anthropometric
 a
 
Height (Cm) 
Weight (Kg) 
Waist circumference (Cm) 
Body fat (%) 
Blood pressure (mmHg) 
 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
Clinical measurements
 a
 
3 sampling  OGTT 
2-hr post glucose load 
HbA1c 
Lipid profile 
Insulin estimations 
Gamma-glutamyl transferase 
Alanine transaminase 
 
X 
 
X 
X 
X 
X 
X 
 
 
X 
 
 
 
X 
 
X 
X 
 
 
 
X 
 
X 
 
X 
X 
X 
X 
X 
a: for individuals who progressed to diabetes (confirmation using 3 sampling 
OGTT), the value at that time point considered as a final values; for these individuals 
complete clinical measurements were carried out. b: only for intervention group. 
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 3 TRIAL RESULTS 
3.1 mHealth – critical review 
Developing countries—both low- and middle-income—often suffer from shortfalls in 
medical information, access to healthcare, treatment quality and affordability, and 
behavioural norms. Most of these disparities stem from gaps in resources, particularly 
financing, infrastructural, and the availability of skilled health workers. There is a clear 
need for innovative, home grown solutions that use technology to leapfrog these 
impediments. The proliferation of mobile technology in developing countries may offer 
this kind of opportunity. It has been predicted that by 2017 there will be ‘‘more mobile 
phones than people’’ on the planet 142, and according to the current estimates, three-
quarters of the world’s population have access to a mobile phone143. Thus, mobile phone-
based interventions may offer an alternative method for delivery of educational advice and 
motivation to achieve lifestyle modification
131,144
.  Early in its development, in 2003, m-
health was defined as wireless telemedicine involving  the application of mobile 
telecommunications and multimedia technologies and their integration with mobile 
healthcare delivery systems
145
.  Especially, text messaging (short message service, SMS) 
by mobile phone is an alternative means of delivery of educational advice and motivation 
to achieve healthy behaviour changes
131,138,144,146
 . The major advantages of mHealth 
include: 
 Temporal synchronisation - many people carry their mobile phone with them 
wherever they go. As mobile technologies can be transported wherever one goes, 
interventions are convenient and easy to access. 
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 Real-time (synchronous) communication - allows interventions to be accessed or 
delivered within the relevant context, i.e., the intervention can be delivered and 
accessed at any time and wherever it is needed. 
 The crux of  mHealth is the exchange of information . It is easy, low cost and 
highly translational to a community at large. 
Table 3-1 shows the details of the important studies which employs text messaging system 
in various behavioural and reminder systems such as smoking cessation, improvement of 
physical activity, diabetes management and improvement in patient adherence. 
Chapter-2 
47 
 
Table 3-1: Trials using SMS as an intervention strategy in behavioural change 
Study   
 
Research design and 
participants 
   
Sample size Duration Tailoring / 
frequency of 
messages 
Intervention effects 
Smoking cessation 
Obermayer 
(2004)
147
 
Design: pre-post pilot 
study 
Setting: Colleges 
from the Washington 
DC 
46 6 weeks Yes / daily At 6-week follow-up, 43% had made at 
least one 24-hour attempt to quit. 
22% were quit--based on a 7-day 
prevalence criterion. 
Rodger 
(2005)
148
 
Design: RCT / Single 
blind 
Setting: New Zealand 
public 
1705 
Control: 853 
SMS: 852 
26 weeks Yes / daily More participants reported not smoking in 
the intervention group (28%) compared to 
the control group (13%) at 6 weeks 
(p<0.0001). 
Free (2011)
149
 Design: RCT / Single 
blind 
Setting: United 
Kingdom 
5800 
Control: 2885 
SMS: 2915 
6 months Yes / daily Biochemically verified continuous 
abstinence at 6 months was significantly 
increased in the txt2stop group (10·7% 
txt2stop vs 4·9% control, relative risk (HR: 
2·20, 95% CI 1·80-2·68; p<0·0001). 
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Study   
 
Research design and 
participants 
   
Sample size Duration Tailoring / 
frequency of 
messages 
Intervention effects 
Physical activity 
Hurling 
(2007)
150
 
Design: RCT / no 
blind  
Setting: Bedfordshire, 
United Kingdom 
77 
Control: 47 
SMS: 30 
9 weeks Yes / daily Participants with access to a fully 
automated behaviour change system 
engaged in, on average, 2 h 18 min more 
physical activity per week than control. 
Kirsty (2009)
151
 Design: RCT / no 
blind  
Setting: New Zealand 
 
78 
Control: 40 
SMS: 38 
12 weeks No  / daily Text messaging and pedometers as 
motivational tools did not increase physical 
activity. 
Adherence to medication 
Lester (2010)
152
 Design: RCT 
Setting: HIV-AIDS 
patients in Kenya 
(Antiretroviral therapy) 
538 
Control: 265 
SMS: 273 
 
1 year No / weekly The number needed to treat (NNT) to 
achieve greater than 95% adherence was 
nine 
(95% CI 5.0-29.5) and the NNT to achieve 
viral load suppression was 11 (5.8-227.3) 
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Study   
 
Research design and 
participants 
   
Sample size Duration Tailoring / 
frequency of 
messages 
Intervention effects 
Downer SR 
(2006)
153
 
Design: Cohort study 
with historical control. 
Setting: Royal Children's 
Hospital, Melbourne, 
Victoria. (Patient 
reminders) 
45110 
Control: 22452 
Intervention: 
22658 
1 year Frequent 
appointment 
reminders 
Failure-to-attend rate was significantly 
reduced in the SMS reminders group (9.8% 
vs. 19.5%; P < 0.001). 
Vervloet 
(2012)
154
 
Design: RCT 
Setting: Netherlands 
(diabetes- adherence to 
oral hypoglycaemic 
agents) 
104 
Control: 48 
SMS: 56 
 
6 month No / daily SMS reminders improves adherence of 
type 2 diabetes patients (50% vs. 39% 
within a 1-h window (p=0.003) up to 81% 
vs. 70% within a 4-h window (p=0.007)). 
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Though, lots of pilot, short term studies demonstrated a feasibility and applicability of 
SMS technology in behavioural intervention, strong supportive data are lacking, however, 
such that a recent World Bank Report, showed that despite more than 500 mHealth pilot 
studies conducted so far 
155
,  we know almost nothing about the likely uptake, best 
strategies for engagement, efficacy, or effectiveness of these initiatives 
156,157
. Currently, 
mHealth interventions lack a foundation of basic evidence, let alone a foundation that 
would permit evidence-based scale up 
156
. There is even less evidence for mobile phone 
messaging in disease prevention 
158
 despite its potential as an aid in smoking cessation 
having been established 
149
.  
3.2 Rationale 
Primary prevention of type 2 diabetes (T2DM) is an important strategy in mitigating its 
rising global burden. As explained in Chapter-1, Diabetes Prevention Programmes 
(DPP’s) conducted in different parts of the world in various ethnic and racial groups have 
demonstrated that by controlling the adverse effects of environmental risk factors through 
lifestyle modification, it is possible to reduce risk of T2DM by 30-60% 
159
. Though these 
studies provide “proof-of-principle” for preventative strategies, their findings have not 
been widely implemented even in developed countries due to high-costs, need for 
expertise and difficulties in translating the benefits of lifestyle intervention to the 
community at large. Hence, there is a need to identify simple and inexpensive methods to 
educate and motivate people at high risk for diabetes. In this trial, we sought to determine 
whether mobile phone text messaging could reduce incident diabetes compared to standard 
lifestyle advice in people with prediabetes in India, the country with one of the largest 
populations of people with diabetes and expanding mobile phone accessibility 
160
. This 
method of delivery, if successful, is potentially scalable as mobile phones are widely used 
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even in low and middle income countries and their ownership is largely unaffected by 
socioeconomic status. 
3.3 Study design and methods: 
Described in detail in Chapter-2. Please refer section 2.2.  
3.4  Statistical analyses: 
With the assumption of a 30% cumulative incidence of  T2DM over 2 years (in our 
previous study in India 
116
, which had similar eligibility criteria, the incidence was 55% 
over 3 years), 214 participants per group were needed for a 40%  reduction in progression 
to T2DM to be detected at 5% significance with 80% power. In a meta-analysis of 
behavioural modification studies 
159
 the mean reduction was 50% 
159
 and we assumed that 
mobile phone messaging would be less effective than personal contact. We aimed to 
recruit 514 participants (257 in each group) to allow for 20% dropout rate during follow-
up. 
The analysis was to be by intention to treat. Two-sided t-tests were used to analyze the 
differences between the groups at base line. 2 test was used to analyze the differences 
between the categorical measures. For participants who developed T2DM, we regarded the 
values at the time of diagnosis as final. Estimated cumulative incidence of T2DM was 
calculated using unadjusted Cox regression
161,162
  analysis to compute the hazard ratio 
(HR) and survival curve for the intervention versus the control groups. The HR indicates 
the relative likelihood of the pre-specified outcome in treated vs. Control individuals at 
any given point in time. The mean survival time is estimated as the area under the survival 
curve in the interval 0 to tmax
163
. Absolute risk reduction (ARR), also called the risk 
difference, was calculated as the difference between the control event rate (CER) and 
experimental event rate (EER).  The ninety five percent confidence interval (95%CI) for 
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the ARR was calculated using the formula: ARR +/-1.96 X SQRT ([CER X (1-CER)/ no. 
of control participants + EER X (1-EER)/ no. of experimental patients]) 
164
. The number 
needed to treat and 95% CI to prevent one case of T2DM as the inverse of the absolute 
risk reduction (RR) and its 95% CI. The greater the risk, the more likely to gain from 
intervention 
164
.  
To assess the effects of the intervention on secondary outcomes (and ancillary analysis 
variables) we used fixed effect, mixed-linear regression modelling 
165,166
 with maximum 
likelihood parameter estimation for continuous variables. The MIXED procedure fits 
models more general than those of the general linear model (GLM) procedure and it 
encompasses all models in the variance components (VARCOMP) procedure. The linear 
mixed-effects models (MIXED) procedure in SPSS enables us to fit linear mixed-effects 
models to data sampled from normal distributions. Therefore, the variables which were 
non-normally distributed such as triglycerides and physical activity score were natural log 
transformed before analysis. Intervention or control group was a fixed effect in this model. 
Differences in the estimated marginal means between the groups with 95% CIs with P 
values were shown. 
We analysed categorical outcomes (adherence to diet and physical activity) with a 
generalised estimating equation-based logistic regression analysis 
167,168
, with adjustment 
for baseline values and time. The corresponding odds ratios (and associated 95% CIs) with 
P values were shown.  
The change in BMI, diet adherence and physical activity were computed by subtracting 
final follow-up from the baseline values. For diabetic cases the values at the time of 
diagnosis were considered as the final values. To evaluate predictors of incident diabetes 
independent of intervention, Cox regression analysis was used. Prior to modelling, the 
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proportional hazards assumption was tested and confirmed by examining interactions 
between follow-up time and each predictor (p> 0.05 for all interactions). The variables 
which showed significant univariate associations with diabetes were entered for 
multivariable modelling. The variables included for this exploratory analysis were: age, 
family history of diabetes, baseline 2-hr plasma glucose (2-hr PG), HOMA-IR and 
insulinogenic index, and baseline and change in BMI, dietary energy intake and physical 
activity. Study group was not included for this analysis, since the components of lifestyle 
interventions (i.e., dietary and physical activity habits) were already included in the model 
as separate variables. All analyses were performed using SPSS software (IBM SPSS 
Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp). 
3.5 Results 
3.5.1 Initial screening 
Figure-3.1 shows the trial profile. Among the 9160 non-diabetic individuals (men: women 
8801:359) invited, 9079 (men: women 8741:338) participated and were tested using the 
2hr post 75g oral glucose load capillary blood glucose method. Of the 8741 individuals 
screened, 4692 (53.7%) had normal glucose tolerance (NGT), 2744 (31.4%) had IGT and 
1305 (14.9%) had undiagnosed diabetes. Those with previously undiagnosed diabetes 
were advised to re-confirm the diagnosis as early as possible elsewhere with a repeat oral 
glucose tolerance (OGTT) and HbA1c to rule out the laboratory error. 
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Figure 3-1: Flowchart showing screening, recruitment and follow-up details of the 
participants. 
The diagnosis of diabetes is based on WHO recommendations: *: 2hr PG value <7.7 
mmol/l; **: 2-hr PG ≥ 11.1 mmol/l; ***: in order to increase the yield during confirmatory 
OGTT and reduce the cost of testing,  participants with 2-hr PG <8.9 mmol/l were 
excluded for the confirmatory testing;  
Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013 
130
.,  
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3.5.2 Characteristics of the individuals in relation to the screening glycaemic results 
Table 3-1 shows the characteristics of the individuals who underwent the screening in 
relation to their glycaemic findings. Mean age was 45.7 ± 5.0 years; positive family 
history of T2DM was present in 32.0%. Diabetic individuals were older, had higher BMI, 
waist circumference and blood pressure (p<0.05) as compared with normal glucose 
tolerance (NGT) and IGT individuals (p<0.05). Positive family history of diabetes, and 
blood pressure showed progressive increase from NGT, through IGT to T2DM (p<0.0001 
for all). 
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Table 3-2: Results of screening OGTT 
Characteristics Total 
 (n=8741) 
NGT  
(n=4692) 
IGT 
 (n=2744) 
Diabetes 
 (n=1305) 
Occupation 
a
  n (%) 
Unskilled 
Skilled 
Executive/ Clerical/ Professional 
 
318 (3.9) 
6297 (77.3) 
1533 (18.8) 
 
202 (4.6) 
3291 (75.4) 
872 (20.0) 
 
79 (3.1) 
1986 (78.0) 
482 (18.9) 
 
37 (3.0) 
1020 (82.5) 
179 (14.5) 
Family history 
ɫ
 
2768 (32.0) 
 
 1351 (29.2) 
 
939 (34.6) 
 
478 (37.0)
* 
Overweight, n (%) 2097 (24.0) 1178 (25.1) 641 (23.4) 278 (21.3)
#
 
Obese, n (%) 4865 (55.7) 2403 (51.2) 1632 (59.5) 830 (63.6)
*
 
Abdominal Obesity, n (%) 
ф
 4003 (58.4) 1870 (53.8) 
 
1444 (61.6) 
 
689 (66.7)
* 
 
Hypertension, n (%)   
(n=8679)
§
 
4819 (55.5) 2353 (50.4) 1593 (58.5) 873 (67.7)
*
 
 Mean + SD 
Age (Years) 45.7 ± 5.0 45.4 ± 5.1 45.8 ± 4.6 46.8 ± 4.9
**
 
Body mass index (kg/m
2
) 25.5 ± 3.4 25.2 ± 3.3 25.8 ± 3.3 26.3 ± 3.5
**
 
Waist circumference (cm) 91.1 ± 8.0 90.1 ± 7.8 91.7 ± 7.9 93.1 ± 8.3
**
 
Blood Pressure  (mmHg)     
                         Systolic  126.7 ± 16.2 125.2 ± 15.5 127.2 ± 16.4 130.8 ± 17.3
**
 
                         Diastolic  84.1 ± 10.9 82.9 ± 10.7 85.1 ± 10.6 87.1 ±11.3
**
 
Legend: Trend 2 square- * p<0.0001, # p=0.011, One Way ANOVA - ** -p<0.0001  
a: occupation data available for 8148 individuals; ɫ : data available for NGT: 4633; IGT: 
2715; DM: 1293; 
§: 
data available for NGT: 4688; IGT: 2722; DM: 1289; 
ф:
data available 
for NGT: 3476; IGT: 2345; T2DM: 1033; Overweight defined as: BMI 23.0 – 24.5 kg/m2 
Obesity defined as: BMI > 25.0 kg/m
2
; Abdominal obesity defined as: waist 
circumference> 90 cm; Hypertension: Blood pressure ≥ 130/85 mmHg on two occasions 
Ram J, Nanditha A, Selvam S. J Assoc Physicians India (2014)
169
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3.5.3 Prevalence of risk clusters stratified according to glycaemic status 
Figure 3-2 shows the prevalence of risk clusters (blood pressure, hypertension and 
parental history of diabetes) stratified based on glycaemic status. In this cohort, risk factor 
clustering was not present in 8% of the screening participants (NGT: 10.1%; IGT: 6.2%; 
T2DM: 4%; P<0.0001). A clustering of risk factors (2 or more) was present in many 
individuals; the most frequent cluster was overweight / obesity (BMI ≥23 kg/m2) and 
hypertension (22.9%). The BMI and hypertension cluster (31.1%) was most prevalent in 
this cohort whereas, clustering of family history of diabetes and hypertension was the least 
(2.4%). Clustering of 3 risk factors occurred in 15.1%. As expected, the prevalence of risk 
clusters increased with degree of hyperglycaemia, the percentage increased linearly from 
NGT, through IGT to diabetes. (NGT: 11.7%; IGT: 17.1%; T2DM: 23.1%; P<0.0001). 
Importantly the presence of positive family history of diabetes had a tendency to cluster 
with modifiable risk factors such as obesity and hypertension rather than to present in 
isolation (isolated family history: 3.1%;family history + BMI: 11.6%; family history of 
diabetes +hypertension: 2.4 family history of diabetes +BMI+ hypertension: 15.1%).
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Figure 3-2: Clustering of diabetogenic risk factors (family history of diabetes, over weight 
and hypertension) according to glycaemic status 
Legend: The figure shows the prevalence of risk factor clusters among the population 
screened, based on glycaemic outcomes. The presence of hypertension, overweight/ 
obesity and positive family history were observed in 11.0% of the study group. Newly 
detected diabetes cases had increased risk factor clusters as compared to NGT & IGT 
group (NGT:7.6%; IGT: 13.2; T2DM: 17.1%; P<0.0001). 
Notes: FH: family history; BMI: body mass index; HTN: hypertension 
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3.5.4 Confirmatory test and recruitment 
Of the 2744 (31.4%) eligible participants, we had, with exclusion of 912 individuals with 
2-hr post glucose (2-hr PG) load <8.9 mmol/l (to enhance the yield for the second OGTT), 
invited 1832 (66.8%) individuals for the confirmatory test. Among them, 1369 (50%) 
agreed to a second OGTT. Of these, 580 (42%) had persistent IGT, of whom 43 (7%) did 
not wish to participate further, leaving 537 participants who were randomly assigned to the 
mobile phone messaging intervention (n=271) or to standard care (n=266), and were 
included in the primary analysis. 
Baseline characteristics were similar between groups (Table 3-2). The study cohort 
sampling mostly comprised of skilled labourers (334 out of 537 (62.9%)) (Table 3-2). At 
entry, no participant in either group was receiving lipid modifying treatment, but 69 (26%) 
in the intervention group and 69 (25%) in the standard care group were taking medication 
for blood pressure reductions. Dietary energy intake, compatibility of diet with advice 
during the trial, and the distribution of physical activity scores were similar in both groups 
at baseline (Table 3.2). 
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Table 3-3: Baseline characteristics of study participants 
Characteristic Control (n=266) Intervention (n=271) 
Age (years) 46.1±4.6 45.9±4.8 
Occupation 
Unskilled workers 
Skilled 
Executives 
 
11 (4.0) 
170 (64) 
85 (32.0) 
 
9 (3.0) 
164 (61) 
98 (36.0) 
Family history of diabetes 131 (49.0) 150 (55.0) 
Body mass index (kg/m
2
) 25.8±3.0 25.8±3.3 
Waist circumference (cm) 92.7±7.3 92.6±7.1 
Blood Pressure (mmHg) 
                                    Systolic 
                                    Diastolic 
 
123.4±14.3 
80.2±8.4 
 
123.1±13.6 
80.2±8.4 
Receiving hypotensive drugs 69 (26) 69 (25) 
Plasma glucose (mmol/l) 
                                    Fasting 
                                    2-hr 
 
5.70±0.55 
8.90±0.86 
 
5.63±0.53 
8.79±0.78 
Serum lipids (mmol/l) 
              Total cholesterol 
              HDL cholesterol 
Triglycerides* 
 
4.91±0.94 
0.90±0.19 
1.6 (1.2-2.3) 
 
4.87±0.89 
0.90±0.21 
1.6 (1.1-2.1) 
HOMA-IR ΔI30-0/G30 (pmol/mmol) 3.2±1.5 
48.9 (27.9-78.5) 
3.0±1.3 
47.6 (30.0-81.7) 
Dietary energy intake (kcal) 
Baseline dietary healthy practice (%) 
2100±278 
136 (51) 
2121±296 
141 (52) 
Physical activity score* 
 
36 (31-56) 
 
36 (27-54) 
Legend: Data are mean ± SD; * Median (inter-quartile range). Homogeneity of the study 
groups was analyzed by two-tailed t-test.  
Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013
130
.,  
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3.5.5 Study outcome analysis 
3.5.5.1 The primary outcome was incident type 2 diabetes 
At final follow-up, the response rate was 96% (n=517; Figure-3.3). The mean time 
(months) to incident diabetes was 20.9 [95%CI: 20.2-21.7] in the control group compared 
with 21.9[95%CI: 21.3-22.5] in the intervention group (P=0.011). Three patients (two 
[<1%] in the control group and one [<1%] in the intervention group) were diagnosed with 
T2DM by treating physicians outside the trial. These patients were included in the analysis 
after the diagnosis was confirmed from medical records. Other cases were ascertained 
during the trial. Including the three patients who had already been diagnosed, 50 (18%) 
men in the intervention group developed T2DM over the 2 years compared with 73 (27%) 
control patients (ARR: 9%; Figure 3-3).The intervention reduced the incidence of T2DM 
during the course of the study (β –0·447; HR: 0·640 [95% CI: 0·446–0·917]; P=0·015; 
Figure 3-3). The number needed to treat to prevent one case of T2DM was 11 (95% CI 6–
55).  
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Figure 3-3: Proportion of individuals without diabetes during the study (Kaplan-Meir 
survival curve) 
Legend: Error bars show 95% CIs. Diagnosis of diabetes was based on WHO criteria
2
. 
HR=hazard ratio;   
Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013 
130
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3.5.5.2 SMS acceptability 
The frequency of mobile phone messaging at baseline was decided individually, in line 
with participants’ wishes. Initially a median of 18 messages per month (range 8–24) were 
requested. At final follow-up, the median requested was 12 (range 8–16). Analysis of the 
acceptability questionnaire data showed that messages were generally welcomed, and the 
median questionnaire score out of 6 was 5 (range 3–6). No more than eight (3%) of 271 
people at any review stated that receiving the messages was disturbing them. 
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3.5.5.3 Secondary outcome analysis 
Secondary outcomes were BMI, waist circumference, systolic and diastolic blood pressure, 
lipid profile (total and HDL-C and triglycerides), total dietary energy intake, and physical 
activity score.  
Linear mixed model analyses showed no significant effect of the intervention on BMI, 
waist circumference, blood pressure, or serum cholesterol and triglycerides, but there was 
a significant improvement in HDL-C in the intervention group compared with the control 
group (Table 3-3). Total dietary energy intake was lower in the intervention group than in 
the control group, whereas physical activity scores did not differ (Table 3-3). At the end of 
follow-up, a greater proportion of participants in the intervention group were adherent to 
diet than in the standard-care group (Table 3-3), but adherence to physical activity 
recommendations did not differ between the two groups.  
One patient in the control group died suddenly at the end of the first year due to cardiac 
arrest.  
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Table 3-4: Secondary outcomes and adherence to dietary intake and physical activity recommendations at the end of follow-up 
Variables Baseline 6 months 12 months 18 months 24 months Estimated marginal 
mean change 
P value 
Body mass index (Kg/m
2
) 
Control 
Intervention 
 
25.8±3.0 
25.8±3.3 
 
24.7±5.8 
24.6±5.9 
 
24.8±5.8 
24.8±6.0 
 
24.9±5.8 
24.8±6.0 
 
24.8±5.8 
24.8±6.0 
 
-0.05(-0.46 to 0.37) 
 
0.828 
Waist circumference (Cm) 
Control 
Intervention 
 
92.7±7.3 
92.6±7.1 
 
92.5±7.8 
92.3±8.1 
 
92.4±7.8 
92.4±8.2 
 
92.7±7.8 
92.9±8.0 
 
92.8±7.7 
92.9±8.2 
 
0.04(-0.56 to 0.64) 
 
0.897 
Systolic blood pressure 
(mmHg) 
Control 
Intervention 
 
123.4±14.3 
123.1±13.6 
 
122.4±13.4 
122.5±13.1 
 
120.8±12.8 
120.2±12.3 
 
120.6±12.1 
121.4±13.0 
 
119.5±12.0 
119.7±12.5 
 
0.04(-0.96 to 1.03) 
 
0.937 
Diastolic blood pressure 
(mmHg) 
Control 
Intervention 
 
80.2±8.4 
80.2±8.4 
 
78.8±7.8 
78.8±6.9 
 
78.4±6.8 
78.1±6.5 
 
78.6±6.5 
78.4±6.9 
 
77.7±7.0 
77.9±7.9 
 
-0.07(-0.64 to 0.49) 
 
0.796 
Total cholesterol (mmol/l) 
Control 
Intervention 
 
4.91±0.94 
4.87±0.89 
 
--- 
 
4.90±0.9 
4.90±0.9 
 
--- 
 
4.8±1.0 
4.9±0.9 
 
0.01(-0.08 to 0.01) 
0.846 
HDLC (mmol/l) 
Control 
Intervention 
 
0.90±0.19 
0.90±0.21 
 
--- 
 
0.99±0.22 
1.04±0.25 
 
--- 
 
0.92±0.19 
0.96±0.22 
 
0.03(0.01 to 0.05) 
 
0.003 
Triglycerides (mmol/l) 
Control 
Intervention 
 
1.6(1.2-2.3) 
1.6(1.2-2.1) 
 
--- 
 
1.6(1.2-2.3) 
1.5(1.2-2.1) 
 
--- 
 
1.6(1.2-2.3) 
1.5(1.2-2.1) 
 
-0.08(-0.17 to -0.06) 
 
0.050 
Dietary energy intake (kcal),  
Control 
Intervention 
 
2100±278 
2121±296 
 
2067±269 
1984±286 
 
2033±266 
1976±293 
 
2016±265 
1971±288 
 
1993±259 
1937±281 
 
-43.7(-65.5 to -22.0) 
 
<0.0001 
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Table 3-3: Secondary outcomes and adherence to dietary intake and physical activity recommendations at the end of follow-up (continued) 
Variables Baseline 6 months 12 months 18 months 24 months Estimated marginal mean change P value 
Diet adherence,  n(%) 
Control 
Intervention 
 
136 (51.1) 
141 (52.0) 
 
140 (52.6) 
179 (66.1) 
 
152 (57.1) 
166 (61.3) 
 
155 (58.3) 
171 (63.1) 
 
143 (53.8) 
184 (67.9) 
 
1.357 [1.008-1.826] 
 
0.0422 
Physical activity 
Control 
Intervention 
 
36(31-56) 
36(27-54) 
 
39(23-52) 
39(25-52) 
 
39(21-52) 
39(25-52) 
 
39(25-56) 
42(27-52) 
 
39(29-56) 
42(28-56) 
 
–1·0(–2·0 to 0) 
 
0.758 
Physical activity, n(%) 
Control 
Intervention 
 
205 (77.1) 
202 (74.5) 
 
203 (76.3) 
203 (74.9) 
 
205 (77.1) 
201 (74.2) 
 
196 (73.7) 
194 (71.6) 
 
197 (74.1) 
202 (74.5) 
 
1.110[0.779-1.573] 
 
0.572 
 
Legend: Data are mean (SD) or median (IQR), unless otherwise indicated. We used mixed-linear regression analysis, taking into account visit 
and intervention, to generate estimated  marginal means and difference in mean change (95% CI) at the end of follow-up.*Log-transformed data 
(by back transformation). †Logistic regression analysis with repeated measures taking into account visit and intervention to compare adherence 
to diet and physical activity between groups; BMI, WC, SBP, DBP, total energy intake and dietary adherence. Physical activity and adherence to 
the physical activity were measured at every 6 months; lipid profile (TC, TG and HD-C) were measured at annual visits. 
Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013 130; 
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3.5.6 Predictors of diabetes 
Among the baseline variables the significant predictors of incident T2DM were: a) 
raised 2 hr plasma glucose, b) increased insulin resistance , and c) lower insulinogenic 
index (Table 3-4). Improvement in dietary compliance was inversely associated with 
the development of T2DM and increase in BMI from baseline was detrimental. 
Significance of each variable was sustained on entry into a Cox proportional hazard 
model. 
Table 3-5: Predictors of diabetes 
Variables HR [95%CI] P value 
Baseline 2-hr plasma glucose (mmol/l) 1.728 [1.406-2.122] <0.0001 
Baseline HOMA-IR 1.175 [1.075-1.285] <0.0001 
Baseline insulinogenic index (pmol/mmol) 0.993 [0.988-0.998] 0.006 
Change in dietary practice improvement 0.482 [0.327-0.710] <0.0001 
Change in BMI (Kg/m
2
) 1.329 [1.151-1.535] <0.0001 
 
Legend: change in BMI, diet adherence and physical activity were computed by 
subtracting final follow-up from the baseline values; for diabetic cases the values at 
the time of diagnosis considered as the final value. 
 Ramachandran A, Snehalatha C, Ram J, et al. Lancet Diabetes Endocrinol 2013 
130
.  
 
3.6 Predictors of normoglycaemia 
Although reversal of prediabetes to normal glucose tolerance (NGT) is not 
uncommon, the effect  of  lifestyle  intervention  on  reversal  from  persistent  
prediabetes  to  NGT  have  not  been studied  in  detail  in  Asian  Indian  population.  
In  view  of  its  potential  importance  of  achieving NGT with the lifestyle 
intervention, the consequences of early reversal to NGT were explored in detail. Also, 
there have only been a few studies on the cardiovascular risk factors during long term 
outcome of prediabetes.  
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The  aims  of  this  ancillary  cohort  analysis  of  a  prospective,  prevention  study  
among  Asian Indians, with IGT were: a) to quantify the risk reduction in incident 
diabetes during a 24 months follow-up in participants who achieved NGT at 6 months 
(NGT-6m) compared with those who remained in the prediabetic state; b) to study the 
factors influencing the reversal of prediabetes to NGT and c) to determine whether the 
cardiometabolicrisk factors improved among those who reverted to NGT at the end of 
the study. 
Risk of T2DM in 2 year was lower by 75% in NGT-6m group (hazard ratio: 
0·25[95%CI:0·12-0·52]). Predictive variables for reversal to NGT-24m were good 
baseline beta-cell function (OR:2.79[95%CI:2.30-3.40]) and its further improvement 
(OR:5.70[95%CI:4.58-7.08]), and NGT-6m(OR:2.10[95%CI:1.14-3.83]). BMI 
decreased in those who reverted NGT. Deterioration to T2DM resulted in increase in 
levels of cardiometabolic risk factors. In summary, early  reversion  to  NGT  by  
lifestyle  intervention  in prediabetic  men  was  associated  with  significant reduction 
in subsequent incidence of diabetes. Good baseline beta-cell function and its further 
improvement, and NGT-6m were associatedwith reversion to NGT-24m. Reversion to 
NGT  resulted  in  modest  improvements  while  conversion  to  T2DM  resulted  in  
significant worsening of cardiometabolic risk profile. 
The findings of this analyses has been accepted in diabetes care and the copy of the 
manuscript was enclosed as an appendix (appendix) 
3.7 Mechanism of action of intervention 
In prevention trials in western populations, the beneficial effects were largely 
attributed to weight reduction 
111,112,170
, whereas in Asian populations the benefit of 
lifestyle intervention was seen to be independent of weight loss 
114,116
. The 
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components of lifestyle intervention that are responsible for the reduced incidence of 
diabetes have not been studied in detail in Asian Indians. Therefore, the objective of 
this section is to unravel the mechanism of action of lifestyle intervention in Asian 
Indian men with prediabetes. 
3.7.1 Effect of weight change on prevention of diabetes 
As shown in Table 3-3 there was no significant difference in BMI between standard 
care advice and intervention groups at the end of the study. It is worth mentioning that 
the baseline BMI in western diabetes prevention studies (Diabetes Prevention 
Programme (DPP)-mean BMI: 34.0 kg/m
2
; Diabetes Prevention Study (DPS)-mean 
BMI: 31.3 kg/m
2
) were much higher than that of the present study (mean BMI: 
25.8kg/m
2
; around 21.0% to 34% lower than that of the western studies). Hence, the 
western studies may demonstrate independent benefits of BMI on the incidence of 
diabetes. On the other hand it is hard to reconcile such benefit in this trial because of 
their lower BMI at baseline and primarily we were not advising participants to lose 
weight rather we were emphasizing healthy dietary habits and benefits of increased 
physical activity. The objective of this post hoc analysis is to find out the relationship 
between modest weight change and incident diabetes in this cohort of Asian Indian 
men. The statistical analyses performed in this exploratory analysis were adopted from 
the Prevention of Diabetes and Obesity in South Asians (PODOSA) study
171
. The 
participants were categorized into 3 groups based on their weight change at the end of 
the study: 
 Group in which weight increased by 2.5% or more  
 Group in which weight remained unchanged (changes < ±2.5%)  
 Group in which weight decreased by 2.5% or more 
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Figure 3-4 : Changes in weight at the end of the study - stratified based on study groups 
 
 
Legend: P value computed by 2 test; categories are based on: unchanged:  <± 2.5% 
weight change from baseline; decrease of 2.5% or more weight change from baseline;  
increase of 2.5% or more weight change from baseline. Percent weight loss was 
calculated using the formula: ((weight (Kg) at final) – (weight (Kg) at baseline) / 
(weight (Kg) at baseline)*100). 
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3.7.2 Effect of healthy lifestyle goals on prevention of diabetes 
The changes in dietary habits and regular physical activity at the end of the study are 
shown in the Table 3-6. A higher percentage of persons in the intervention group 
reported changes in dietary habits compared with the control group. There was no 
difference in levels of physical activity or in change in BMI between the study groups. 
Univariate logistic regression analysis showed that among the goals achieved the 
greatest protection against development of diabetes was achieved by a reduced BMI of 
at least 1 unit (OR: 0.15 [95%CI: 0.01-0.47]).  Among the dietary factors, reduction in 
portion size (OR: 0.39 [95% CI: 0.25-0.60]), reduction in oil intake (OR: 0.46 [95% 
CI: 0.30-0.69]) and reduced consumption of carbohydrates (OR: 0.52 [95% CI: 0.34-
0.78]) all had inverse associations with diabetes. Improvement in the physical activity 
did not show any association with incident diabetes.  The proportion of individuals 
who achieved ≥ 3 lifestyle goals was higher in the intervention than in the control 
group (132 (50.6%) vs. 105 (41.0%); P=0.028).  
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Table 3-6: Number (%) of study individuals showing improved diet habits and regular physical activity   at the end of the study 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: 
*
: P values were determined by the 2 test between the two groups; 
                
**
:Nutrient intakes were calculated from diet questionnaire 
                 
§
 : Exercise habits were assessed by self-reported physical activity questionnaire;  OR: odds ratio; CI: confidence intervals. 
Variables n (%) Control 
(n=256) 
Intervention 
(n=261) 
P
 
value
 *
 
Diabetes 
incidence 
n(%) 
OR (95 % CI) 
(all individuals)  
Decreased consumption of 
carbohydrates 
**
 
121 (47.3) 149 (57.1) 0.025 49(18.1) 0.52 (0.34-0.78) 
Decreased portion size
**
 107 (41.8) 137 (52.3) 0.015 37(15.2) 0.39 (0.25-0.60) 
Decreased consumption of oil 
intake 
**
 
124 (48.4) 162 (62.1) 0.002 50(17.5) 0.46 (0.30-0.69) 
Decreased BMI of at least 1 unit 
(Kg/m
2
) 
34 (13.3) 27 (10.3) 0.301 3 (4.9) 0.15 (0.01-0.47) 
Regular physical activity 
§
 197 (76.9) 202 (77.4) 0.899 97(24.3) 1.14 (0.70-1.89) 
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3.7.3 Association of Lifestyle goals with diabetes 
There was a strong inverse correlation between the success score and the incidence of 
diabetes as shown in the Figure 3-4. Among the 15 individuals who did not achieve 
any of the lifestyle goals (control: 12; intervention: 3), 8 (53%) developed diabetes. 
None of the individuals who achieved all the five lifestyle goals (control: 5; 
intervention group: 13) developed diabetes.  
Multivariable logistic regression analysis adjusted for baseline values of age, BMI and 
2-hr PG showed that individuals who achieved ≥ 3 goals were at reduced risk of 
developing diabetes (odds ratio: 0.30 [95% CI: 0.19-0.48]; P<0.0001) compared with 
the individuals who achieved <3 goals.  
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Variables Zero One Two Three Four Five 
DM case 8 39 42 23 11 0 
Total 15 101 164 135 84 18 
 
Figure 3-5: Diabetes incidence rate by lifestyle goals (number of intervention goals   
achieved at year 2).  
Legend: Intervention and control groups were combined for this analysis;  
               Error bars show 95% CIs. Diagnosis of diabetes was based on WHO criteria2.                  
                HR=hazard ratio.
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3.8 Discussion 
The present trial is the first to demonstrate benefit of SMS as a tool in the prevention 
of T2DM. The 36% reduction in progression to diabetes is similar to that reported 
previously in India using personal contact methods by our group
116
. The participants 
included in the trial were at especially high risk, having 2-hr PG levels ≥8.9mmol/l in 
their first OGTT. Their high rate of progression to diabetes, at 30%, was similar to 
that reported in our earlier Indian diabetes prevention programme 
116
. The text 
messages were generally well accepted by most of the participants. Therefore, this 
study provides initial evidence that text messaging can be an effective and acceptable 
tool for lifestyle modification to reduce diabetes incidence. Though, short-term studies 
showed effectiveness of SMS in diabetes management 
172-176
, asthma 
177,178
, smoking 
cessation 
149
 and adherence to the medication and reminders for outpatient 
appointments 
153,179,180
, to our knowledge this is the first long-term trial to demonstrate 
the effectiveness of SMS in diabetes prevention. In fact, the effect of intervention was 
significant during the first 6 months and was sustained for over 2 years. 
In this study, baseline 2-hr PG, baseline insulin resistance, increasing BMI during the 
follow-up were perilous whereas a high baseline early insulin secretion (insulinogenic 
index) and improved dietary compliance during the study were protective. Based on 
this finding, this analysis supports the hypothesis that progressive weight gain is an 
etiological factor before the onset of T2DM
181
.  
In this study, the effect of intervention was through the maintenance of weight and/or 
prevention of weight gain from occurring rather than from weight loss. The 
relationship between obesity and diabetes prevalence rates were a complex 
phenomenon and was appear to be modified by ethnicity. India, for instance, has a 
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very low prevalence of obesity than the U.S., but higher rates of T2DM 
182
; besides 
that, in Asian populations increased risk of diabetes starts at a relatively lower BMI 
than that of Europeans
183
. The recently published UK bio bank study demonstrated 
that compared with whites with a BMI of 30 kg/m
2
, South Asians had an equivalent 
prevalence of diabetes at a BMI of 22.0 kg/m
2
 in women and 21.6 kg/m
2
 in men, 
which is lower end of the normal BMI range for white populations
184
. Thus, even a 
modest amount of weight gain may be particularly detrimental to diabetes risk for 
Asians compared with other ethnic populations
185
.    
Furthermore, the present trial post hoc analysis to study the mechanism of benefit of 
intervention showed that the favourable outcome of reduced incidence of diabetes in 
the intervention group was associated with the increased compliance to the healthy 
lifestyle goals relative to the control group. The outcome of lifestyle modification was 
more pronounced among individuals who achieved ≥ 3 goals; on the other hand, the 
failure to make any changes resulted in an increased incidence of diabetes in either 
group. Amongst the dietary goals, the strongest association was observed with 
decrease in portion size (total energy intake) followed by decreased consumption of 
oil. Similar observations were also reported in the DPS 
111
, in the DPP 
112
 and in the 
Nurses’ Health Study 186. In these studies, reduction in incidence of diabetes was 
mainly attributed to the benefits of weight reduction which occurred due to the 
improvements in diet habits and in physical activity levels. In our study, a reduction in 
BMI had an independent protective effect, though the quantum of reduction was small 
and occurred only in small percentages in both groups. Therefore, the benefit of 
lifestyle intervention appeared to be largely related to improvements in diet habits 
which led to biochemical and behavioural improvement unrelated to weight loss. 
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In this study, the beneficial outcome of decreased incidence of diabetes was not 
associated with improved physical activity levels. In this study, we assessed physical 
activity by questionnaire only, a method that could have missed small changes. It is 
conceivable that activity information derived from self-report is potentially subject to 
response bias (e.g. imprecise recall, influence of social desirability) which is 
unavoidable in epidemiological settings. The beneficial effects of improved physical 
activity  in the prevention of diabetes
111,112,114
 was already established including 
previous trial in India
116
 by our group. It is also to be noted that 64% of the cohort 
already had good levels of occupational physical activity at baseline.  Therefore, 
objective measurements such as accelerometer are required to ascertain the beneficial 
changes of physical activity with incident diabetes. 
HDL-C levels were slightly but significantly higher at the end of the trial in the 
intervention compared with the control group.  This finding was analogous to the Oslo 
Diet and Exercise study
187
 in high-risk individuals, which showed an improvement in 
HDL-C after diet intervention compared to control. Weight loss and increased 
physical activity are two positive determinants of circulating HDL-C but in our study 
we cannot be sure of the mechanism. Such small differences in HDL-C have been 
reported previously in conventional diabetes prevention studies and may well have 
cardio-protective effects
111,188
, and anti-inflmmatory and anti oxidant properties
189
. 
3.9 Limitations 
Our study has some limitations. Firstly, the trial included only working men. Hence, 
the efficacy and acceptability of SMS among women, and amongst other groups of 
men, need to be addressed. Secondly, the setting was an urban population in India. 
The applicability of text messaging to other populations, such as those living in rural 
areas, needs to be studied. Thirdly, we did not objectively measure the beneficial 
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improvements of physical activity levels in this study cohort. In our latest prevention 
trial which is presently commenced we rectified most of those limitations (study 
sample mostly comprised of semi-urban population; number of women participants: 
30%; actigraph as an objective measure of physical activity improvements). 
Nevertheless, the proof of principle has been established that automated SMS delivery 
is a practical and successful tool for education and motivation of people with 
prediabetes. 
3.10 Comments 
By 2025, it is estimated that 70% of the Asian Indians will be of working age group 
and this would make India—by an order of magnitude—the largest single positive 
contributor to the global workforce over the next three decades 
190
. The prevalence of 
undetected diabetes among industrial workers in Asian Indian individuals is very 
high
191
. Furthermore, IDF predicted that there are around 65.1 million individuals with 
prediabetes in India with the potential to develop diabetes at a later stage
1
. Hence, it is 
important to identify pragmatic, innovative and scalable strategies to prevent or 
postpone lifestyle diseases such as diabetes and obesity. Our results provided initial 
and important evidence that motivation through SMS may be a highly effective and 
acceptable tool to substantially reduce incidence of diabetes. According to our 
findings, the lifestyle intervention through mobile phone based text messaging was 
effective, with one case of diabetes prevented by treating 11 persons with prediabetes 
for two years. Text messaging may now become part of an alternative strategy to 
disseminate healthy lifestyle principles effectively in the field of preventive medicine.
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 4 PREDICTORS OF TYPE 2 DIABETES – CLASSICAL RISK FACTORS 
4.1 Predictors of diabetes 
The putative predictors of type 2 diabetes (T2DM) such as glycaemic measures and 
surrogate insulin measures were already explained in detail in Chapter-1. In this 
chapter the findings of the association of classical risk factors with diabetes are 
presented. 
4.2  Research objectives 
The main objectives of this chapter are to investigate simple, inexpensive, accurate 
markers which could predict incidence of T2DM. The markers explored in this chapter 
relate primarily to elucidation of the pathogenesis and mechanisms of disease and 
demonstrate that a prediction model based on the pathophysiology of the disease 
performs superiorly to other clinical models in predicting the risk of future T2DM. 
The overview of approaches to clinical predictors for T2DM is depicted in Figure 4-1. 
Dysregulation of many biological pathways leads to the development and progression 
of T2DM
120
.  According to the current understanding of the pathogenesis of diabetes 
there exist vicious circles which link insulin resistance and beta-cell dysfunction 
through  hyperglycemia, hyperlip-idemia, glucotoxicity and lipotoxicity 
192
. 
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Figure 4-1: Approaches to clinical predictors for type 2 diabetes 
Legend: GGT: Gamma-glutamyl transferase; ALT: alanine transaminase; HTWP: 
hypertriglyceridemic waist phenotype; FPG: fasting plasma glucose; 2-hrPG: 2hr 
plasma glucose after glucose load (75gms); HbA1c: glycosylated haemoglobin; 
HOMA-IR: Surrogate measure for insulin resistance. Figure adopted from Bonora 
(2008) 
192
 
 
 
4.3  Liver enzymes and diabetes 
4.3.1 Rationale 
‘Insulin resistance syndrome’ refers to the constellation of anthropometric and 
metabolic abnormalities such as abdominal obesity, glucose intolerance, hypertension 
and dyslipidemia
193
. Nonalcoholic fatty liver disease (NAFLD) refers to the hepatic 
manifestation of insulin resistance syndrome
194-197
. The liver, a major site of insulin 
clearance
198
, plays an important role in maintaining fasting and postprandial glucose 
homeostasis
199
. Unlike in the skeletal muscle, where there may be extra cellular 
storage, all triglycerides are stored intra-cellularly in the liver. Hence, hepatic fat 
accumulation can adversely affect major aspects of hepatic metabolism, including 
insulin clearance and hepatic glucose output, with associated derangements of 
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intermediary metabolism. It has been suggested that hepatic dysfunction resulting 
from the insulin resistance syndrome and NAFLD may contribute to the development 
of T2DM
200
. Evidence from several large prospective epidemiological studies in 
multi-ethnic populations provides a strong link between elevated liver enzymes such 
as gamma-glutamyl transferase (GGT) 
201-212
  and alanine transaminase (ALT) 
205,206,211,213,214
 with development of diabetes.  
There are, however, several shortcomings in the current evidence base: firstly, 
incident diabetes has been generally determined from self-reported information in 
medical records or the diagnosis was based on single fasting glucose measurements 
202,207,211,212
. This could lead to potential misclassification bias. Furthermore, except 
two studies
205,211
, other studies did not adjust for confounding variables such as insulin 
resistance, 2-hr plasma glucose (2-hr PG) and HbA1c. Hence, we have studied the 
association of GGT with incident diabetes, ascertained in a prospective 
epidemiological setting, after adjusting for a comprehensive array of covariates known 
to be associated with diabetes risk. 
4.3.2 Methods 
As described in detail in chapter-2, the underlying study design comprised 517 
individuals with impaired glucose tolerance (IGT) at baseline. Since, both the control 
and intervention groups received one- to -one lifestyle advice at baseline, and with the 
major objective to explore the association of GGT with incident diabetes, we 
considered the cohort as a single group for this analysis. 
4.3.3 Statistical analysis 
Descriptive statistics of baseline measurements stratified based on glycaemic status, 
were analyzed by one way ANOVA with Bonferroni posthoc correction. Within group 
differences in GGT levels stratified based on glycaemic categories were assessed 
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using paired t-test. Cox’s proportional hazard models161,162 were computed to assess 
the relative risk of incident diabetes according to GGT activity: model-1, unadjusted 
GGT activity (dichotomized based on the median activity), model-2, adjusting for age, 
body mass index (BMI), family history of diabetes, smoking and drinking; model-3, 
included model-2 plus ALT activity; and model-4, included model-3 plus 2-hr PG, 
HbA1c, triglycerides, HOMA-IR (measure of insulin resistance) and insulinogenic 
index (measure of β-cell function). In order to determine the predictive power of 
baseline GGT in predicting diabetes, non-parametric, receiver operating characteristic 
(ROC) analyses were performed with the cumulative incidence of diabetes at the end 
of 2 years as the outcome variable 
215
. The ROC is one of the most commonly used 
statistics, and is defined as a plot of sensitivity on the vertical axis against the plot of 
specificity on the horizontal axis. The value of ROC ranges from 0 to 1. A value of 0.5 
equates to chance, and a value of 1 indicates perfect discrimination 
215
. The area under 
the curve (AUC) of the ROC and a 95% confidence interval (CI) were calculated by 
the Delong method to evaluate the diagnostic utilities of the marker for diabetes 
prediction 
216
.  The optimal cut-off point of each marker was estimated by calculating 
the Youden index 
217
. Specificity and sensitivity were calculated using that cut-off. 
The positive likelihood ratio was calculated using the formula: sensitivity / (1-
specificity). A test for the equality between two AUC’s was evaluated using an 
algorithm suggested by DeLong et al 
216
. 
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4.3.4 Results 
4.3.4.1 Baseline characteristics of the study participants according to glycaemic 
status at the end of the study 
Table 4-1 shows the baseline anthropometric and metabolic risk factors, according to 
OGTT-status at the end of the study. Individuals who developed T2DM had higher 
baseline fasting and 2-hr PG compared with regressors (IGT to normal glucose 
tolerance (NGT)). Also, the mean fasting plasma insulin was higher and the mean of 
OGTT-induced 30 minutes plasma insulin was lower in the progressors group 
compared with the regressors group. 
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                 Table 4-1: Baseline characteristics of study individuals based on the glycaemic outcomes at the end of 2
nd
 year. 
Variables IGT  to NGT 
(n=170) 
IGT to IGT 
(n=224) 
IGT to T2DM 
(n=123) 
Age (Yrs) 46.1±4.8 46.1±4.7 46.1±4.5 
Body mass index (Kg/m
2
) 25.9±3.2 25.5±2.9 26.1±3.6 
Waist circumference (Cm) 93.0±7.4 91.9±6.8 93.0±8.0 
Blood pressure (mmHg) 
Systolic 
Diastolic 
 
123.8±12.8 
80.1±8.0 
 
122.0±14.0 
79.6±8.4 
 
124.0±14.4 
81.2±9.0 
Family history of diabetes, n 
(%) 
a
 
 
82 (48.2) 
 
122 (54.5) 
 
69 (56.1) 
Smoking, n (%)
a
 37 (21.8) 44 (19.6) 36 (29.3) 
Drinking habits, n (%)
a
 60 (35.3) 84 (37.5) 47 (38.2) 
Glucose (mmol/l) 
Fasting 
2-hr 
 
5.5 ± 0.5 
8.5 ± 0.7 
 
5.6 ± 0.5 
8.7 ± 0.8* 
 
5.8 ± 0.5†,¶ 
9.2 ± 0.9†,¶ 
HbA1c (%) 6.0±0.3 6.1±0.3 6.3±0.4†,¶ 
Insulin (pmol/l)
b
 
Fasting 
Min 30 
2-hr 
 
81.3 (57.8-102.6) 
620.2 (425.4-957.7) 
848.0 (581.9-1389.2) 
 
80.0 (58.3-99.7) 
531.8 (350.3-809.3) 
857.4 (583.6-1255.4) 
 
93.2 (72.2-118.1) *, ‡ 
468.0 (338.9-832.7) *, ‡                       
847.3 (604.4-1286.0) 
Gamma-glutamyl transferase
 b
 23.0 (17.9-33.8) 23.0 (17.4-35.5) 30.1 (22.6-48.8) † 
Alanine transaminase 14.7±9.9 14.6±7.2 16.5±9.4 
     Legend: Data are mean±SD (for normally distributed variables) and analyzed by oneway ANOVA;  
    a: expressed as counts (percentage) for categorical measures – analyzed by  test; 
   b: expressed as median (inter quartile range) for skewed variables – analyzed by Kruskal Wallis test. 
   * P< 0.05 vs. NGT; † P<0.001 vs. NGT; ‡ P< 0.05 vs. IGT; ¶ P<0.001 vs. IGT;  
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4.3.4.2 Serum GGT activity according to glycaemic status at the end of the study 
During the 2 year follow up, there were 123 incident cases of diabetes among 505 
non-diabetic men in this cohort. Mean age and BMI were 46.0 ± 4.7 years and 
25.8±3.1 kg/m
2 
respectively. The median values of serum GGT and ALT were 24.0 
(inter quartile range (IQR: 18.0-36.1)) UL
-1
 and 13.0 (IQR: 10-19) UL
-1
 respectively. 
38.0% of the study individuals consumed alcohol regularly and 23.6% were current 
smokers. The levels of GGT were significantly higher in those who developed 
diabetes at the end of the study (IGT to NGT: 23.0 (17.9-33.8) UL
-1
; IGT to IGT: 23.0 
(17.4-35.5) UL
-1
; IGT to T2DM: 30.1(22.6-48.8) UL
-1
; P<0.0001).The levels of ALT 
did not differ statistically between the groups (NGT: 14.7±9.9 UL
-1
; IGT: 14.6±7.2 
UL
-1
; T2DM: 16.5±9.4 UL
-1
, P=0.101). Hence, for the subsequent analysis, we studied 
only the effect of GGT on the incidence of diabetes.  
4.3.4.3 GGT activity at the end of the study 
In the total group, over the two years, the median GGT activity did not change 
significantly (final: 25.0 (19.0-37.0) UL
-1
). However, changes were noted when they 
were categorized based on the final glycaemic outcomes. The mean change in GGT 
activity was significantly negative (95% CI <0) in individuals who reverted to NGT, 
whereas it was significantly positive (95% CI >0) in individuals who developed 
diabetes. There was no change in GGT levels in individuals who remained as IGT 
(mean change (95%CI) NGT: -3.5 (-6.4 to -0.6); IGT: -0.3 (-3.0 to 2.4); T2DM: 8.3 
(3.6 to 13.0) UL
-1
; P<0.0001). 
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4.3.4.4 Correlates of GGT 
We observed significant, positive, univariate relationships between baseline GGT and 
triglycerides, total cholesterol, ALT, HbA1c and HOMA-IR (P< 0.0001). Present  
alcohol consumption and obesity measures (BMI and waist circumference) were also 
correlated with baseline GGT levels (P<0.01). Hemodynamic measures and High 
Density Lipoprotein (HDL-C) did not correlate significantly with GGT levels. 
4.3.4.5 GGT and diabetes 
Figure 4-2 shows the association of GGT with incident diabetes. In model-1, GGT 
activity greater than or equal to the median of 24 UL
-1
 was associated with a 
significantly increased risk of diabetes (HR: 2.23 [95%CI: 1.53-3.25]; P<0.0001). In 
model-2 and model-3, the association of GGT remained unchanged even after the 
adjustment for study group, age, BMI, family history of diabetes, smoking, drinking 
and ALT (HR:2.14 [95%CI: 1.45-3.15]; P<0.0001). However, when GGT was further 
adjusted for 2hr PG, HbA1c, triglycerides, HOMA-IR and insulinogenic index, the 
relationship became somewhat weaker (HR: 1.75 [95%CI: 1.75-2.65]; P=0.006). 
ROC analyses showed that the optimum discrimination of diabetes risk over the two-
year follow-up period by baseline GGT activity was achieved with a cut-off of ≥ 26.4 
UL
-1
 (AUC ROC [95% CI]: 0.637 [0.581-0.692]; P< 0.0001; sensitivity: 61.2%; 
specificity: 60.9%). 
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0 1 2 3 4
Model-1
Model-2
Model-3
Model-4
Hazard ratio [95%CI]
2.23[1.53-3.25]
2.20[1.50-3.23]
2.14[1.45-3.15]
1.75[1.15-2.65]
 
 
Figure 4-2: Cox proportional hazard showing predictive power of baseline GGT (in 
medians) 
Legend: 
Dependent variable: incident diabetes vs. non-diabetes; GGT values are dichotomized 
into below median (<24 UL
-1
) and above median (≥24 UL-1) values. 
Model-1: Unadjusted model. 
Model-2: adjusted for study group, age, BMI, family history of diabetes, smoking and 
drinking 
Model-3: model-2 adjusted for ALT 
Model-4: model-3 adjusted for 2-hr PG, HbA1c, TG, HOMA-IR (measure of insulin 
resistance) and insulinogenic index (measure of β- cell function). 
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4.3.4.6 Discussion 
Elevated GGT activity in prediabetic individuals was associated with increased risk of 
developing diabetes even after adjustment for potential confounding variables. GGT 
activity above the median of 24.0 UL
-1
 were predictive of incident diabetes. The 
optimum threshold of ≥26.4 UL-1 in the ROC analysis was much lower than that of the 
conventional upper limit of normal (50 UL
-1
) for GGT
218
. Revision of the current 
normal concentration range may be warranted if GGT is to be used in prediction of 
diabetes. Previous large, epidemiological, prospective studies demonstrated an 
association between elevated GGT levels and risk of diabetes in normoglycaemic 
individuals among white 
211,219,220
, Black 
221
 Japanese 
222
 and Korean populations 
194
. 
The present analysis provides new evidence about the link between GGT and incident 
diabetes in Asian Indian individuals with IGT. A systematic meta-analysis showed 
that a 1U/l increase of natural logged GGT was associated with a 92% increase in 
diabetes risk (HR: 1.92 [95%CI: 1.66 –2.21]) in variably adjusted model 219. This 
consistent evidence across all ethnic populations suggests this simple marker may be a 
useful test to identify individuals at high risk of diabetes.  
No independent association between raised ALT levels and incident diabetes was seen 
in our population. This finding was in accordance with the findings from some 
206,223,224
  but not all 
205,206,214,225
  previous studies.  
In this cohort of individuals with IGT, plasma GGT levels decreased in those 
individuals who regressed to NGT, whereas they increased in those who progressed to 
diabetes. This finding is in accordance with the previous prospective studies which 
showed a positive association of increases in GGT with T2DM 
220
, metabolic 
syndrome 
226
 and cardiovascular disease 
227
.  
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Increased GGT is conventionally interpreted as a marker of excessive alcohol 
consumption
228
. This relationship did not explain the association between GGT and 
diabetes seen in this cohort. The association of GGT with diabetes could be due to the 
excessive lipid accumulation in hepatocytes
229,230
 and the resultant hepatic insulin 
resistance, possibly related to decreased portal insulin extraction
231
 and increased 
glucose output, thereby contributing to the development of total body insulin 
resistance
230
 and diabetes
232
. However, in this study the association of GGT with 
incident diabetes was independent of insulin resistance as measured by HOMA-IR. 
Therefore, the association of GGT with diabetes could be through pathways other than 
hepatic insulin resistance. Furthermore, GGT plays a pivotal role in extracellular 
catabolism of antioxidant glutathione
233,234
 and is an early marker of sub-clinical 
inflammation 
235
. In addition to its role in diabetes, elevated levels of GGT within its 
reference range are associated with metabolic syndrome 
236,237
 and cardiovascular 
mortality 
238-240
 and it considered as a proatherogenic marker because of its indirect 
relationship with biochemical steps that lead to low-density lipoprotein cholesterol 
oxidation 
241,242
. 
Another, possible explanation is that, even mild chronic dysglycaemia (as in IGT in 
this cohort) is associated with oxidative stress
243
, and raised levels of GGT might 
synergistically damage intracellular systems through excessive oxidative stress 
235,242,244
 which might play a role in causation and development of diabetes. In 
summary, we have demonstrated a positive association between GGT with incident 
diabetes in this cohort. 
Predictors of Type 2 Diabetes – Classical predictors 
90 
 
4.4 Association of hypertriglyceridemic waist phenotype with incident diabetes 
4.4.1 Study rationale 
Visceral adiposity precedes the development of diabetes
245,246
. There is strong 
evidence that excess of visceral fat, measured by enlarged waist circumference, is 
closely associated with insulin resistance and disturbances in lipid and glucose 
metabolism
247
. Previous studies in South Asians 
134
, including our study 
248
, have 
reported an association of waist circumference with diabetes, suggesting that the 
increased accumulation of fat in the abdominal cavity may be one of the contributors 
to diabetes in this ethnic group. The increasing prevalence of central-obesity, 
sedentary behaviour and unhealthy dietary habits leads to hypertriglyceridemia which  
is a risk factor for insulin resistance, T2DM and prediabetes 
249
. Enlarged waist 
circumference cannot be distinguished from intra-abdominal adiposity and 
subcutaneous fat depots 
250
. Therefore, Lemieux et al 
251
 proposed the presence of 
elevated triglyceride levels in the presence of central adiposity as a “proxy” measure 
to identify individuals with an increased risk of the atherogenic lipid triad (increased 
triglyceride levels, decreased HDL-C concentrations and the presence of small, dense 
LDL particles), hyperinsulinemia and sub clinical inflammation. In fact, the 
hypertriglyceridaemic waist phenotype (HTWP) was proposed as a simple screening 
method to identify participants at high cardiometabolic risk
252,253
. Though cross-
sectional studies
254-257
, including ours
258
, had demonstrated an association of the 
phenotype and diabetes, the utility of this measure for the prediction of incident 
diabetes has not been studied much. This ancillary cohort analysis was done with the 
objective of analyzing the possible association of HTWP with incident diabetes 
considering the simplicity of identifying the presence of HTWP and its association 
with other cardiometabolic risk factors. 
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4.4.2 Methods: 
The characteristics of the study participants and methods were already explained in 
detail in Chapter-2. Briefly, of the 537 individuals recruited for the study, 517 
individuals responded till the final follow-up (response rate: 96.3%) out of which 123 
individuals developed diabetes. The present analysis was limited to those individuals 
who completed the final year follow-up. 
4.4.3 Definition of variables 
The cut-off values for the waist circumference and triglycerides recommended for the 
Asian population by the International Diabetes Federation 
6
 were used to categorize 
the participants to four groups: 
 Normal waist-line and triglycerides level (NWTG): waist circumference <90 
cm; serum triglycerides <1.7 mmol/l  
 Enlarged waist-line and normal triglycerides level – Isolated enlarged waist 
(iEW): waist circumference ≥90 cm; serum triglycerides < 1.7 mmol/l 
 Normal waist-line and raised triglycerides level – Isolated 
hypertriglyceridemia (iHTG): waist circumference <90 cm; serum triglycerides 
≥ 1.7 mmol/l 
 Hyper triglyceridemic waist phenotype (HTWP): waist circumference ≥90 cm; 
and serum triglycerides ≥ 1.7 mmol/l. 
4.4.4 Statistical analysis 
General characteristics of individuals among the study phenotypes were compared by 
one way ANOVA for normally distributed variables following Bonferroni post hoc 
correction, Kruskal Wallis test for skewed variables with Dunn’s multiple comparison 
test and 2 test for categorical measures after with Bonferroni P value correction. 
Linear regression analyses were used to assess associations of iEW, iHTG and HTWP 
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with insulin resistance as measured by HOMA-IR (dependent variable). Adjusting for 
age, BMI, family history of diabetes, hypertension, fat%, smoking and alcohol 
consumption was performed in model-1 and in model-2 additionally for 2-hr PG and 
HDL-C. Cox regression analysis was used to calculate HR and corresponding 95% CI 
for the risk of T2DM for different categories of enlarged waist and/or 
hypertriglyceridemia as shown above after adjusting for potential confounding factors 
known to affect the outcome variable. Cox’s proportional hazard models were 
computed to assess the relative risk of HTWP with incident diabetes after adjusting for 
the potential confounding variables. The covariates which showed significant 
univariate associations with HTWP were chosen for the multivariate analyses. Age, 
family history of diabetes and 2-hr PG values were included in the model due to their 
strong associations with diabetes. Analyses were adjusted for the dichotomous 
variables: study group, family history, known hypertension, smoking and drinking 
habits and for the continuous variables: baseline age, BMI, fat%, 2hr PG, GGT and 
HOMA-IR. Survival curve was computed based on the phenotype categories. P <0.05 
was considered statistically significant. SPSS (IBM SPSS Statistics for Windows, 
Version 19.0. Armonk, NY: IBM Corp) was used for the analyses. 
4.4.5 Results 
4.4.5.1 The prevalence of isolated enlarged waist, isolated hypertriglyceridaemia and 
hypertriglyceridaemic waist phenotype 
Baseline characteristics of the participants classified on the basis of waist 
circumference and triglycerides levels are shown in Figure 4.2. iHTG was present in 
64 (12.4%), 167 (32.3%) had HTWP and a total of 231 (44.7%) had fasting 
hypertriglyceridemia. Central adiposity was present in 358 (69.2%) participants 
amongst whom 191 (36.9%) had the iEW phenotype. 
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Figure 4-3: The prevalence of single abnormality (iEW and iHTG) and combination 
of both (HTWP) 
Legend: iEW: isolated enlarged waist; HTWP: hypertriglyceridemic waist phenotype; 
iHTG: isolated hypertriglyceridemia. 
 
 
4.4.5.2 Baseline characteristics of four sub-groups 
The baseline characteristics of the four sub-groups are presented in Table 4-2. 
Participants with iEW and HTWP categories had significantly higher BMI, waist 
circumference and fat% compared with NWTG and iHTG groups (P<0.0001). 
Participants with HTWP had raised diastolic blood pressure compared with NWTG 
(P<0.05). No significant differences in fasting and 2-hr PG levels were observed 
between the groups.  HTWP and iHTG phenotypes had significantly higher total 
cholesterol, and lower HDL-C levels compared with NWTG and iEW groups 
(P<0.0001). The HTWP group had higher insulin resistance compared with NWTG, 
iHTG (p<0.0001 for both) and iEW (P<0.05) phenotypes. The participants with 
HTWP also showed an increased insulinogenic index compared with NWTG 
(P<0.05). 
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                 Table 4-2: Anthropometric and clinical characteristics of individuals based on the categories of waist and triglycerides levels. 
Variables Total  NWTG iEW iHTG HTWP 
n (%) 517 95 (18.4) 191 (36.9) 64 (12.4) 167 (32.3) 
Age (years) 46.1±4.7 46.2 ± 4.8 46.0 ± 4.8 45.3  ± 4.4 46.4 ± 4.5 
Body mass index (Kg/m
2
) 25.8±3.2 23.5 ± 2.3 26.8 ± 2.7 
†, ¶
 23.8 ± 2.7 26.8 ± 3.2
†, ¶,**
 
Waist circumference (cm) 92.6±7.3 85.2 ± 3.6 95.8 ± 5.4 
†, ¶
 84.9 ± 3.2 96.4 ± 6.4
†, ¶,**
 
Total body fat (%) 27.5 ± 4.7 24.6±4.5 28.6±4.4 
†, ¶
 26.1±4.3 28.3±4.3
†, ¶,**
 
Blood pressure (mmHg) 
Systolic 
Diastolic 
 
123.1±13.7 
80.2±8.4 
 
120.6±13.3 
77.8 ± 8.4 
 
124.3 ± 13.0 
80.6 ± 7.9 
*
 
 
120.2 ± 12.9 
80.0 ± 6.8 
 
124.2 ± 14.9 
81.1 ± 9.3
*
 
Hypertension, n(%) 133 (25.7) 21 (22.1) 59 (30.9) 10 (15.6) 43 (25.7) 
Family history n(%) 273 (53.3) 43 (45.2) 107 (56.9) 35 (54.8) 88 (53.4) 
Smoking, n(%) 117 (22.7) 17 (17.6) 40 (21.3) 19 (26.8) 41 (26.2) 
Drinking, n(%) 191 (38.0) 30 (30.2) 64 (35.5) 24 (40.2) 73 (41.8) 
Plasma glucose (mmol/l) 
Fasting 
2-hr 
 
5.62±0.54 
8.78±0.82 
 
5.57±0.54 
8.72±0.82 
 
5.63±0.53 
8.82±0.82 
 
5.54±0.52 
8.82±0.81 
 
5.67±0.56 
8.73±0.82 
Lipid profile (mmol/l) 
Triglycerides 
Total cholesterol 
HDL cholesterol 
 
1.60(1.19-2.11) 
4.87±0.91 
0.89±0.20 
 
1.20 (0.99-1.39) 
4.67±0.66 
0.95±0.18 
 
1.23 (1.04-1.47) 
4.63±0.88 
0.93±0.23 
 
2.35 (1.93-2.82)
†,¶ 
5.09±1.02
* 
0.84±0.17 
*
 
 
2.19 (1.91-2.70)
†,¶ 
5.16±0.92
† 
0.85±0.17
*
 
Gamma-glutamyl 
transferase 
32.6±25.5 25.8±15.6 29.8±21.6 37.2±37.2
*
 37.7±27.3 
*,‡
 
Alanine transaminase 15.0±8.8 14.3±8.6 14.1±7.1 16.5±10.3 15.8±8.8 
HOMA-IR 3.1±1.4 2.5±1.1 3.1±1.4 
*,§
 2.7±1.0 3.6±1.5 
†,‡,**
 
Insulinogenic index 
(pmol/mmol) 
48.1 (28.8-79.7) 41.8 (24.0-62.2) 50.3 (30.6-81.5) 45.2 (26.9-73.6) 53.8 (32.1-83.0) 
*
 
Data are means ± SD, median (inter quartile range) and counts; P values are calculated by One way ANOVA after post-hoc correction  with 
Bonferroni, Kruskall Wallis test (for skewed variables) after post-hoc correction with Dunns and 2 test (categorical measures) after 
correction with Bonferroni. NWTG: Normal waist-line and triglycerides level; iEW: Isolated enlarged waist; iHTG: Isolated 
hypertriglyceridemia; HTWP: Hyper triglyceridemic waist phenotype; *  P< 0.05 vs. NWTG;  † P<0.001 vs. NWTG; ‡ P< 0.05 vs. iEW; ¶ 
P<0.001 vs. iEW; § P<0.05 vs iHT; ** P<0.001 vs. iHTG 
Predictors of Type 2 Diabetes – Classical predictors 
 
95 
 
4.4.5.3 Association between insulin resistance and HTWP 
The association between insulin resistance and the categories of abnormalities assessed 
by multiple linear regression analyses are shown in Table 4-3. HTWP was positively 
associated with insulin resistance after adjustment for an array of potential 
confounders. iEW showed a significant association with insulin resistance in an 
unadjusted model, but the association was attenuated when anthropometric and other 
confounding variables were entered in the equation. iHTG did not show any significant 
association with HOMA-IR. 
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Table 4-3: Linear regression analyses showing the association of different abnormalities with insulin resistance. 
Variables 
Baseline 
Unadjusted Model-1 Model-2 
β (95%CI) P value β (95%CI) P value β (95%CI) P value 
NWTG Ref -- Ref -- Ref -- 
iEW 0.25(0.13-0.36) <0.0001 0.1 (-0.01- 0.26) 0.052 0.13 (-0.01-0.26) 0.067 
iHTG 0.14(-0.02- 0.28) 0.090 0.08 (-0.08-0.22) 0.345 0.04 (-0.12-0.20) 0.620 
HTWP 0.38(0.27-0.50) <0.0001 0.27 (0.14-0.41) <0.0001 0.23 (0.09-0.37) 0.001 
 
 Legend: Dependent variable: Insulin resistance (HOMA-IR – log transformed); data are regression co-efficient (β) and 95% confidence 
intervals. 
Model-1: adjusted for age, BMI, family history of diabetes, hypertension, body fat percentage, smoking and drinking habits.  
Model-2: Model-1 further adjusted for 2-hr PG during OGTT and HDL cholesterol. 
NWTG: Normal waist-line triglycerides level; iEW: Enlarged waist-line normal triglycerides level; iHTG: Normal waist-line 
Raised triglycerides level; HTWP: hypertriglyceridemic waist phenotype 
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4.4.5.4 Association between HTWP and incident diabetes 
Table 4-4 shows the hazard ratio attributed to the different abnormalities for T2DM 
variables with and without adjusting for the study groups (intervention vs. standard 
care), baseline age, BMI, fat%, family history, smoking, drinking alcohol habits 
(model-1), 2-hr PG, total cholesterol, HDL-C (model-2) and GGT levels (model-3). 
The HR of the unadjusted model was 1.53 ([95% CI: 1.07–2.20]; P=0.019). The 
relationship remained significant after adjusting for the above confounding factors 
(model-3: HR: 1.49 [95%CI: 1.01-2.21]; P=0.047). Addition of insulin resistance to 
model-3 nullified the significance (model-4; HR: 1.39 [95%CI: 0.92-2.10]; P=0.119). 
However, addition of β-cell function (as estimated by insulinogenic index, omitting 
insulin resistance) did not affect the relationship of HTWP with incident diabetes 
(model-5; HR: 1.59 [95%CI: 1.05-2.23]; P=0.040).  
Alternative combinations of cut-offs for waist circumference and triglycerides were 
explored in relation to incident diabetes and baseline insulin resistance (HOMA IR 
≥4.1), but offered no improvement regarding sensitivity and specificity over the chosen 
cut-off of waist circumference ≥90 cm and triglycerides ≥1.7 mmol/l (results not 
shown). 
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Table 4-4: Cox-proportional hazard model for incident diabetes during the 2 year 
follow-up. 
 
 
 
 
 
 
Legend: Dependent variable: Diabetes Vs non-diabetes 
HTWP categories was dichotomized (HTWP vs. others); TG only ≥ 1.7 mmol/l; WC 
only ≥ 90 cm 
Model-1: Adjusted for age, group, BMI, total body fat percentage, family history of 
diabetes, hypertension, smoking and drinking. 
Model-2: model-1 + 2-hr plasma glucose, cholesterol and HDL-C 
Model-3: model-2 + GGT 
Model-4: model-3 + insulin resistance (HOMA-IR) 
Model-5: model-3 + insulinogenic index 
β (s.e.): regression co-efficient and standard error 
HR [95% CI]: Hazard ratio [95% confidence intervals] 
 
4.4.6  Discussion 
The present analyses showed that HTWP is associated with insulin resistance and 
increased risk of diabetes in Asian Indian men with IGT.  Persons with HTWP also 
showed raised compensatory early phase insulin secretion. Although baseline 
glycaemia levels was similar in the four subgroups, the presence of HTWP alone 
conferred an increased risk of diabetes. The findings are in accordance with other 
studies: a Canadian study of healthy men where HTWP was associated with 
hyperinsulinemia as well as elevated apolipoprotein B, and small dense low density 
lipoprotein 
251,255
, a Chinese-community based prospective study in urban adults which 
showed an association of HTWP with diabetes 
259
 and a study in elderly men which 
showed an increased association of HTWP with glucometabolic risk and decreased 
Variables β (s.e) HR [95% CI] P value 
Unadjusted 0.43 (0.18) 1.53 [1.07-2.20] 0.019 
Model-1 0.38 (0.19) 1.47 [1.02-2.13] 0.041 
Model-2 0.41 (0.20) 1.50 [1.01-2.22] 0.043 
Model-3 0.40 (0.20) 1.49 [1.01-2.21] 0.047 
Model-4 0.35 (0.21) 1.39 [0.92-2.10] 0.119 
Model-5 0.41 (0.19) 1.59 [1.05-2.23] 0.040 
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insulin sensitivity 
257
. Earlier, our group showed an association of hypertriglyceridemia 
either in isolation (iHTG) or as HTWP as a strong predictor of atherogenic 
dyslipidemia and glucose intolerance in a cross-sectional analysis among Asian 
Indians
258
. The present prospective data suggested a possible etiological association of 
HTWP with T2DM. This was rendered non-significant by inclusion of IR in the model, 
suggesting that the association between HTWP and risk of incident T2DM was 
mediated through insulin resistance.   
In this cohort, hypertriglyceridaemia showed a marginal association with incident 
diabetes, whereas raised waist circumference did not show an association. A strong 
association of central adiposity with T2DM had been reported earlier by us in a cross-
sectional study in Indians 
248
.  McKeigue PM et al.
134
 reported a association between 
central adiposity and diabetes risk among migrants south Asians in UK .  This 
discordant observation noted in the present study could be due to the fact that the 
majority of the at-risk participants in our study had enlarged waist circumference at 
baseline (69.2%), such that enlarged waist circumference per se might have offered 
less potential for T2DM risk discrimination than in the general population.  
In an earlier study of normoglycaemic individuals, we noted a strong association 
between triglycerides and insulin resistance in the Asian Indian population. Using the 
ROC procedure, triglycerides concentration of > 1.7 mmol/l was found to have a 
sensitivity of 66.2% and specificity of 62.2% to distinguish insulin resistance (HOMA-
IR≥4.1) 249. The positive association of triglycerides with incident diabetes noted in the 
present study suggested that it might have a pathogenic role mediated through insulin 
resistance.  However, the effect was enhanced when hypertriglyceridemia co-existed 
with enlarged waist. 
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The association of HTWP with incident diabetes was significant even after the 
adjusting for 2-hr PG and GGT. But, the relationship was attenuated after adjusting for 
HOMA-IR.  Additionally, HTWP had been shown to be associated with increased 
visceral adiposity in glucose intolerant patients 
253
. For a given BMI, Asian Indians 
have higher waist-hip ratio and increased accumulation of abdominal fat than many 
other populations
7,248
. The presence of upper body adiposity coupled with 
hypertriglyceridemia, even in non-obese Asian Indians appears to induce a high degree 
of insulin resistance
258
 even among non obese Asian Indians. 
There is no universally accepted, clinically approved numeric expression that defines 
insulin resistance and β-cell dysfunction. The cut-off for insulin resistance varies 
among different ethnic groups and, hence the use of these measures requires careful 
interpretation and expertise which may not be feasible in routine clinical practice 
260’ 
261
. Although the HOMA model provides a robust, clinical and epidemiological tool to 
assess insulin action, its application may be limited in non-obese participants
260,262
. 
Plasma insulin is not routinely measured in most clinical laboratories, especially in the 
developing countries 
263
. Hence as an alternative simple approach, clinical measures 
such as BMI, waist circumference 
264
, and lipids (HDL-C/TG ratio) 
265,266
  have been 
proposed as proxy measures to identify participants with high risk of insulin resistance 
and compromised β-cell function. However, these measures explain the only a 
relatively modest amount of the variations in directly measured insulin resistance 
compared with insulin-based indices.  Hence, HTWP offers  alternative method to 
screen for individuals with increased risk of incident diabetes among prediabetic 
subjects. 
The strengths of this analysis are: a) the prospective design of the study; b) the study 
has been done in Asian Indians who have a high susceptibility for developing diabetes 
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and  c) it shows that even among a group of high-risk individuals with IGT, HTWP 
could be used to predict incident diabetes.  This study also has a few limitations. The 
study group was comprised only of men and hence, the association of HTWP with 
incident diabetes in women needs to be studied. Though, imaging data would be ideal 
for the determination of visceral adiposity, it is generally not feasible for a large 
epidemiological analysis, due to its high cost and need for specialized technical 
expertise. The use of HTWP as a predictor of incident diabetes has significant public 
health importance in implementing preventive studies. It is suggested that presence of 
HTWP, which can be assessed by routine laboratory measures and can serve as a 
simple screening tool to identify persons with insulin resistance and therefore at a high 
risk for diabetes. 
4.5  Oral disposition index and incident diabetes 
4.5.1 Study rationale 
Adaptation of insulin secretion to prevailing insulin sensitivity  is a tightly regulated 
mechanism and a deterioration of each function is found to be the associated with the 
development of T2DM
25
. As demonstrated by Bergman and associates
267
, there is a 
rectangular hyperbolic relationship between insulin secretion and insulin action and 
according to this paradigm there is a strict reciprocal relationship between these 
variables 
41,268
. The product of these measures approximates a constant, termed the 
“disposition index”. T2DM occurs only if β-cell function is inadequate to compensate 
for chronic insulin resistance 
268. Thus, accurate estimation of β-cell function requires 
determination of both variables because they need to be judged in relationship to each 
other. 
Methods for assessment of insulin action and secretion such as the euglycaemic and 
hyperglycaemic clamp  and intravenous glucose tolerance test minimal modelling and 
Predictors of Type 2 Diabetes – Classical predictors 
 
102 
 
evaluation of the acute insulin response to intravenous glucose are laborious and 
expensive procedures and, therefore, are rarely used in the large-scale epidemiological 
or clinical research setting 
267,269. A variety of surrogate mathematical “paradigm” 
models derived from fasting (HOMA) or OGTT plasma glucose and insulin 
concentration measurements have been proposed and validated  as alternative measures 
to evaluate insulin sensitivity and secretion, for example - Matsuda’s insulin sensitivity 
index and the insulinogenic index)  
61,67,139,140
. In fact, these measures have been shown 
to perform reasonably well for discrimination of individuals with differing levels of 
insulin resistance and β-cell dysfunction. But, the major shortcoming is that these 
measures were evaluated against the reference methods rather than as antecedents of 
diabetes. Recently, various versions of the disposition index as derived from OGTT 
(e.g: 1) insulinogenic index / HOMA-IR; 2) insulinogenic index / fasting insulin and 3) 
total AUCins/glu* Matsuda’s insulin sensitivity index) have been proposed as analogous 
to the disposition index derived from the frequently sampled intravenous glucose 
tolerance test (IVGTT, i.e., acute insulin response to glucose, AIRg*insulin sensitivity, 
Si) and have been shown to have a moderate association with reference methods 
78,79
. 
It is now well established that, a healthy diet with a lower glycaemic load 
214,225,270
, 
increased exercise
271
 and weight reduction
272
 improve insulin sensitivity in individuals 
with high risk for diabetes. Most studies of the pathogenesis of diabetes and effect of 
lifestyle intervention on the improvement of insulin sensitivity and β-cell function 
among high-risk individuals have been conducted in white populations 
214,225,270-272
; 
very few studies have addressed the pathogenic mechanisms in Asian Indians 
30,61
. 
Asian Indians have a strong predisposition for T2DM and have several peculiar 
pathophysiological features including a young age of onset of diabetes, a relatively 
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lower BMI, with high rates of insulin resistance, and lower thresholds for the risk 
factors for diabetes 
273
 compared with Caucasians.  
The objective of this analysis is to assess the predictive power of baseline disposition 
index derived from the OGTT in relation to the subsequent incidence of T2DM and to 
study the association of lifestyle parameters (dietary compliance and physical activity) 
with changes in oral disposition index. We hypothesize that, higher β-cell 
compensation at baseline, and improvement of the same during intervention, will be 
associated with decreased incidence of diabetes. We also hypothesizes that any 
improvement in the oral disposition index is mediated through improved dietary 
compliance in this study. 
4.5.2 Methods 
The description of the cohort was already explained in detail in Chapter-2 and 3. For 
this present analysis, we combined both the groups as a single cohort to unravel the 
association of oral disposition index with incident diabetes. 
4.5.3 Statistical analysis 
A relationship between insulin sensitivity and insulin secretion is thought to be a 
“rectangular hyperbola” wherein the product of the two measures approximates a 
constant. The validity of oral disposition index was assessed by demonstrating a 
hyperbolic relationship between the measure of insulin secretion and insulin sensitivity 
derived from the OGTT. Regression analysis was applied to different combinations of 
insulin secretion and insulin sensitivity index to determine the regression coefficient β 
for the following model: ln(insulin secretion) = constant  + β× ln(insulin sensitivity). In 
this context, the product of OGTT-based surrogate insulin measures obeys a 
hyperbolic relationship if the following criteria are satisfied: (i) regression coefficient 
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(β) is approximately equal to −1 and if the 95% confidence interval (CI) of β includes -
1 and excludes 0
82,274
.  
Results of the OGTT were used to designate a participant’s glucose tolerance status as: 
regressors (IGT to NGT), unchangers (IGT to IGT) and progressors (IGT to T2DM). 
Normally distributed variables were compared across glycaemic categories using one-
way ANOVA after post-hoc corrections according to Bonferroni. For non-parametric 
variables Kruskal- Wallis test with Dunn’s post-hoc corrections was used. Changes 
from baseline to follow-up were compared between groups by t test when variables 
were normally distributed and by Wilcoxon’s test for variables non-normally 
distributed. The power of oral disposition index and other surrogate insulin measures 
to predict a progression to diabetes was assessed with a ROC curve
216,217
. All analyses 
were performed using SPSS software (IBM SPSS Statistics for Windows, Version 
19.0. Armonk, NY: IBM Corp). 
4.5.4 Results 
The baseline characteristics of participants stratified according to their glycaemic 
outcome at the end of the study were shown previously (Table 4-1).  
4.5.4.1 Demonstration of hyperbolic relationship 
Using OGTT data, the two measures of insulin secretion (1) AUCins/glu from 0 to 2-hr; 
2), insulinogenic index) and three measures of insulin sensitivity (1) 1/HOMA-IR; 2) 
1/fasting insulin; 3) Matsuda’s insulin sensitivity index were tested for the existence of 
a hyperbolic relationship. The following combinations of composite β-cell function 
were calculated from the OGTT: a) insulinogenic index / HOMA-IR; b) insulinogenic 
index /fasting insulin; c) insulinogenic index * Matsuda’s insulin sensitivity index; d) 
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AUCins/glu from 0 to 2-hr/ HOMA-IR and e) AUCins/glufrom 0 to 120 min * Matsuda’s 
insulin sensitivity index (ISSI-2) 
79
. 
As shown in Table 4-5, the only pairing that satisfied both of the hyperbolic criteria 
was that of total AUCins/glu and Matsuda’s insulin sensitivity index (β: -0.954  [95% CI: 
-1.015 to -0.893]).  Importantly, the pairing of total AUCins/glu and Matsuda’s insulin 
sensitivity index yielded distinct hyperbolae for each glucose tolerance group (NGT: β: 
-0.946 [95% CI: -1.048 to -0.842]; IGT: β: -1.000 [95% CI: -1.085 to -0.915]; T2DM: 
β: -1.063 [95% CI: -1.202 to -0.923]), consistent with the existence of a hyperbolic 
relationship (Figure 4-4). The mean product of total AUCins/glu and Matsuda’s insulin 
sensitivity index progressively decreased from NGT to IGT to T2DM consistent with 
the notion of declining of β-cell function across these groups (IGT to NGT: 175.5 ± 
56.1; IGT to IGT: 159.3 ± 49.3; IGT to T2DM: 130.5 ± 52.5); P <0.0001). The product 
of total AUCins/glu and Matsuda’s insulin sensitivity index was therefore taken as the 
measure of oral disposition index in this cohort. 
4.5.4.2 Factors associated with improvement in oral disposition index 
Multiple linear regression analysis adjusted for age, family history of diabetes, baseline 
and change in BMI, dietary energy intake and physical activity demonstrated that 
weight reduction (β: -11.7 (95%CI: -8.1 to -15.2)) and decreased energy intake (β: -4.0 
(-2.8 to -5.2)) from baseline were independently associated with improvement in oral 
disposition index. 
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            Figure 4-4: Demonstration of hyperbolic relationship 
0 2 4 6 8 1 0
0
5 0
1 0 0
1 5 0
2 0 0
MISI
A
U
C
I/
G
0 1 2
3
4
5
6
L in e a r  re g re s s io n  a n a ly s is
L n [M IS I]
L
n
[A
U
C
I/
G
]
 
                                                           Insulin sensitivity [MISI] 
 
Legend: Estimated regression coefficient (β) and 95% CI for β, for combinations of 
insulin secretion, and sensitivity measures regressed using the following model: 
log(secretion measure) = constant + β × log(sensitivity measure); Overall:   Y= -
0.954*X+4.982 O: NGT:   Y= -0.946*X+5.079; □: IGT:     Y= -1.000*X+5.028;  ∆: 
DM:     Y= -1.063*X+4.868 
 
Table 4-5: Demonstration of hyperbolic relationship between surrogate measures of 
insulin secretion and sensitivity 
Secretion Sensitivity β 95% CI 
Insulinogenic index 1/HOMA-IR -0.496 -0.620 to -0.371 
Insulinogenic index 1/Fasting insulin -0.621 -0.745 to -0.496 
Insulinogenic index Matsuda’s insulin sensitivity index -0.865 -0.977 to -0.754 
AUCins/glu  1/HOMA-IR -0.584 -0.672 to -0.496 
AUCins/glu  1/Fasting insulin -0.689 -0.774 to -0.603 
AUCins/glu  Matsuda’s insulin sensitivity index -0.954 -1.015 to -0.893 
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4.5.4.3 Change in oral disposition index levels according to glycaemic status at the 
end of the study 
Overall, transition from IGT to NGT was associated with an improvement of insulin 
sensitivity and oral disposition index, and a reduction in insulin secretion (Figure 4-5, 
Panels A-C; Table 4-6). In individuals who underwent the transition IGT to T2DM, 
there were reductions in insulin sensitivity (-4.8%) and oral disposition index (-34.6%) 
and a greater reduction in insulin secretion (-28.1%) than in those undergoing the IGT 
to NGT transition. In individuals who remained IGT during the study, there was an 
intermediate increase in insulin sensitivity and a decrease insulin secretion and no 
change in oral disposition index. 
To illustrate the changes in oral disposition index associated with the three different 
transitions during the course of the study, insulin secretion was plotted against 
sensitivity in each of the three groups at baseline and then on completion of the study; 
in this way, six hyperbolic curves were generated and the point on each curve located 
by the mean insulin secretion and mean insulin sensitivity for each curve represented 
the oral disposition index (Figure 4-6). In the group that underwent the IGT to NGT 
transition, there was a rightward shift from the baseline towards higher insulin 
sensitivity and improved oral disposition index, whereas in the group undergoing the 
IGT to T2DM transition there was a shift toward the origin of the plot, with lower 
insulin secretion and sensitivity and lower oral disposition index. In the IGT to IGT 
group there was little apparent change. 
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Table 4-6: Baseline and final levels of insulin sensitivity, insulin secretion and oral 
disposition index according to glucose tolerance categories 
 Baseline Follow-up % 
change 
P value 
IGT to NGT  
Insulin sensitivity index 2.4±1.4 3.4±1.3 41.7 <0.0001 
AUCins/glu 81.2 (51.5-110.7) 68.6 (52.8-92.2) -15.5 0.003 
Oral disposition index 168.8 (136.3-203.8) 217.5 (179.3-281.0) 28.9 <0.0001 
IGT to IGT  
Insulin sensitivity index 2.6±1.5 3.0±1.7 15.4 <0.0001 
AUCins/glu 71.2 (48.3-99.1) 54.8 (38.9-74.7) -23.0 <0.0001 
Oral disposition index 154.8 (125.3-184.1) 146.1 (113.9-180.3) -5.6 0.115 
IGT to T2DM  
Insulin sensitivity index 2.1±1.0 2.0±0.8 -4.8 <0.0001 
AUCins/glu 62.6 (43.9-94.3) 45.0 (34.3-60.1) -28.1 <0.0001 
Oral disposition index 124.1 (101.3-155.8) 81.2 (69.6-100.8) -34.6 <0.0001 
 
Legend: Data are mean ± SD for normally distributed variables and median (inter quartile 
range) for skewed variables; IGT: impaired glucose tolerance; NGT: normal glucose 
tolerance; DM: diabetes; AUCins/glu: ratio of total area-under-curve between insulin and 
glucose. % change is calculated by (final values –baseline values / baseline values)*100. 
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Figure 4-5: Changes in insulin measures throughout the study. Individuals were all IGT at 
baseline and groups were distinguished by glycaemic status at the end of the study 
 
Legend: Changes in Matsuda’s insulin index (A), AUCins/glu ratio (B) and oral disposition 
index (C) throughout the study. Individuals were all IGT at baseline and groups were 
distinguished by glycaemic status at the end of the study. Change represents the difference 
between the absolute value at the study end minus baseline. * P< 0.05 vs. NGT; † P<0.001 
vs. NGT; ‡ P< 0.05 vs. IGT; ¶ P<0.001 vs. IGT. 
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Figure 4-6: Change in oral disposition index in relation to the final glycaemic outcomes 
 
 
Legend: The baseline and final year oral disposition index are plotted for individuals with 
NGT, IGT and DM relative to the hyperbolic curves; individuals deteriorated to diabetes had 
decreased β cell function at baseline. Those who regressed to normoglycaemia showed an 
improvement in β cell function at the end of follow-up. Symbols represent the mean values. 
●: NGT baselibe; ○ : NGT Final; ■: IGT baseline; □: IGT final; ∇: T2DM baseline; Δ: 
T2DM final; 
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4.5.4.4 Discussion 
In the present analyses we have demonstrated a hyperbolic relationship between 
OGTT-based total AUCins/glu and the Matsuda’s insulin sensitivity index in Asian 
Indian men with prediabetes. Importantly, IGT individuals with better β-cell 
compensation at baseline were the least likely to develop diabetes. These observations 
were consistent with the results of other studies: a prospective study in Hispanic 
women with gestational diabetes 
75
, the ACT NOW study 
77
 and an observational study 
in Japanese-American individuals which showed a strong association of oral 
disposition index with incident diabetes over 10 years duration 
82
. A recent cross 
sectional analyses in 1264 individuals conducted in Asian Indians had also found early 
reductions in β-cell function as a primary etiological factor for the development of 
diabetes 
275
.  
In this cohort, the combination of total AUCins/glu and the Matsuda insulin sensitivity 
index yielded distinct hyperbolae for different degrees of glucose tolerance. 
Furthermore, these hyperbolae exhibit a shift towards the origin as glucose tolerance 
worsens, in a manner analogous to the disposition index curves measured by 
euglycaemic and IVGTT methods 
53
. This shift in hyperbola position is a hallmark of 
T2DM pathophysiology and is considered as one of the earliest indicators of β-cell 
dysfunction
53
.  
Although, insulin resistance is a core pathophysiologic abnormality in the progression 
from NGT to IGT to diabetes, overt diabetes only occurs if β-cells fail to compensate 
for compounding insulin resistance. As reported by Petersen et al 
276, β-cell 
compensation for a given insulin resistance is around 60% lower in healthy Asian 
Indians compared with White populations matched for age, sex, BMI and lifestyle 
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factors. These findings suggest the possibility of ethnic differences in the optimal 
relationship between insulin sensitivity and insulin response
54. Declining β-cell 
compensation may be the primary aetiological precursor for glycaemic deteriorations 
from NGT to diabetes
277
.  
In this cohort, decreased total dietary energy consumption from baseline  and minimal 
weight reduction was associated with significantly improved β-cell function. Given the 
relative abundance of energy supply in much of the westernized world, the 
compensatory ability of the β-cell is the single physiological process that protects well-
fed individuals from the scourge of diabetes. While individuals living in developed 
nations have long been able to muster adequate food supplies, populations recently 
exposed to energy dense food have an inherent inability to adapt metabolically to the 
high calorie diet compared with the Caucasians 
278
.  
In summary, based on these findings, we infer that an OGTT derived measure of 
disposition index may be an alternate surrogate measure to identify high risk 
individuals. Importantly, improving insulin sensitivity by caloric restriction and 
minimal weight reduction may have beneficial effects on β-cell function and prevent 
diabetes for relatively long periods of time in genetically susceptible individuals. 
4.6  Comparison of classical risk factors 
Table 4-7 shows the ability of the baseline glycaemic measures, GGT, HTWP, insulin 
sensitivity and β-cell function to predict incident T2DM, as explored in this analysis, 
and their corresponding optimal cut-off points in predicting incident diabetes. As 
expected baseline FPG ≥ 5.6mmol/l (AUC: 0.615 [95%CI: 0.558-0.672]), 2hr PG ≥ 8.6 
mmol/l (AUC: 0.670 [95%CI: 0.614-0.725]) and HbA1c ≥ 6.1% (AUC: 0.674 [95%CI: 
0.616-0.732)]) predicted incident diabetes in this cohort.  
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Table 4-7: Area under the receiver operating characteristics and predictabilities of glycaemic, non-glycaemic and surrogate insulin 
indices for progression of diabetes 
a
 
 
Legend: a: Diabetes was diagnosed based on WHO recommendations; b: Significance level P (Area=0.5); c: P value computed by 
categorical contingency analysis; The units of each optimal cut-off point was shown in respective tables. 2hr PG: 2hr plasma glucose; 
FPG: fasting plasma glucose; GGT: gamma glutamyl transferase, HTWP: hypertriglyceridemic waist phenotype; HOMA-IR: 
homeostatsis model assessment of insulin resistance; MISI: Matsuda’s insulin sensitivity index.  
Indices 
AUC ROC  
(95% CI) 
P value
b
 
Sensitivity % 
(95% CI) 
Specificity % (95% CI) 
Positive 
likelihood ratio 
Glycaemic measures 
2hr PG 0.675 (0.614-0.725) <0.0001 58.5 (49.3-67.3) 67.5(62.6-72.1) 1.8 
FPG 0.620 (0.558-0.672) <0.0001 78.1(69.7-85.0) 40.9(36.0-45.9) 1.3 
HbA1c 0.677 (0.634-0.717) <0.0001 56.9(47.7-65.8) 71.1(66.3-75.5) 2.0 
Non-Glycaemic markers 
GGT 0.637 (0.593-0.679) <0.0001 71.1(62.1-79.0) 52.9(47.7-57.9) 1.5 
HTWP 
c
  0.016 41.0 (33.0-51.0) 71.0 (66.0-75.0) 1.4 
Combination of GGT and glycaemic measures 
FPG+GGT 0.668 (0.613-0.722) <0.0001 59.5 (50.2-68.3) 64.8(59.8-69.6) 1.70 
2hrPG+GGT 0.705 (0.653-0.757) <0.0001 74.4(65.6-81.9) 58.1(53.0-63.1) 1.77 
HbA1c+GGT 0.702 (0.648-0.755) <0.0001 59.5(50.2-68.3) 71.6(66.8-76.1) 2.1 
Insulin surrogate measures 
Oral disposition index 0.717 (0.675-0.756) <0.0001 70.0 (61.0-78.0) 64.1 (59.0-68.9) 1.95 
HOMA-IR 0.642 (0.598-0.685) <0.0001 59.2 (49.8-68.0) 62.7 (57.6-67.6) 1.58 
1/Fasting insulin 0.615 (0.570-0.658) 0.001 73.3 (64.5-81.0) 43.7 (38.6-48.9) 1.30 
MISI 0.598 (0.554-0.642) 0.0005 61.7 (52.4-70.4) 53.9 (48.7-59.0) 1.34 
Insulinogenic index 0.599 (0.554-0.642) 0.0013 45.0 (35.9-54.3) 72.5 (67.7-77.0) 1.64 
AUCins/glu 0.554 (0.509-0.599) 0.0728 60.0 (50.7-68.8) 50.4 (45.2-55.6) 1.19 
HOMA-β 0.530 (0.485-0.575) 0.3104 85.8 (78.3-91.5) 23.7 (19.5-28.4) 1.13 
Predictors of Type 2 Diabetes – Classical predictors 
 
114 
 
Among the glycaemic measures, baseline levels of HbA1c showed the highest 
predictive value for detecting diabetes. As already described, baseline GGT levels of ≥ 
26.4 UL
-1
 predicted incident diabetes over a 2 year period (AUC: 0.637 [95%CI: 
0.581-0.692]; P< 0.0001; sensitivity: 61.2%; specificity: 60.9%) in this cohort. In 
separate analyses, we have studied the predictive utility of GGT when combined with 
the glycaemic measures (Table 4-7). The results showed that the model comprising of 
FPG and GGT (AUC: 0.668 [95%CI: 0.613-0.722]; P<0.0001) was equally effective in 
identifying individuals with risk of diabetes as compared to the 2-hr PG and HbA1c. 
Furthermore, the addition of GGT to glycaemic measures improved the sensitivity for 
detecting diabetes. The association of HTWP with incident diabetes was found to be 
modest (specificity: 71.6 (66.8-76.1); sensitivity: 41.0 (33.0-51.0)). 
Among the surrogate insulin measures, the area under the ROC curve was highest for 
the oral disposition index (AUC: 0.717 [95%CI: 0.664-0.770]). The optimal cut-off 
value for predicting incident diabetes for the oral disposition index was ≤ 144.7 
(sensitivity: 70.0 (95%CI: 61.0-78.0); specificity: 64.1 (95%CI: 59.0-68.9)). Other 
surrogate insulin measures, HOMA-IR (AUC:  0.642 [950.598-0.685]), 1/fasting 
insulin (AUC: 0.615 [95%CI: 0.570-0.658]), Matsuda’s insulin sensitivity index 
(AUC: 0.598 [95%CI: 0.554-0.642]) and insulinogenic index (AUC: 0.599 [95%CI: 
0.554-0.642]) also showed significant predictability. In this cohort, total AUCins/glu did 
not show an association with T2DM. This discordant observation noted in the present 
study could be due to the fact that IGT itself is a compromised β-cell responsive 
state
279
, so total AUCins/glu per se may have offered less potential for T2DM risk 
discrimination. Furthermore, AUCins/glu ratio may not be a good surrogate index for 
predicting diabetes
280
. 
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4.7 Classical risk factors as a predictor of diabetes - Final thoughts  
In this cohort, oral disposition index was a better predictor of incident diabetes 
compared with other OGTT-based insulin measures such as the combination of 
HOMA-IR and insulinogenic index. Previously, our group showed independent 
associations of both insulin resistance and impaired early insulin secretion in the 
development of diabetes
61
. The oral disposition index as a composite measure may 
be a better index than either insulin secretory measure or sensitivity alone. There 
seems to be an ethnic disparity in the interaction between insulin action and secretion 
in Asian Indians. For a given BMI and waist circumference, Asian Indians usually 
have a poorer β-cell reserve and decreased insulin sensitivity compared with 
Caucasians
281
. As reported by Petersen et al 
276, β-cell compensation for a given 
insulin resistance is around 60% lower in healthy Asian Indians compared with 
White populations matched for age, sex, BMI and lifestyle factors. These findings 
suggest the possibility of genetic determinants that cause early β-cell failure in the 
presence of chronic insulin resistance. 
Not surprisingly, glycaemic measures were predictive of incident diabetes. In this 
cohort, baseline GGT levels showed a modest association with diabetes, possibly 
suggesting its role in the pathogenesis of diabetes. In this analysis, additive values of 
combining GGT and glycaemic measures in prediction of incident diabetes were also 
studied.  The diagnostic power was moderately improved when GGT was added to 
FPG or HbA1c. Therefore, we propose that combination of measures of glycaemia 
(FPG and HbA1c) and GGT may be an alternate and sensitive tool to identify 
individuals at risk. But, it should be emphasize that neither HbA1c nor GGT levels 
provide information about oral disposition in this cohort. 
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Declining β-cell compensation may be the primary aetiological precursor for 
glycaemic deterioration from NGT to diabetes. However, this measure of β-cell 
function requires performance of the OGTT with determination of the plasma insulin 
and glucose concentrations. The existing glucose-based diagnostic tests have a few 
performance limitations
282
. The OGTT is the reference test for the diagnosis of 
diabetes according to World Health Organization (WHO)
85
. But it is time-
consuming, unpleasant for the patients and not used routinely in large 
epidemiological studies. Though, FPG is easy to perform it has poor specificity for 
identifying high risk individuals, especially in Asian populations. Recently, the 
American Diabetes Association (ADA) and the WHO recommended HbA1c as a 
surrogate measure of chronic hyperglycaemia over 8-12 weeks for diagnosis of 
diabetes
83,87
. In our cohort, the combination of HbA1c and GGT was found to be 
associated with diabetes. In fact, this composite measure was as predictive as the 
disposition index for this purpose. In an epidemiological setting, the use of the 
OGTT may be limited. Therefore, we propose that a simple clinical model 
comprising of HbA1c and GGT, both of which are routinely available, could provide 
an alternate screening tool to identify individuals with high risk of developing 
diabetes. These findings could have important public health implications. 
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 5 ASSOCIATION OF NOVEL BIOMARKERS AND DIABETES 
5.1 Background 
In addition to the “classical” biomarkers derived from glycaemic measures, surrogate 
insulin measures, hepatic enzymes and abnormal lipid profile, there is a broad range of 
measurements of specific plasma proteins that may provide valuable information 
concerning type 2 diabetes (T2DM) risk. Candidates for a “novel panel” of biomarkers 
were selected from searches of the PubMed database using search terms associated with 
mechanisms known to be important in the development of diabetes such as carbohydrate 
and lipid metabolism, insulin resistance, β- cell dysfunction, inflammation and oxidative 
stress. Over 1000 abstracts were reviewed; from this rigorous literature research I 
shortlisted 7 biomarkers for this pilot project. 
5.2  Justification of proposed biomarkers 
5.2.1 Justification: systems biology approach:  
In order to explore the interaction of these selected biomarkers and illustrate their 
functional complexity, selection of this panel was informed by the systems biology 
bioinformatics tool STRING (Search Tool for the Retrieval of Interacting Genes) 
283,284
. 
This tool is an exploratory database designed with the goal to assemble, evaluate and 
disseminate protein-protein association information in a user-friendly and 
comprehensive manner. The tool has been employed here to distinguish networks of 
association between potential biomarkers and illustrate the strengths of association 
between them. In the database, the associations between proteins are derived from: 1) 
experimental evidence; 2) manually curated database evidence (from, for example, the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) database)
285
; 3) text mining 
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evidence (PubMed)
286
; and 4) genomic context analysis (co-expression and 
neighbourhood analysis)
287
. These associations are then quantitatively expressed by a 
probabilistic confidence score ranging from 0 to 1. This is computed under the 
assumption of independence for the various sources, in a naïve Bayesian fashion
284
. 
Figure 5-1 shows the STRING-generated network view of the proposed biomarkers 
under investigation. 
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Figure 5-1: Graphical representation of association / functional interaction of proposed 
biomarkers 
Legend: STRING generated network of proposed biomarker (http://string-
db.org/newstring_cgi/show_input_page.pl). Stronger associations are represented by 
thicker lines. From this network view we can affirm that these proteins are associated 
with each other functionally. Cross-talk between these functional proteins might then 
mean that derangement of function in one protein could affect proteins involved in distal 
pathways and promote pathogenesis of T2DM. ADIPOQ: adiponectin, LEP: leptin, INS: 
insulin, RBP4: retinol binding protein-4, IL-6: interleukin-6, GGT: gamma-glutamyl 
transferase, GPT: Alanine transaminase. *: Confidence scores are derived from the 
addition of: 1) experimental evidence; 2) manually curated database evidence; 3) text 
mining evidence (PubMed); and 4) genomic context analysis (co-expression and 
neighbourhood analysis); confidence range (low confidence: scores<0.4; medium: 0.4 to 
0.7; high:>0.7)
 
Variable-1 Variable-2 Score
*
 
ADIPOQ LEP 0.954 
ADIPOQ INS 0.923 
ADIPOQ IL-6 0.878 
RBP4 IL-6 0.432 
RBP4 LEP 0.613 
LEP INS 0.980 
IL-6 INS 0.968 
GGT1 INS 0.542 
GGT1 GPT 0.508 
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5.2.2 Justification - mechanistic approach: 
Mechanistic justifications for this network can be found in well-established biochemical 
and physiological connections 
288
. For instance, abnormal levels of chemokines released 
by the expanding adipose tissue during obesity and insulin resistance impair insulin 
action by altering the secretion of cytokines, specifically of leptin and adiponectin 
289
, 
and also leads to inflammatory conditions, with increased inflammatory cytokines such 
as interleukin-6 (IL-6). Such cytokines, in turn, increase insulin resistance in adipose 
tissue, skeletal muscle and liver. This contemporaneous effect contributes to an 
unfavourable shift in the pro-inflammatory / anti- inflammatory balance. Leptin, apart 
from its role in energy expenditure and inflammation, also indirectly reduces the levels 
of the anti-oxidant enzyme Paraoxonase-1(PON1) 
290
 in the circulation and could, 
therefore promote oxidation of LDL particles. Usually, Asian Indians have elevated 
levels of free fatty acids in plasma 
291
 , which can result in accumulation of ectopic fat, 
non alcoholic fatty liver disease and increased levels of liver enzymes in circulation. 
Hepatocytes and adipocytes also secrete retinol binding protein 4 (RBP4), the specific 
transport protein for retinol (vitamin A)
292-295
. Several studies have demonstrated that 
increased levels of RBP4 result in insulin resistance in peripheral tissues such as liver 
and skeletal muscle by an interaction with the insulin-sensitive GLUT4 glucose 
transporter
296-298
. A normal level of vitamin D itself is essential for the release of insulin 
from pancreatic β- cells and decreased levels have been related to development of β- cell 
dysfunction 
299
. However, these reports are not uniformly confirmed in other studies
300
. 
Thus, the rationale of using one biomarker to predict T2DM is uncertain, when the risk 
of progression to T2DM actually varies with a range of biomarkers affected in various 
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pathways. This justifies study of the co-association of multiple biomarkers in the 
development of T2DM.  
5.3 Clinical relevance of proposed biomarkers 
The clinical relevance of each biomarker is explained in detail in the subsequent section.
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5.3.1 Adiponectin 
Epidemiological evidence: 
 In Asian Indian individuals (IDPP-1) with   
    lower BMI, lower adiponectin level at baseline   
    was a strong predictor of future diabetes (OR   
    0.87 [0.79-0.95]) 
301
. 
 In the Insulin Resistance and Atherosclerosis  
    study (IRAS) family study in 1,906 Hispanic,   
    American Africans participants, baseline    
    adiponectin level was associated with incident  
    diabetes (0.54 [CI 0.38–0.76]). The association  
    remained significant after adjustment in  
    individual models for BMI, HOMA-IR and  
    visceral adipose tissue 
302
. 
 The DPP study showed that baseline  
    adiponectin and improvement in adiponectin  
    level was associated with reduced incidence of   
    diabetes 
303
. 
 A recent meta-analysis of 13 prospective  
    studies with a total of 14, 598 participants and  
    2,623 incident cases of T2DM provided  
    unequivocal evidence that higher adiponectin  
    levels are associated with a reduced risk of  
    diabetes (HR 0.72 [0.67-0.78]) 
304
.
Adiponectin – In brief: 
Molecular weight: 30 KDa 
Synthesis: Exclusively 
synthesized from adipocytes. 
 
Chromosome location: 3q27 
Structure: Collagen-like 
domain; structural similarity 
with Complement C1Q 
Plasma half-life:  2.5hr 
Clearance: Mainly in liver 
Function: 
 Normal metabolic 
homeostasis 
 Stimulate beta-oxidation 
in muscle and increase 
insulin sensitivity in liver. 
 Anti-inflammatory activity 
Remarks: 
Unlike other adipokines 
“adiponectin” levels decrease 
with increased fat mass 
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5.3.2 Interleukin-6 
Epidemiological evidence: 
 In the British Regional Heart Study (BRHS),  
   IL-6 predicts incident diabetes (HR: 2.12    
   [1.18-3.81]), after adjustment  for BMI,  
   lifestyle factors and insulin resistance  
305
. 
 
 In the Multi-Ethnic Study of Atherosclerosis  
  (MESA), involving  5,571 participants,  IL-6  
  was associated with incident diabetes (HR:  
  1.5 [95%CI: 1.1–2.2]) 306 after adjustment for  
  age, sex, race, lifestyle factors, HOMA-IR  
  and BMI. 
 
 A recent meta-analysis of 10 prospective 
studies with a total of 19, 709 participants and 
4,480 incident cases of T2DM demonstrated a 
significant dose-response relationship of IL-6 
with incident diabetes (relative risk [RR] 1.31 
[95%CI 1.17–1.46]) 307. 
Interleukin 6 – In brief: 
Molecular weight:~20-30 KDa 
Synthesis: activated 
leukocytes, endothelial cells, 
and adipocytes. 
 
Chromosome location:7p21 
Structure: helical glycoprotein 
Plasma half-life:<6.0 hr 
Clearance: Mainly in Kidney 
 
Function: 
 Involved in acute phase 
response 
 Role in bone metabolism, 
reproduction, arthritis,  
neoplasia, and aging. 
 It is also associated with 
lifestyle diseases such as 
diabetes, cancer and 
cardiovascular diseases. 
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5.3.3  Leptin 
Epidemiological evidence: 
 In the British Regional Health Study, leptin   
    (top Vs bottom tertile) was associated with a  
    relative risk of diabetes (HR: 1.91 [95%CI:  
    0.97-3.76]), after adjustment for potential  
   confounders, but further adjustment for  
   insulin resistance abolished the association 
305
. 
 In Japanese Americans, greater baseline leptin 
levels were associated with an increased risk 
of developing diabetes (HR: 1.8 [95%CI: 
1.02-3.17]) in men but not in women 
308
. A 
similar finding was observed in Mauritian 
men but not in women 
309
 and in the 
PROspective Study of Pravastatin in the 
Elderly at Risk trial (PROSPER) study 
310
. 
    In a multi ethnic, Atherosclerosis Risk In 
  Community study (ARIC), was significantly 
   associated with a 40% lower risk of subsequent   
  diabetes 
311
 after adjustments for potential  
  covariates. 
Leptin – In brief: 
Molecular weight: 16 KDa 
Synthesis: Mainly in 
adipocytes and in low levels 
by the gastric fundic 
epithelium, intestine, skeletal 
muscle, and brain 
 
Chromosome location: 7q31.3 
Plasma half-life: 25 min 
Clearance: Mainly in Kidney 
Function: 
 Food intake and energy 
metabolism 
 Body weight 
regulation, puberty and 
reproduction 
 Immune regulation 
Remarks: Exhibits diurnal 
rhythm and levels varies 
between sex. 
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5.3.4 Retinol Binding Protein-4 (RBP4) 
Epidemiological evidence: 
 Cross-sectional study from South Korea 
demonstrated that RBP4 concentrations were 
raised in IGT and in T2DM 
312
. 
 Circulating RBP4 is associated with hepatic 
insulin resistance 
298
, and its levels are elevated in 
obese individuals 
298,313
 and in association with 
cardiovascular risk factors such as raised lipid 
levels and insulin resistance 
314
. 
 In the Co-operative Health Research in the 
Region of Augsburg (KORA) F4 study, RBP-4 
(top Vs bottom quartile) level was associated 
with prediabetes independent of known metabolic 
and lifestyle variables (OR: 1.63[1.17-2.27] 
315
. 
 In the ARIC study, there was a borderline 
association between serum RBP4 levels (top Vs 
bottom tertile) and diabetes (HR: 1.68; 
[95%CI:1.00-2.82])
316
 after adjusting for 
demographic, metabolic and clinical  
     variables in women. 
RBP4 – In brief: 
Molecular weight: ~ 21 KDa 
Expression: Liver and mature 
adipocytes. 
Chromosome location: 10q23–
q24 
Structure: Lipocalin family 
Plasma half-life:  12hr 
Clearance: Renal excretion 
Function: 
 Vitamin A transport 
protein. 
 Prevents the excretion of 
transthyretin  by kidney 
 Increased RBP4 levels 
increases gluconeogenesis 
in liver and decreases 
insulin sensitivity in 
muscle. 
Remarks: 
Adipokine associated with 
obesity and  insulin resistance 
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5.4 Research methods: 
5.4.1 Study participants:  
The complete study design, eligibility criteria, recruitment of participants, and methods 
have been described elsewhere (Chapter-2 and 3). Figure-5-3 shows the pictorial 
representation of sample stratification for the present study. At the end of the study, of 
the 517 (96.3%) responders: 
 170 (34.6%) had reverted to normoglycaemia (non-progressor). 
 224 (43.3%) had remained IGT (non-progressor). 
 123 (23.8%) had progressed to diabetes (Progressors).  
For this sub study, we had selected 71 newly detected diabetes cases (i.e. IGT to 
T2DM) and 76 randomly selected controls (43 IGT to NGT and 33 IGT to IGT). 
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Figure 5-2: Selection of samples for biomarker analysis 
 
Legend: At the end of the study, 497 participants were responded for the 2
nd
 year 
follow-up, among them 71 cases (diabetes) and 76 control (NGT: 43; IGT: 33) were 
chosen for the analysis. 
 
Chapter-5 
 
128 
 
5.4.2 Measurements:  
Routine anthropometric and clinical measurements were described in Chapter-2. 
 
5.4.3 Analytical procedures:  
Measurements of biomarkers with typical standard curves shown in Figure 5.3.  Plasma 
leptin were measured by were determined using sandwich enzymelinked immunosorbent 
assay (ELISA) (dbc diagnostics, canada). The intra- and interassay coefficients of 
variation (CVs) were <5.5% and <7% respectively, over the sample concentration range 
1-100 ng/ml. The detection limit of the assay was 1 ng/ml. Plasma adiponectin 
concentrations were determined using solid phase ELISA (Organium, Finland.). The 
intra- and interassay CVs were <10% and <12%, respectively. The detection limit was 
<0.185 ng/ml. IL-6 was assayed using a sandwich ELISA (eBiosciences). The intra- and 
interassay CVs were each <10%. Plasma RBP4 were measured by competitive enzyme 
immune assay (EIA) (RayBiotech, Norcross). The intra- and interassay CVs were <10% 
and <15% respectively. All the biomarkers were estimated in a freshly freeze-thawed 
stored plasma fasting samples. 
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Figure 5-3: Typical standard curve obtained for various adipokines studied 
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5.5 Statistical analysis 
5.5.1 Sample power calculation 
 Adiponectin: Studies from IDPP-1301, and Funagat317 found a strong inverse 
association between adiponectin and incident T2DM. From our IDPP-1 cohort 
study, the mean baseline adiponectin was lower in the T2DM group as compared 
with normoglycaemic group (11.7 ± 5.5 vs. 16.7 ± 7.6 µg/ml). With 50 individuals 
in each group, this expected difference, and with these expected standard 
deviations, can be demonstrated as significant at p<0.05 and with 88% power. 
 Retinol binding protein 4 (RBP4): From a previous cross sectional study in China 318 
it was reported that the mean levels of RBP4 were higher in T2DM individuals than 
in the normoglycaemic group (T2DM: 30±11 µg/ml; normal: 24±7 µg/ml). With 53 
participants in each group, and with these standard deviations, the expected 
difference can be demonstrated as significant at 5% significance and 80% power. 
 Interleukin 6 (IL-6): The European Prospective Investigation into Cancer and 
Nutrition (EPIC)–Potsdam study demonstrated that IL-6 was elevated in T2DM 
compared to controls and this study also evidenced that combined elevation of 
interleukin 1 β and IL-6 predict incident T2DM rather than the single variable 319. 
With 90 individuals in each group, the expected difference with these standard 
deviations [1.67 ± 1.59 vs. 2.45 ± 1.80 pg/ml 
319
], can be demonstrated as significant 
at p<0.05 and 80% power for IL-6. 
 Leptin: The British Regional Heart Study305, demonstrated that leptin was elevated 
in T2DM individuals than in the non-diabetic group (T2DM: 14.3 (IQR: 10.2-21.9); 
normal: 8.93 (IQR: 10.2-21.9); assumed standard deviation: 11.5; P<0.0001). With 
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72 individuals each group, and with these standard deviations, the expected 
difference can be demonstrated as significant at 5% significance and 80% power. 
In total for this study, 76 cases and 71 controls were studied for biomarker analysis. 
 
5.5.2 Statistical methods 
Normally distributed variables were expressed as mean ± SD and compared using two-
tailed student t-test. Non-parametric variables were expressed as median (25
th
 and 75
th
 
quartile range) and compared using Mann Whitney test. Before statistical analysis, non-
normally distributed parameters were natural logarithmically transformed to 
approximate a normal distribution. Pearson correlation and multiple linear regression 
analysis (stepwise addition) were performed to evaluate the association of biomarkers 
with surrogate insulin measures and cardiovascular risk factors. Multiple logistic 
regression models were used to assess the multivariable-adjusted relative risk for the 
development of diabetes. The power of each biomarker to predict a progression to 
diabetes was assessed with a receiver-operating-characteristic (ROC) curve. The area 
under the curve (AUC) of the ROC and a 95% confidence interval (CI) were calculated 
by the Delong 
216
 method to evaluate the diagnostic utilities of the marker for diabetes 
prediction.  The optimal cut-off point of each marker was estimated by calculating the 
Youden index 
217
. Then, its specificity, sensitivity were calculated using that cut-off. The 
positive likelihood ratio was calculated using the formula: sensitivity / (1-specificity). 
For this assessment, we have created three models: 1) a univariate biomarker model to 
evaluate the predictive power of each biomarker in  separate analysis; 2) multivariable 
model (FPG + biomarker) using a logistic regression equation with those biomarkers as 
explanatory variables for predicting diabetes; 3) the combination of non-glycaemic 
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biomarkers which was shown to be associated with diabetes in step-1. For each curve, a 
test for the equality of the AUC of ROC between FPG and the additional model was 
evaluated using an algorithm suggested by DeLong et al 
216
. Statistical analysis was 
performed using SPSS version 19.0 (IBM SPSS Statistics for Windows, Version 19.0. 
Armonk, NY: IBM Corp).  
5.6 Results: 
5.6.1 Characteristics of the participants: 
Participant characteristics are presented in Table-5.1.  Mean age and BMI of the cohort 
was 47.1 ± 4.7 years and 26.0 ± 3.0 Kg/m
2 
respectively. As compared to non-progressors 
(NGT+IGT group), the mean values of diastolic blood pressure (P=0.046), fasting 
plasma glucose (FPG), 30 minutes glucose, 2-hr post glucose (2-hr PG) and HbA1c 
(P<0.0001 for all), and triglycerides (P = 0.022) were significantly higher in progressors. 
Accordingly, progressors were more insulin resistant (P<0.0001) and had decreased β- 
cell function (P<0.0001) as compared to non-progressors. 
5.6.2 Biomarker levels 
The baseline levels of adiponectin was decreased by 30% in those who progressed to 
T2DM (non-progressors: 16.4 (IQR: 11.6-21.4) vs. progressors: 11.5 (IQR: 8.6-15.0); 
P<0.0001). The baseline GGT activity was increased by 55% ((22.0 (IQR: 17.2-35.8) vs. 
34.1 (IQR: 24.7-56.0); P<0.0001)) in participants who progressed to T2DM. The levels 
of RBP4 ((17.3 (IQR: 13.1-21.0) vs. 21.3 (IQR: 17.7-24.9); % change: 23.1%; P=0.010)) 
and IL-6 ((5.3 (IQR: 4.7-12.4) vs. 14.9 (IQR: 5.8-24.9); %change: 181.0%; P<0.0001)) 
were increased in individuals who progressed to diabetes compared to non-progressors. 
The levels of leptin and vitamin D3 did not differ between the groups. 
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Table 5-1: Baseline characteristics of individuals stratified based on 
glycaemic categories 
Variables Non-progressors 
n=76 
Progressors 
n=71 
P value 
Age (years) 47.7±4.8 46.7±4.6 0.217 
Body mass index, Kg/m
2
 25.9±2.7 26.2±3.5 0.491 
Waist circumference, Cm 92.6±7.1 93.5±7.4 0.465 
Total body fat, % 26.8±5.5 27.2±5.2 0.683 
Systolic blood pressure, mmHg 122.8±16.2 124.5±14.6 0.519 
Diastolic blood pressure, mmHg 79.2±10.1 82.4±8.6 0.046 
Fasting plasma glucose, mmol/l 5.39±0.50 5.82±0.58 <0.0001 
2-hr plasma glucose, mmol/l 8.42±0.65 9.28±0.88 <0.0001 
HbA1c, % 6.0±0.3 6.3±0.4 <0.0001 
Triglycerides, mmol/l 
a
 1.49 (1.09-2.05) 1.84 (1.32-2.33) 0.022 
Cholesterol, mmol/l 5.01±0.90 4.93±0.92 0.604 
HDL cholesterol, mmol/l 0.91±0.26 0.87±0.23 0.335 
GGT, UL
-1 a
 22.0 (17.2-35.8) 34.1 (24.7-56.0) <0.0001 
HOMA-IR 3.0±1.3 3.7±1.3 <0.0001 
Insulinogenic index 
a
 62.7 (43.5-97.0) 34.5 (23.7-52.0) <0.0001 
Disposition index 187.0(144.9-204.3) 113.9(95.1-138.3) <0.0001 
Adiponectin, µg/ml 
a
 16.4 (11.6-21.4) 11.5 (8.6-15.0) <0.0001 
IL-6, pmol/ml 
a
 5.3 (4.7-12.4) 14.9 (5.8-24.9) <0.0001 
Leptin, ng/ml 
a
 8.9 (6.8-16.5) 12.3 (8.0-17.4) 0.170 
RBP4, µg/ml 
a
 17.3 (13.1-21.0) 21.3 (17.7-24.9) 0.010 
Vitain D3, nmol/ml 40.9 (24.7-56.6) 44.0 (23.7-58.3) 0.797 
Baseline energy intake (Kcal) 2069 (1918-2292) 2091 (1880-2277) 0.729 
Baseline physical activity 36.0 (21.8-46.0) 39.0 (23.0-50.0) 0.617 
 
Legend: The data are expressed as mean ± SD for normally distributed 
variables – P value computed by two-tailed t-test 
a
: data expressed as median (inter quartile range) – P value computed by 
Mann-Whitney test. 
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5.6.3 Correlates of biomarkers 
Correlations of biomarkers with core metabolic and anthropometric risk factors are 
shown in Table 5-2. IL-6, leptin and RBP-4 were positively correlated with BMI 
whereas adiponectin was negatively correlated. Leptin, RBP-4 and GGT were 
significantly positively whereas adiponectin was inversely correlated with HOMA-IR. 
RBP-4 and leptin were positively correlated with HbA1c levels. GGT and RBP-4 were 
positively and strongly correlated with triglycerides levels (P<0.0001).  In contrast, 
vitamin D3 levels did not correlate with the classical and core risk factors of 
dysglycaemia. There were extensive inter-correlation between biomarkers.  
Table 5-2: Pearson coefficient correlation between  adipokines and risk 
factors for diabetes 
Variables Adiponectin IL-6 Leptin RBP-4 
Adiponectin (µg/ml)
*
 
IL-6 (pmol/ml)
*
 
Leptin (ng/ml)
*
 
RBP-4 (µg/ml) 
*
 
-- 
-0.057 
-0.121
 
-0.112 
-0.057 
-- 
0.277
‡
 
0.122 
-0.121 
0.277
‡
 
-- 
0.204
†
 
-0.124 
0.160 
0.204
†
 
-- 
Age (years) 
Body mass index (Kg/m
2
)  
Waist circumference (Cm) 
Fat% 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
0.166
† 
-0.238
†
 
-0.126 
-0.052 
-0.114 
-0.084 
-0.065 
0.169
†
 
0.174
† 
0.221
†
 
-0.006 
0.139 
0.024 
0.433
‡
 
0.349
‡ 
0.275
†
 
0.146 
0.228
†
 
-0.043 
0.303
‡
 
0.272
†
 
0.145 
0.183
†
 
0.181
†
 
Fasting glucose (mmol/l) 
2-hr glucose (mmol/l) 
HbA1c (%) 
Triglycerides (mmol/l)
*
 
HDL cholesterol (mmol/l) 
-0.192
†
 
-0.154 
-0.115 
-0.008 
0.234
†
 
0.119 
0.194
†
 
0.027 
0.045 
0.068 
0.021 
0.280
†
 
0.153 
0.154 
0.063 
0.245
†
 
0.102 
0.256
‡
 
0.314
‡
 
-0.077 
HOMA-IR
*
 
Insuliongenic index (pmol/mmol)
*
 
-0.211
†
 
0.088 
0.080 
-0.153 
0.222
†
 
0.185
†
 
0.242
†
 
0.036 
*: 
Log transformed; 
†: 
P<0.01; 
‡: 
P<0.001; IL-6: Interleukin 6; RBP4: retinol 
binding protein 4;  
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5.6.4 Association of biomarkers with incident diabetes: 
The association of adipokine markers with incident diabetes is shown in Table-5.3. 
Adiponectin (OR: 0.86 [95%CI: 0.80-0.93]; P<0.0001), IL-6 (OR: 1.04 [1.01-1.07]; 
P=0.015), and RBP4 (OR: 1.06 [95%CI: 1.00-1.13]; P=0.048) were significantly 
associated with T2DM even after adjustment for potential confounders including age, 
BMI, body fat% and HOMA-IR . Leptin and vitamin D3 was not associated with 
diabetes in our cohort in an unadjusted model. The inclusion of all six novel risk factors: 
adiponectin, leptin, RBP-4 and IL-6, along with GGT and HTWP, which were identified 
as significant predictors in chapter-4, in a logistic regression model showed that raised 
levels of IL-6 (OR: 1.05 [95%CI: 1.01-1.09]; P=0.010), GGT (OR: 1.04 [95%CI: 1.01-
1.05]; P=0.010) and lower levels of adiponectin (OR: 0.86 [95%CI: 0.79-0.95]; 
P=0.006) were independently associated with incident diabetes in our cohort  (Table 5-
4).  
Chapter-5 
 
136 
 
Table 5-3: Adjusted relative risk (RR) of incident type 2 diabetes by of adiponectin, IL-6, leptin, GGT and RBP4 
 Unadjusted Adjusted* 
β (s.e) OR [95%CI] P value β (s.e) OR [95%CI] P value 
Adiponectin (µg/ml) -0.137 (0.034) 0.87 [0.82-0.93] <0.0001 -0.150 (0.040) 0.86 [0.80-0.93] <0.0001 
IL-6 (ng/ml) 0.037 (0.014) 1.04 [1.01-1.07] 0.010 0.037 (0.015) 1.04 [1.01-1.07] 0.015 
Leptin (ng/ml) 0.022 (0.022) 1.02 [0.98-1.07] 0.314 --- --- --- 
GGT (IUL
-1
) 0.021 (0.008) 1.02 [1.01-1.04] 0.008 0.019 (0.010) 1.02 [1.00-1.04] 0.042 
RBP4 (µg/ml) 0.073 (0.025) 1.08 [1.02-1.13] 0.004 0.059 (0.030) 1.06 [1.00-1.13] 0.048 
VitaminD3 (nmol/ml) -0.005 (0.007) 1.00 [0.98-1.01] 0.437 --- --- --- 
 
Dependent variable: diabetes vs. non-diabetes; odds ratios computed from logistic regression analysis; β: regression 
coefficient; OR: odds ratio 
* The covariates which showed significant univariate associations with biomarkers were chosen for the multivariate 
analyses. 
-Adiponection: age, body mass index, HDL-C and HOMA-IR. 
-IL-6: Fat%, leptin 
-RBP4: BMI, systolic blood pressure, triglycerides, GGT, leptin and HOMA-IR 
Leptin and vitamin D3 did not show an association with incident diabetes in an unadjusted analysis. Hence, an adjusted model 
was not explored. 
If the biomarkers showed a multiple correlation with anthropometric measures (BMI, waist circumference, Fat%), or 
haemodynamic measures (SBP, DBP) whichever showed a strongest  association alone was chosen for the modeling to minimize 
co-linearity. 
Glycaemic markers were not included as covariates because participants were selected according to their having raised glycaemia. 
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Table 5-4: Adjusted relative risk of incident type 2 diabetes when all the biomarkers 
were included as a single model 
 
 
 
 
Legend: 
Dependent variable: diabetes vs. non-diabetes. 
Non-significant variables: RBP4, leptin and HTWP; Leptin was included in the model 
because of its multiple correlation with biomarkers. 
Equation: Ln[odds ratio]=  -0.151 (adiponectin) + 0.040 (IL-6) + 0.022 (GGT) 
 
Candidate predictors identified (in Table-5.3) were entered together for the final 
prediction model using multiple logistic regression analysis (probability to enter=0.01; 
probability to remove=0.2 to protect against type 1 errors); *adjusted for age, family 
history of diabetes, HOMA-IR, insulinogenic index, HbA1c; the predictive probability (β 
coefficient) of that model was saved for the ROC analysis. 
Variable Unadjusted Adjusted* 
OR [95%CI] P value OR [95%CI] P value 
Adiponectin 0.86 [0.80-0.93] <0.0001 0.86[0.79-0.95] 0.006 
IL-6 1.04 [1.01-1.07] 0.006 1.05[1.01-1.09] 0.010 
GGT 1.02 [1.01-1.04] 0.013 1.04[1.01-1.06] 0.006 
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5.6.5 Predictive power of biomarkers for progression of diabetes 
The predictive ability of each marker individually and its corresponding optimal cut-off 
point is shown in table 5-5. The AUC’s to predict the progression to diabetes among 
glycaemic biomarkers were 0.708 (95%CI: 0.625-0.791) for FPG, 0.779 (95%CI: 0.704-
0.844) for 2-hr PG and 0.725 (95%CI: 0.643-0.808) for HbA1c. As expected, glycaemic 
markers were the best predictors for diabetes prediction. Amongst the biomarkers, IL-6 
displayed highest predictive value (AUC: 0.719 (95%CI: 0.635-0.803)), followed by 
adiponectin (AUC: 0.695 (95%CI: 0.613-0.768)) and RBP4 (AUC: 0.658 (95%CI: 
0.571-0.749)). 
Table 5-6 shows the improvements in predictive power of the models when the 
adipokines when combined with FPG (base model) as derived from the logistic 
regression analysis. Significant improvements were achieved by including adiponectin 
or IL-6 in the model. The results showed that the model comprised of FPG + adiponectin 
was effective in identifying individuals at high risk of diabetes (AUC: 0.774 (95%CI: 
0.698-0.839); P=0.034; sensitivity (%): 76.1 (95%CI: 64.5-85.4); specificity (%): 71.1 
(95%CI: 59.5-80.9); positive likelihood ratio: 2.63). Though, IL-6 was equally effective 
in identifying incident diabetes the sensitivity was lower (sensitivity (%) 65.8 (95%CI: 
54.0-76.3)) compared with adiponectin. The addition of RBP-4 above FPG did not 
statistically improve the predictive power in our analysis. The combination of non-
glycaemic biomarkers (AUC: 0.761 (95%CI: 0.684-0.838)) alone did not show 
substantial improvement to predict diabetes compared with FPG + biomarker model. 
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Table 5-5: Area under the receiver operating characteristics and predictabilities of single markers for progression of diabetes 
 
Biomarker AUC (95% CI) P value 
Optimal 
cut-off 
point 
a
 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
Positive 
likelihood 
ratio 
Non-glycaemic             
Adiponectin 0.695(0.613-0.768) <0.0001 ≤ 14 67.6 (55.5-78.2) 63.2 (51.3-73.9) 1.84 
IL-6 0.719(0.635-0.803) <0.0001 ≥ 7.2 70.4 (58.4-80.7) 69.7 (58.1-79.8) 2.33 
GGT 0.694(0.608-0.781) <0.0001 ≥23.3 80.3(69.1-88.8) 59.2(47.3-70.4) 1.97 
RBP4 0.658(0.571-0.749) 0.001 ≥ 14.2 69.0 (56.9-79.5) 55.3 (43.4-66.7) 1.57 
Glycaemic             
FPG 0.708(0.625-0.791) <0.0001 ≥ 98.0 71.8 (59.9-81.9) 60.5 (48.6-71.6) 1.82 
OGTT 2-hr 
glucose 0.779(0.704-0.844) <0.0001 ≥ 157.0 67.6 (55.5-78.2) 77.6 (66.6-86.4) 3.02 
HbA1c 0.725(0.643-0.808) <0.0001 ≥ 6.0 77.5 (66.0-86.5) 57.9 (46.0-69.1) 1.84 
       AUC: area-under-curve; CI: confidence interval; IL-6: interleukin-6; RBP4: retinol binding protein 4; FPG: fasting plasma 
glucose; The units of each optimal cut-off point was shown in Table-6.1 
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Table 5-6: The area under the receiver operating characteristics and predictabilities of multiple markers for progression of 
diabetes by logistic regression models 
Multiple 
biomarkers 
AUC (95% CI) 
Incremental 
AUC above 
0.5 
P value
b
 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
Positive 
likelihoo
d ratio 
FPG 
a
 0.708 (0.625-0.791) -- -- 71.8 (59.9-81.9) 60.5 (48.6-71.6) 1.82 
FPG+IL-6 0.775 (0.698-0.839) 0.07 0.0323 77.5 (66.0-86.5) 65.8 (54.0-76.3) 2.26 
FPG+RBP4 0.723 (0.641-0.792) 0.01 0.5347 52.1 (39.9-64.1) 80.3 (69.5-88.5) 2.64 
FPG+Adiponectin 0.774 (0.698-0.839) 0.07 0.0374 76.1 (64.5-85.4) 71.1 (59.5-80.9) 2.63 
FPG+GGT 0.740 (0.660-0.819) 0.03 0.1957 71.8(59.9-81.9) 67.1(55.4-77.5) 2.18 
FPG+HbA1c 0.768 (0.692-0.845) 0.06 0.0551 81.7(70.7-89.9) 64.5(52.7-75.1) 2.00 
Adiponectin+ 
GGT+IL-6 0.761 (0.684-0.838) 0.05 0.3432 85.9(75.6-93.0) 63.2(51.3-73.9) 2.33 
 
Legend: AUC: area-under-curve; CI: confidence interval; IL-6: interleukin-6; RBP4: retinol binding protein 4; FPG: fasting 
plasma glucose; a: FPG is the base model; b: P value was for comparing the AUC between base model (FPG) and additional 
models with multiple markers (FPG+ adipokine marker). 
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5.7  Conclusions 
In this case-control cohort study in middle-aged Asian Indian men with prediabetes, 
participants with low levels of  adiponectin, and high levels of IL-6, GGT and RBP4 
had a higher risk for development of diabetes independent of age, obesity and a 
comprehensive array of other potential confounders or explanatory factors. The effect 
persisted even after the adjustment for HOMA-IR and insulinogenic index. 
As reported in the recent meta-analysis by Li et.al 
304
, higher adiponectin levels have 
been shown to be consistently shown to be associated with incident diabetes after 
multivariate adjustment across a range of populations. Consistent with our previous 
findings 
301
 this study also provides evidence that adiponectin could be a predictive 
marker for identification of T2DM in Asian Indian individuals; the predictive power 
persists even after the multivariate adjustments. These observations corroborate the 
validity and usefulness of adiponectin as an independent baseline or cross-sectional 
measure of metabolic status in general and of diabetes risk in particular. This study also 
shows that HOMA-IR was inversely associated with adiponectin. A similar relationship 
was also reported previously in Asian Indian adult men and women 
320
 but not in non-
diabetic teenagers 
321
. Adiponectin, an anti-inflammatory cytokine produced by adipose 
tissue, is an important regulator of insulin sensitivity in skeletal muscle and liver 
322-324
. 
In addition to its beneficial effects on insulin sensitivity, adiponectin also has direct 
antiatherogenic and anti-inflammatory effects 
323
.  
Amongst the biomarkers studied in this cohort, baseline levels of IL-6 showed the 
strongest associations with incident diabetes. These findings support the hypothesis that 
there exists an association of chronic inflammation and development of diabetes. 
Inflammation both predicts and precedes diabetes
325
. Although raised IL-6 levels have 
been previously associated with subsequent diabetes in multi-ethnic 
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populations
305,307,326
, the exact mechanism of its action remains to be unravelled. It is 
important to study the link between chronic inflammatory mediators and insulin 
resistance because, low-grade systemic inflammation could mediate higher diabetes risk 
via insulin resistance 
327
, but several observations also suggest that the independent 
association of IL-6 with diabetes operates through alternative mechanisms 
305,326,328
. In 
accordance with our findings, in the BRHS study, the relationship of IL-6 was 
independent of measures of insulin resistance in aged men 
305
. At present, there is no 
evidence for an independent role of IL-6 in impaired β-cell function/apoptosis. A 
comprehensive review by Kristiansen OP and Mandrup-Poulsen
329
 concluded that 
chronically elevated IL-6 levels might contribute to the development of T2DM via 
mechanisms including altered insulin signalling in hepatocytes/adipocytes and effects 
on the central nervous system to impair energy regulation. Further observations are 
required to identify the causality of IL-6 and diabetes. 
In this case-control cohort study, baseline serum RBP-4 levels were independently 
associated with incident diabetes after adjustments for known metabolic risk factors 
including GGT, triglycerides, BMI and HOMA-IR. Previously, a large cross-sectional, 
general population study showed a strong association of RBP4 with prediabetes
315
. 
Recently, a prospective association of RBP4 with incident diabetes over 9 years was 
observed in a population-based cohort in women (HR = 1.68 [95%CI 1.00 – 2.82] but 
not in men 
316
. In addition, cross-sectional studies 
312,330
 conducted in middle-aged 
Chinese adults also showed a strong positive association between RBP4 and impaired 
glucose regulation. The present analysis provides new evidence on the link between 
RBP4 and incident diabetes in Asian Indian individuals with IGT.  
The serum RBP4 levels were positively associated with cardiometabolic risk factors, 
especially increased levels of triglycerides in this cohort.  These findings were in line 
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with previous studies 
297,313,330
. Regarding the mechanism underlying the association 
between RBP4 and triglycerides, a direct effect of RBP4 on hepatic fat accumulation 
may be plausible
294
. In addition, production of triglycerides in the liver and release of 
very low-density lipoprotein into the circulation generally increase in an insulin-
resistant state, and this may also partially explain the close nexus between RBP4, 
triglycerides and insulin resistance. On the contrary other studies failed to show an 
association between RBP-4 and insulin resistance
295,331
. Though the serum RBP-4 level 
correlated with BMI, the relationship between the serum RBP-4 and insulin resistance 
was independent of obesity. It is conceivable that contrary to those of other 
populations
298,313
 liver could be the primary source of RBP-4 in circulation in Asian 
Indians.  
In this study, the levels of serum RBP-4  were relatively low compared with those 
reported in Caucasians 
313,315,316,332
 and were closely matched with those observed in 
Chinese 
330
, Japanese 
297
 and Korean 
312
 adults. A plasma concentration of 
approximately 24-79 µg/ml RBP-4 was reported in normal lean Japanese individuals
333
. 
But, in this cohort, the levels of RBP-4 were lower even in those who developed 
T2DM.  It may be possible that the assay used in this study underestimated the RBP-4 
level, compared with methods such as quantitative Western blotting and this could 
account for the varied results reported by different laboratories
334
. Further study is 
needed to investigate ethnic variations among RBP-4 measurement methods.  
To summarise, the aforementioned findings suggest at least three divergent areas in the 
pathophysiology of diabetes. Firstly, the association of adiponectin with incident 
diabetes has been well-documented: adiponectin increases insulin sensitivity, improves 
glucose tolerance and inhibits inflammation. Secondly, the association of GGT with 
diabetes could be due to the excessive lipid accumulation in hepatocytes and the 
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resultant hepatic insulin resistance possibly related to decreased portal insulin extraction 
and increased glucose output, thereby contributing to the development of total body 
insulin resistance and diabetes. Thirdly, IL-6 was associated with diabetes independent 
of insulin resistance and other diabetogenic risk factors. These findings are obviously 
important in considering the pathogenesis of diabetes.  
In this study additive value of non-glycaemic markers over and above FPG was also 
evaluated. Though, the combination of non-glycaemic biomarkers with FPG improved 
the diagnostic power, the predictive utility was seen to be very marginal. Neither did the 
combination adiponectin, IL-6 and GGT substantially improve the diagnostic 
predictability above glycaemic measures. This clearly demonstrates that the utility of 
non-glycaemic biomarkers may offer little or marginal improvement to predictive 
precision when added to the glycaemic markers. In line with our study, Salomma et al 
335
 showed an marginal, non-significant improvement when adding the novel 
biomarkers, adiponectin, apolipoprotein B, interleukin 1-receptor A and ferritin, to the 
classical risk factors, age, BMI, sex, HDL-C, non-HDL-C, TG, systolic blood pressure, 
antihypertensive medication, current smoking, blood glucose, and history of CVD at 
baseline, in predicting T2DM in high risk middle aged populations from the 
FINRISK97 cohort over 5 years.  
Amongst the markers studied in this cohort, baseline disposition index, a measure of β-
cell function was the most discriminatory measure associated with incident diabetes 
(explained in detail in chapter-4). In the present analysis, the combination of 
FPG+HbA1c did not incrementally improve the AUC ROC in predicting diabetes 
compared with individual glycaemic measures. It should be noted that the individuals 
were prediabetic at baseline; accordingly, the narrow range of FPG and HbA1c our 
study encompassed, with little variation among individuals, may have limited our 
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ability to detect a significant relationship. However, other prospective studies clearly 
demonstrated a predictive utility of adding HbA1c with FPG 
336
. 
As regards leptin’s link with diabetes, we have demonstrated that the levels of this 
adipokine do not predict incident diabetes in a completely adjusted model. A similar 
result was also observed in the Health, Aging, Body Composition (Health  ABC) study, 
which demonstrated that after controlling for BMI, visceral fat, fasting glucose, fasting 
insulin, high-density lipoprotein cholesterol, triglycerides, and hypertension at baseline, 
leptin was not associated with incident diabetes 
337
. In fact, much of the association 
between leptin and subsequent diabetes could be accounted for by obesity and insulin 
resistance
338
.  
The main strength of the analysis includes simultaneous measurements of multiple 
biomarkers and the study cohort comprised of a sample derived from Asian Indian 
individuals. However, the study has a few limitations. Firstly, the association between 
biomarkers with diabetes observed in this study was derived from a small sample size. 
However, the study design was adequately powered to detect the association. Secondly, 
we included only men in our study. The pathogenesis of biomarkers with diabetes needs 
to be ascertained in women. Thirdly, though we included a comprehensive array of 
biomarkers we do miss out several potential candidates such as C-reactive protein, 
markers of endothelial dysfunction and oxidative stress which may affect the predictive 
ability of these proposed biomarkers. Finally, we did not assess the prevalence of non-
alcoholic fatty liver disease in this cohort to ascertain the causal link between fatty liver 
and diabetes.  
To summarise, we have demonstrated that combination of adiponectin, IL-6 and GGT 
independently associated with diabetes. But, these markers have little additive value 
over and beyond glycaemic markers for the prediction of diabetes. It can be noted that 
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non-glycaemic biomarkers have a role in understanding the underlying pathogenesis of 
diabetes, but the “classical” glycaemic biomarkers seem to be sufficient as a risk marker 
in clinical practice. 
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 6 SUMMARY 
The overall summary of the thesis is presented below:
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6.1 Chapter-3 – Trial findings 
6.1.1 What is already known on this topic? 
 According to the recent International Diabetes Federation (IDF) estimates, India 
accounts for around 31.9 million with undiagnosed diabetes. Unlike western 
populations, Asian Indians develop diabetes at a younger age, mostly in the working 
age group. Hence, identification and prevention of diabetes at this age group is of 
great public health importance.  
 Findings from several multi-ethnic, randomized controlled trials across all 
geographic spectrums including Indian Diabetes Prevention Progarmme-1 have 
consistently established that T2DM can be postponed or delayed by lifestyle 
modification in prediabetic individuals by repeated motivational strategies. 
 Mobile phone messaging can be a powerful medium for health communication. 
Though, its role in adherence to antiretroviral therapy, smoking cessation, asthma and 
for malarial treatment adherence is already established, its effectiveness in the 
prevention of diabetes has not been studied so far in a prospective setting. 
6.1.2 The novelty of the data presented and its impact on the field 
 Mobile phone-based text messaging can be an effective technique for  
disseminating healthy lifestyle modification principles. The cumulative incidence 
of T2DM was significantly reduced in the intervention group compared with the 
standard-care group (HR: 0·64, 95% CI 0·45–0·92; p= 0·015). 
 The benefit of intervention was independent of body weight reduction. The 
intervention group showed an improvement in dietary compliance levels compared 
with the standard care group. 
 Our results demonstrated initial evidence that motivation through SMS may be a 
highly effective and acceptable tool to substantially reduce incidence of diabetes. 
According to our finding, 11 (95% CI 6–55) individuals with IGT must be 
provided with such an intervention for two years to prevent one case of diabetes.
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6.2 Chapter-4A: Liver enzymes and incident diabetes 
6.2.1 What is already known on this topic? 
 Evidence from several prospective studies in multi-ethnic populations provides a 
strong link between elevated liver enzymes such as gamma-glutamyl transferase 
(GGT) and alanine transaminase (ALT) and development of diabetes. 
 The objective of this analysis was to find out the association of liver enzymes with 
the prediction of incident diabetes in Asian Indians. 
6.2.2 New findings of this analysis 
 Baseline GGT, but not ALT was significantly higher in incident diabetes cases. 
The levels of GGT decreased in individuals who reverted to normal glucose 
tolerance (NGT), whereas it increased in individuals who deteriorated to diabetes 
(P<0.0001). 
 The risk of T2DM significantly increased with increasing baseline GGT after 
adjusting for confounders (HR: 2.02 [95%CI: 1.35-3.02]; P=0.001).  
 Receiver operating characteristic curve showed that the model comprising of 
baseline fasting plasma glucose and GGT was as sensitive in identifying 
individuals with risk of diabetes as 2-hr plasma glucose (2-hr PG) and HbA1c. 
 GGT is an independent predictor of incident diabetes. The combination of GGT 
and HbA1c offers a simple and sensitive tool to identify individuals at high risk of 
diabetes. 
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6.3 Chapter -4B: Hypertriglyceridemic Waist Phenotype and the Risk of 
Incident Diabetes in Asian Indian individuals with IGT 
6.3.1 What is already known on this topic? 
 Hypertriglyceridemic waist phenotype (HTWP) is known to be associated with 
insulin resistance and can be used as a simple proxy for insulin resistance. 
 The prevalence of central adiposity and hypertriglyceridemia are particularly high 
in Asian Indian descendants.  
 Though, cross-sectional studies have demonstrated an association of the HTWP 
phenotype with diabetes, the utility of this measure for the prediction of incident 
diabetes has not been much studied. 
 This cohort analysis was done with the objective of analyzing the possible 
association of HTWP with incident diabetes, considering the simplicity of 
identifying the presence of HTWP and its association with other cardio-metabolic 
risk factors. 
6.3.2 The novelty of the data presented and its impact on the field 
 HTWP was strongly associated with insulin resistance: (β: 0.23 (0.09-0.37); 
P=0.01). 
 In this study among Asian Indian men with impaired glucose tolerance (IGT), 
presence of HTWP at baseline was found to predict incident diabetes, over the two 
year follow-up period (HR: 1.49 [95%CI: 1.01-2.21]; P=0.047) after adjusting for 
age, study group, BMI, total body fat percentage, family history of diabetes, 
hypertension, smoking and drinking, 2-hr PG, total and HDL-C and GGT levels. 
However, the predictive power was abolished after the addition of HOMA-IR into 
the model (HR: 1.39 [0.92-2.10]; P=0.119). 
 HTWP offers a simple, alternate tool to help to screen individuals with increased 
risk of incident diabetes and the association is mediated by insulin resistance. 
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6.4 Chapter-4C: Disposition index and diabetes 
6.4.1 What is already known on this topic? 
 There exists an inverse relationship between insulin sensitivity and insulin secretion 
and the product of these measures approximates a constant, termed the “Disposition 
Index”.  
 Several prospective and cross-sectional studies have shown that disposition index is 
an early marker of inadequate β-cell compensation and predicts incident diabetes.  So 
far no prospective study had shown this association in Asian Indian individuals. 
 Therefore the objective of this analysis was to elucidate the association of a 
disposition index derived from the oral glucose tolerance test (OGTT) measures with 
incident diabetes. 
6.4.2 The novelty of the data presented and its impact on the field 
 The product of the OGTT area-under-curve (AUC) insulin to AUC glucose from 0 
to 120 min and insulin sensitivity index (ISI) was the best equation to depict 
disposition in this cohort (Y=-0.9642*X+4.982). 
 Individuals with IGT with good β-cell compensation at baseline were least likely to 
develop diabetes.  
 In this cohort, decreased dietary intake and minimal weight reduction significantly 
improved the β-cell function. 
 The present analysis demonstrated that the OGTT-derived measures of disposition 
index may be an alternate surrogate composite measure to predict incident diabetes. 
Furthermore, improving insulin sensitivity by caloric restriction and minimal weight 
reduction may have beneficial effects on β-cell function and prevent diabetes for 
relatively long periods of time in individuals with genetic susceptibility for the disease. 
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6.5 Remarks – Classical predictors: 
Among the classical markers studied, disposition index (AUC: 0.717 (95%CI: 0.675-
0.756); sensitivity (%): 70.0 (95%CI: 61.0-78.0); specificity (%): 64.1 (95%CI: 59.0-
68.9)) was a better predictor of incident diabetes compared with other OGTT based 
insulin measures such as HOMA-IR (AUC: 0.642 (95%CI: 0.598-0.685); sensitivity 
(%): 59.2 (95%CI: 49.8-68.0); specificity: 62.7 (95%CI: 57.6-67.6)) and insulinogenic 
index (AUC: 0.599 (95%CI: 0.554-0.642); sensitivity (%):  45.0 (35.9-54.3); 
specificity (%): 72.5 (67.7-77.0)). However, this measure requires performance of the 
3 sampling OGTT with estimations of plasma insulin and glucose which is labour 
intensive test. We propose that combination of HbA1c and GGT may be an alternate, 
simple measure to identify high-risk individuals in this cohort. 
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6.6 Chapter-6: Novel biomarkers and diabetes 
6.6.1 What is already known on this topic? 
 There is scarce information available on the association of non-glycaemic      
biomarkers with diabetes in Asian Indian individuals. 
 This chapter examined the evidence for associations between novel biochemical 
markers including adiponectin, leptin, inerleukin-6 (IL-6), retinol binding protein-4 
(RBP4), vitamin D3 with T2DM.  
 Also, the additive utility of non-glycaemic biomarkers over and above that of 
glycaemic measures in identifying individuals with diabetes was also assessed. 
6.6.2 The novelty of the data presented and its impact on the field 
 The present analysis demonstrates that the serum level of lower adiponectin (OR: 
0.860 [95%CI: 0.800-0.925]; P<0.0001), higher IL-6 (OR: 1.041 [95%CI: 1.012-
1.071]; P=0.006) and GGT (OR: 1.022 [95%CI: 1.005-1.040]; P=0.013) were 
associated with diabetes. 
 Serum RBP4 levels showed a modest association with diabetes (OR: 1.061 [95%CI: 
1.001-1.125]; P=0.048). But, in a multiple biomarker model its association was 
attenuated. 
 Serum leptin and Vitamin D3 were not associated with diabetes.  
 Though, these biomarkers provided may offer novel information regarding 
mechanisms of diabetes pathogenesis, they did not improve the predictive power 
over and above that of glycaemic measures in identifying individuals with diabetes. 
 Nevertheless, the non-glycaemic biomarkers may have a pathogenic role in the 
development of diabetes. 
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6.7 Overall conclusion 
The existing primary  prevention programmes for T2DM are resource-intensive, labour 
expensive and it is hard to translate the results from a research setting to the 
community at large. The present trial affirms that delivery of lifestyle intervention 
content through mobile phone based text messaging service may be an alternate means 
to disseminate healthy lifestyle principles in the field of preventive medicine.  Also, it 
is important to identify simple, cost-effective screening tools to identify high-risk 
individuals requiring intervention. Most importantly, identification of novel 
biochemical markers from various organs such as the liver and adipose tissue provides 
important information regarding their pathological links with diabetes. This 
dissertation serves to evaluate the associations of routine clinical variables and novel 
biomarkers with T2DM among high-risk individuals, and supports that routine clinical 
measures are sufficient to predict diabetes in this cohort. However, the non-glycaemic 
biomarkers have a role in understanding the pathogenesis of diabetes. 
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8 APPENDICES 
Appendix - 1 
PARTICIPANT INFORMATION PAMPHLET  
              Proposal Title: Role of information technology in the prevention of diabetes 
Proposal Version: 1.0  
Principal Investigator/ Address: Dr. A. Ramachandran, India Diabetes Research 
Foundation and Dr. A. Ramachandran’s Diabetes Hospitals, No. 28 Marshalls Road, 
Egmore, Chennai 600 008.    
Project Identification Number: UKIERI-IDRF/08/039  
Funder: UK-India Education and Research Initiative (IND/CONT/06-07/187E) 
 
  
 
1. Why is this programme conducted? 
India has a large population with diabetes in the working age group and the number is 
increasing disproportionately. The rates of urbanization, migration from rural to urban 
areas and adoption of modern lifestyle have resulted in reduced physical activity and 
unhealthy diet habits. Diabetes is preceded by subclinical forms of increased blood 
glucose levels, known as prediabetes or Impaired Glucose Tolerance (IGT). People with 
prediabetes have a high risk of developing diabetes. India has a large number of persons 
with IGT. 
Primary prevention of type 2 diabetes by lifestyle modification is a possible solution to 
postpone the rising epidemic of the disease. Our team has already conducted 2 large 
primary prevention programmes which have shown that diabetes is largely preventable. 
Now, in this programme, we are trying to prevent diabetes in a large group of persons at 
risk of developing the disease.  
This community-based programme will be conducted in various industrial townships and 
commercial organizations located in Tamil Nadu and other parts of South India. We plan 
to include 514 participants, both men and women. The project proposal and this consent 
form have been carefully reviewed and approved by the independent Ethics Committee, 
India. These committees are set-up to protect the rights and well-being of the study 
participants and they will closely monitor the study progress at regular intervals.  
Participant ID: 
 
 
Subject ID:  
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   2. What will happen when you participate in this programme? 
You are being asked to participate in the Indian Diabetes Prevention Programme because 
you are aged between 35-55 years with a high risk of developing diabetes in the future.        
It is important that you read the information about the programme and understand what 
you will be asked to do if you decide to be in the study. You also need to understand the 
possible benefits and inconveniences of participation. It you decide to participate, you 
will need to sign this form, which states that you have given consent to participate. Feel 
free to discuss this with your employer or family member / friend before you take your 
decision.  
 
3. Details of the Programme:     
During the initial screening your 2 hr post glucose value was in a prediabetic range (2hr 
post glucose value: ≥ 160- ≤ 199 mg/dl).  
Enrollment Visit: In this confirmatory test you will undergo the standard oral glucose 
tolerance test (oral glucose tolerance test (OGTT, glucose load 75g) at fasting and at 30 
and 120 minutes after 75g glucose ingestion). Based on the result the following inference 
will be made. If the value is between 140-199 mg/dl, you will be enrolled in this 
programme.  
 
 
 
You will be required to come in fasting state for this visit. During this visit you will be 
assigned to either the intervention group or to usual care. Participants assigned to usual 
care will have an initial interview conducted by the IDRF team, delivering advice on 
health lifestyle behavior with focus on personalized diet and exercise. Participants in the 
intervention group will undergo the same interview and will also receive text messages 
in the mobile phone (frequency of the messages as per the wish of the participants) on 
diabetes education, diet advice and motivation.  
Blood tests such as Fasting, 30 and 120 min plasma glucose and insulin, liver enzymes 
and Lipid Profile will be performed during this visit and at annual visits. During 6 and 
18 months we will perform 2 hr post glucose load test. If the value reached ≥ 200 mg/dl 
we will repeat the test within two weeks time. Our staff will administer questionnaires to 
assess your quality of life, dietary pattern and levels of physical activity. 
 
 
Range Interpretation 
<140 mg/dl Normal 
140-199 mg/dl Eligible to participate in the study (High Risk) 
≥ 200 mg/dl Referred to physician  
Appendices 
176 
 
 
3. What are the possible risks / discomforts in this study?  
As the programme involves lifestyle modification no possible risk is anticipated. 
Identification of undetected diabetes or hypertension may cause anxiety or fear, in which 
case you will receive suitable advice and support from the physician regarding 
management for these disorders. You will also be refereed to your company’s physician 
should the need be.  
When blood samples are taken you may experience some discomfort which will subside 
in due course. 
4. What are the possible benefits of participation?  
By ascertaining your risk factors you will understand your future chances of diabetes.  
You will receive advice on healthy lifestyle – with individualized counseling on diet and 
physical activity.  
By participating in this study you will have a better understanding of diabetes awareness 
and ways of prevention.  
During assessment there may be chances of detecting diabetes or hypertension which 
was previously undiagnosed.    
You will be followed up for the next two years with annual blood investigations.  
 
5. Your choice of participation?                                                                                         
Participation in this study is entirely voluntary. Refusal to participate will not affect any 
benefits you are entitled. If you feel that this programme is disturbing / harming you by 
any means you can withdraw from this study at any point of time. 
6. Will your personal information be kept confidential?                                          
During your participation in this study we will collect personal information and 
information related to your health. India Diabetes Research Foundation will be 
responsible for managing your data. The data may be shared with other institutions to 
effectively analyse the study outcomes. Under all circumstances your personal identity 
will not be disclosed.    
  
7. Will it cost you anything to be in this study?           
Your participation in this study will not cost you any money. You will not be charged for 
any of your blood tests in this programme.  
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INFORMED CONSENT FORM  
 
 
If you have understood the information explained above and willing to participate 
in this programme, kindly sign the form below:  
 
1. I confirm that I have read and understood the information for the above 
programme.  
 
2. I understand that my participation in the programme is voluntary and I am free to 
withdraw at any time. 
 
3. I understand that my identity will not be revealed in any information given  
to the third parties or published. 
 
4. I agree not to restrict the use of any data or results that arise from this  
study for scientific purpose(s).             
 
5. I agree to take part in this programme and follow procedures as explained to me.                                                                                                                           
                                                                                                             
 
(A)________________     /      _____________________  /       ______________  
 Signature of the Participant            Name of the participant                           Date                                                                                                                                                                                                                   
 
 
(B)________________     /      _____________________  /       ______________  
Signature of the Person                  Name of the Person                                 Date            
obtaining consent                          obtaining consent                                                                                                                                                                                        
 
 
 
Participant ID: 
 
 
Subject ID:  
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Appendix - 2 
Physical activity assessment 
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Appendix – 3  
Diet Assessment data capture 
Habitual nutrient intake was assessed during each visit using 24 hr recall method. 
Participants were interviewed by a trained nutritionist using a standardised protocol to 
recall the actual food intake during the previous 24 hr or the previous day.  A detailed 
description of the food list including the estimation of quantities is recorded. This is 
repeated over several visits and analysed using food composition tables. The total energy 
intake (kcal) and components of individual food constituents (carbohydrates, proteins 
and fat (in grams)) consumed by the participants were calculated with an in-house diet 
analysis program (visual basic programming tool) which uses the National Institute of 
Nutrition guidelines for India.  
 
Figure-1 shows the template of 24 hr recall method specifically employed for this trial. 
 
 
 
Appendices 
180 
 
To simplify the process of data entry and to capture the nutrient intake in a more 
effective and simplified way the researcher developed an in-house diet inventory 
programme along with a software technician (using Visual Basic tool). This module 
comprised of two components: 
 
a. Food master – a repository of 217 Indian food items are preloaded and stored in 
this component.  Each food item  has its total energy (kcal), carbohydrates 
(Gms), proteins (Gms), total  fats (Gms) and fiber intake (Gms)  calculated by the 
in-house department of  nutrition (Dr. A. Ramachandran’s diabetes hospitals). 
 
b. Diet inventory – the participants’ nutrient intake are recorded in this component. 
It consists of three domains: i) domain-1: wherein the basic information of 
individuals are recorded along with the visit type viz., baseline, 6 months, 12 
months, 18 months and 24 months; ii) domain-2: the information regarding the 
food item and quantities are recorded; and iii) domin-3: once food items are 
added, each food item is displayed in the below pane and expands as food items 
are added further. Finally it gives the cumulative energy intake value along with 
the individual diet components in Gms. 
 
Once the baseline dietary chart for each participant is entered in the database, it 
automatically reflects the stored data for the subsequent visits. For instance, if we wish 
to enter the 24 month data, the previously entered data of 18 months will be displayed 
automatically, which could be modified (quantity of each item added /reduced) to the 
current observation in a user friendly manner. This is under the assumption that the food 
pattern of an individual does not change drastically at 6 monthly intervals. 
 
Table: Classification of scores for adherence to diet prescription  
 
Dietary adherence (no sugar, ↓ refined carbohydrates, ↓calories,  ↑ fibre,  ↓ fat) was 
evaluated every 6 months. Scores were given at each time point to assess the adherence  
 
 
 
 
 
 
Classification  Self-reported adherence  
 
Poor  
 
Not following — <2 days/week (non-adherent)  
 
Fair  
 
Occasional deviation 2–4 days/week (adherent)  
 
Good  
 
Following diet strictly — >5 days/week (adherent) 
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Figure-2: Scrrenshot of the diet inventory manager developed in-house specific for this 
trial 
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Appendix - 4 
SMS Acceptability questionnaire 
 
Given below are a few questions related to the SMS you receive, kindly give your 
valuable responses and comments to improve our services. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. Questions Yes No 
1. 
Are you happy with the messages  
 
  
2. 
Are you happy with the frequency of SMS 
 
  
3. 
Do you find it easy to understand the SMS 
 
  
4. 
Do you find it difficult to understand the SMS 
 
  
5. 
Do you want us to increase the frequency of SMS 
 
  
6. 
Do you feel the SMS helps to improve your health 
 
  
7. 
What is your preferred time to receive SMS; morning, 
afternoon, evening or after 8.00 p.m. 
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